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Cancer is one of the main causes of morbidity and mortality, being responsible for an estimated 18.1 
million new cancer cases, and 9.6 million cancer deaths per year [1]. One in five men and one in six 
women worldwide will develop cancer during their lifetime, and one in eight men, and one in eleven 
women die from the disease. The majority of cancers, 90%-95% of cases, are induced by 
environmental and lifestyle factors, which may include smoking, diet, alcohol, sun exposure, 
environmental pollutants, infections, stress, obesity, and physical inactivity. About 5-10% of cases are 
due to inherited genetic aberrations. Carcinogenesis is a complex multi-step process that usually 
proceeds over several years and starts from one single cell. Endogenous and exogenous agents can 
lead to DNA damage, epigenetic defects and gene mutations. A series of mutations in cancer known 
as “driver genes” (oncogenes and tumour suppressors) as well as  other “passenger genes” initiate  
the transformation from a normal cell to a cancer cell, which results in aberrant cell behaviour, such 
as cell migration, growth, differentiation and failure of apoptosis. These events are part of a multistep 
process and contribute progressively to the generation and development of cancer. The different 
characteristics of cancer pathogenesis and disease progression have been outlined  by Hanahan and 
Weinberg as “Hallmarks of cancer” [2]. However, the biology of tumours should be investigated not 
only by focusing on the traits of single cancer cells, but should also consider the contributions of the 
tumour microenvironment, the interactions between tumour cells and the supportive stroma, the 
role of the immune system and the preferential tropism of spreading tumour cells to specific 
metastatic sites [3].  
 
The clinical diagnosis of cancer is based on medical tests, including blood tests, X-rays, CT scans,  
endoscopy and MRI. Current treatments include surgery, chemotherapy, radiation therapy, hormonal 
therapy, targeted therapy and palliative care, depending on the type, location and grade of the 
tumour. There are two main reasons restricting the efficacy of existing treatments: one is the 
observation of heterogeneity, as based on a patients’ genetic background, gene mutations, lifestyle, 
tumour size and tumor metabolism. All of these may affect treatment results. Therefore, a deeper 
understanding of inter- and intratumoral heterogeneity of tumours is needed for personalized 
interventions. A second problem is cancer cell resistance to the currently used therapeutics. Common 
targeting strategies aimed at inhibiting specific molecular pathways often have only a temporary 
success and are followed by a tumour relapse.  The use of a combined approach with several drugs 
can give rise to higher efficiency and avoidance of chemoresistance but so far, the results have not 
achieved the required efficacy in all malignancies. Therefore, there is still an unmet clinical need to 
develop new drugs and cancer models for testing the anti-cancer efficacy of targeted drug delivery to 
avoid adverse side effects and increase the success rate of treatments. In this thesis, we are going to 










Tumour clonality is one of the fundamental features of cancer and describes the development of 
tumours from a single cell. The accumulation of gene mutations leading to abnormal cell proliferation 
can be thought of as tumour initiation [4] (Figure 1). The outgrowth of a population of clonally-
derived tumour cells into adjacent tissues will form a tumour microenvironment (TME), which 
supports tumour cell growth. The abilities to sustain  proliferative signalling [5], evade growth 
suppressors [6], resist cell death [7], enable replicative immortality [8], induce angiogenesis [9], and 
activate invasion and metastasis [10] sustain tumour cell proliferation [2]. During tumour progression, 
further gene mutations keep occurring.  Similar to a microevolutionary process, the stepwise progress 
of cancer consists of a stage I, which is the evolution of tumours from normal tissues and stage II, 
which represents  the evolution within tumours [11]. Tumor progression drives intratumor diversity 
and heterogeneity. At the primary site, the tumour cells can grow thanks to enough nutrition and 
oxygen derived from the surrounding normal tissue. When the nutrition and oxygen become limited, 
the tumour center often transforms to a  necrotic core. The term Oxidative Stress refers to elevated 
intracellular levels of reactive oxygen species (ROS) and oxygen limitation initiates tumour 
angiogenesis after the so-called “angiogenic switch”, which causes the normal quiescent vasculature 
to sprout and produce new branches (neovascularization) [12]. The new vessels in the tumour have 
an aberrant morphology and are characterized by abnormal level of endothelial cell proliferation and 
apoptosis. In addition, leakiness of tumour vessels is one of the major reasons for the low efficiency in 
the delivery of therapies specifically to tumour lesions [13].  
 
It takes time for the tumour cells to grow at the primary site and develop the capacity to invade and 
metastasize. In this context, transformed epithelial cells acquire a motile mesenchymal phenotype in 
a process referred to as “epithelial-to-mesenchymal transition” (EMT) [14]. This invasive phenotype is 
generally associated with an increased migratory capacity of the tumour cells. Both blood and 
lymphatic vessels provide an escape route by which tumour cells can leave the primary site, through a 
process called intravasation. After tumour cells have invaded the circulatory system, they have to 
survive in the circulation and resist necrosis, until the tumour cells adhere to the vascular wall and 
extravasate [15].  
 
Most circulating tumour cells will die, only a few tumour cells go into an anchorage-independent 
survival. Once tumour cells have extravasated, they can invade the distant tissue and organ and 
undergo mesenchymal-to-epithelial transition, which allows the tumour cells to switch back to their 
epithelial and proliferative state. Once micrometastases are formed, sustained growth and 
angiogenesis allow them to grow out into secondary tumours. Additionally, tumour cells can also 
remain dormant for several years and then suddenly re-initiate proliferation and form a metastatic 






Fig. 1 Scheme of tumour cell growth, angiogenesis, invasion and the metastasis process.  
 
 
Metabolic reprogramming in cancer 
In addition to the above mentioned specific hallmarks, tumour cells can also adapt their metabolism 
and switch to the so-called “aerobic glycolysis”, converting their metabolism largely to glycolysis and 
lactate production (i.e. Warburg-effect) [16]. This is one of the bases of the non-invasive visualization 
of tumour-dependent positron emission tomography (PET) with a radiolabelled analogue of glucose 
as reporter. In proliferating cancer cells, the mitochondrial oxidative phosphorylation (OXPHOS) is 
reprogrammed towards a macromolecular synthesis to sustain multiple cell divisions [17]. The 
advantage of such a deregulated metabolism is to favour the accumulation of glycolytic 
intermediates, fuelling derivative anabolic pathways, such as the pentose phosphate pathway, the 
hexosamine pathway, and amino acid synthesis, thereby sustaining cell proliferation [18]. However, 
recent advances have highlighted substantial intratumoral metabolic heterogeneity and even 
metabolic plasticity, depending on the tissue context, tumour stage, TME, that regulate the metabolic 
strategies in tumour cells, leading, for example, to concurrent glycolysis and glucose oxidation in the 
same tissue [19]. Nevertheless, the majority of cancer cells enhance glucose and glutamine 
consumption to satisfy their requirements for rapid proliferation. In aerobic glycolysis in tumour cells, 
glucose is partially oxidized into pyruvate, which is subsequently reduced to lactate, that is then 
extruded into the extracellular space. Emerging evidence now argues that lactate plays a role in 
regulating different signalling pathways and the behaviour of malignant and non-malignant cells. 
Lactate can affect multiple biological processes during tumour progression, plays roles in the immune 
and inflammatory responses in TME, and also influences proliferation, metastasis and angiogenesis 
[20].  
 
Moreover, oncogenic mutations in metabolic enzymes such as the cytosolic NADP+-dependent 
isocitrate dehydrogenase 1 gene (IDH1) and the mitochondrial homolog IDH2, responsible for 
converting α-ketoglutarate to 2-hydroglutarate (2HG), a metabolite found only in reduced amounts in 
mammalian cells under normal conditions, have been reported [21]. Interestingly this has also an 
effect on epigenetic mechanisms, resulting in altered histone methylation marks, hypermethylation at 










The function of macrophages in the tumour microenvironment  
More knowledge now starts to elucidate the role of the TME and immune system during tumour 
initiation, growth and progression. Importantly, TME also shapes therapeutic responses and 
resistance [22,23]. 
 
During cancer progression, the stroma co-evolves with the tumour and creates a dynamic signaling 
network of paracrine signals that promotes cancer progression. The different stromal components of 
TME include cancer-associated fibroblasts (CAFs), pericytes, and immune cells, which surround blood 
vessels and are present in the extracellular matrix (ECM) [24,25]. These stromal cells are recruited to 
the tumour, and need to adapt to their new environment to allow them to survive. The immune 
system has evolved to discriminate between normal and malignant cells. It launches immune 
responses to eliminate damaged or malignant cells and protects the host [26]. Growing evidence 
suggests that cancer immunosurveillance not only protects the host against the development of 
primary cancer, but also shapes the immunogenicity of tumours [27,28]. However, upon cancer 
initiation and formation, tumour cells activate tolerogenic signalling pathways, resulting in cancer 
immune tolerance and escape from classical immune attack [28,29]. The first generation of antibody-
based immunotherapies against so-called immune-checkpoints (Immune-checkpoint blockade or ICB), 
works by blocking the receptor and/or ligand interactions of molecules, such as CTLA-4 and PD-1, 
which are involved in dampening T cell activation or function [30]. Unfortunately, ICB therapies have 
shown significant clinical benefit for only a minority of patients and there is still need to search for 
novel therapeutic targets. 
 
Within the TME, cancer cells release soluble molecules to activate their own oncogenic signalling for 
growth and metastasis, and alter the surrounding cells to enhance tumour progression [31]. 
Macrophages, a major cell population in the TME, play an essential role in immune homeostasis. They 
are activated and polarized by signals from the TME to become classically-activated (M1) or 
alternatively--activated (M2) phenotypes [32,33]. A large body of evidence suggests that 
macrophages within the TME are activated by tumour-derived cytokines into M2-polarized tumour-
associated macrophages (TAM), which promote tumour progression and suppress anti-tumour 
responses [34]. Importantly, therapeutic targeting of macrophages enhances chemotherapy efficacy 
of platinum-based chemotherapeutics by unleashing type I interferon responses [23]. 
 
TAM are either derived from tissue residence, or peripheral reservoirs such as the bone marrow (BM) 
and spleen [35]. Transcriptome profiling of freshly-isolated TAM suggests that they are similar to 
those that are involved in development [36]. TAM can contribute to many aspects of cancer 
development. In particular, they can regulate senescence, interact with and modulate the 
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extracellular matrix [37,38], promote cancer cell proliferation, invasion and metastasis [39,40] and 
promote tumor angiogenesis [41,42]. TAMs regulate tumor angiogenesis largely through production 
of vascular endothelial growth factor (VEGF-A) [43]. Genetic deletion of the VEGF-A gene in 
macrophages attenuates tumor angiogenesis and results in a morphologically more physiological 
vasculature [44]. Colegio et al discovered that lactate, as a by-product of aerobic or anaerobic 
glycolysis, has a critical function in signalling, by inducing the expression of VEGF and the arginase 1 
dependent M2-like polarization of TAMs [45]. They demonstrated that lactate-induced VEGF 
expression in macrophages is mediated by hypoxia-inducible factor 1α (HIF-1α). Recently, metabolic 
analysis coupled with enzyme activity assays, identified that cancer-derived succinate promotes 
macrophages polarization to M2-like TAMs via the succinate receptor-triggered PI3K-hypoxia-HIF-1α 
axis and increases macrophage migration and lung cancer metastasis [46]. 
 
In a zebrafish tumour model, innate immune cells (neutrophils and macrophages) were thought to 
contribute to different steps of tumour progression, including the formation of tumour vasculature 
and metastasis [47]. In zebrafish embryos, the caudal haematopoietic tissue (CHT) is known as a 
transient site of haematopoiesis and leukocyte differentiation [48]. The macrophage population of 
zebrafish embryos has been studied in detail and similarities with human macrophage functions have 
been reported [49,50]. Therefore, the transparent zebrafish embryonic tumour model is very suitable 
to dissect how macrophages respond to tumour environmental factors and contribute to 
angiogenesis. 
 
Zebrafish embryonic tumour xenografts: a model for cancer research  
In the last decades, zebrafish (Danio rerio) have been applied to the cancer research field, due to 
several advantages [51]. Benefits include the relatively short generation time of three months, cost-
effective maintenance, ex utero development, temporal separation between innate and adaptive 
immunity, transparency and easy manipulation of embryos [52]. Human and zebrafish share a high 
grade of similarity: 71% of human proteins and 82% of disease-causing human proteins have an 
orthologue in zebrafish [53]. There is a high conservation of oncogenes and tumour-suppressor genes 
between zebrafish and humans [54], and various oncogenic transgenic zebrafish lines have been 
developed [55,56]. The histology of zebrafish tumours has been shown to be highly similar to tumours 
found in humans [57].  The adaptive immune system in zebrafish does not reach maturity until four 
weeks post fertilization [58], allowing circumvention of graft rejection by using early stage zebrafish 
for human or murine cancer cell engraftment. Zebrafish embryos can absorb various small molecular 
weight compounds from water, allowing easy drug administration, which is advantageous when 
screening for anti-cancer compounds [59]. Use of transgenic lines with fluorescent vasculature or 







There are several approaches to generate human cancers in zebrafish, such as the development of 
mutant and transgenic zebrafish lines, and transplantation of tumour cells  [51]. Chemical 
mutagenesis, irradiation mutagenesis, or viral vector mutagenesis as well microinjection of exogenous 
DNA into one-cell-stage zebrafish embryos can induce transgenic cancer models. Currently, zebrafish 
genetic cancer models have been developed for many types of cancer e.g. cutaneous melanoma [61], 
neuroblastoma [62], rhabdomyosarcoma [55], leukaemia (specifically T-ALL) [63] and liver cancer 
[56,64].  
 
Another approach to generate cancer in zebrafish is the transplantation of tumour cells. The 
engraftment of murine or human cancer cells into a zebrafish embryo is a fast way to build a new in 
vivo model. The injection site for transplantation can vary, depending on the research purpose. These 
sites include the Yolk sac, the Duct of Cuvier, the perivitelline space, the hindbrain ventricle, the 
swimming bladder, and the retro-orbital space [65-76]. This model helps us to understand the 
processes of angiogenesis, tumour cell extravasation, invasion, metastasis onset as well as 
interactions with the microenvironment [77]. Interactions between human cancer cells and the 
zebrafish microenvironment have been extensively described [78-80].  Yi Feng et al observed that 
H2O2 production in oncogene-transformed cells led to leukocyte recruitment and a host inflammatory 
response that contributes to increased growth of the transformed cells [81]. He et al found that 
zebrafish neutrophils guide human cancer cell extravasation and invasion by reorganizing the 
extracellular matrix at the metastatic site at caudal hematopoietic tissue (CHT), the transient site of 
haematopoiesis and leukocyte differentiation [47,48]. The motility and adhesion of zebrafish 
neutrophils during metastatic niche preparation is orchestrated by the CXCR4 receptor, which is 
expressed on zebrafish neutrophils [47]. Next, Tulotta et al proved that engrafted human cancer cells 
expressing the CXCR4 receptor can sense the host’s (zebrafish) CXCL-12 ligand, which is produced by 
mesenchymal stem cells in zebrafish CHT [82], inducing metastatic colonization [29,30]. Targeting of 
either CXCR-4 (the CXCL-12 receptor) in breast human cancer cells and zebrafish neutrophils or CXCL-
12 in zebrafish significantly inhibited extravasation and metastatic tumour growth at the CHT area. 
Britto et al used an embryonic zebrafish xenograft model to show that zebrafish macrophages can 
enhance VEGF-A-driven tumour angiogenesis [83]. Moreover, human cancer cells can comparably 
respond to the microenvironment of zebrafish and mice, by inducing activation of the NF-ĸB–Activin A 
signalling axis, which drives the metastatic cancer stem cell (CSC)-like phenotype of prostate cancer 
cells [84]. Transplantation of zebrafish BRAFV600E-driven melanoma cells into casper fish showed 
that the degree of pigmentation is a key feature defining cells with metastatic capability [85]. De 
Sousa Pontes et al used (fli:GFP) Casper zebrafish embryos to establish  a model for human 
conjunctival melanoma [86]. Heilmann et al used transparent casper zebrafish to generate single-cell 
resolution of the metastatic process to evaluate the tumour cell’s metastatic ability [85]. Importantly, 
several groups described successful xenotransplantation of human patient samples into zebrafish 
larvae for phenotypic testing of drug responses [87].  
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Zebrafish embryonic tumour xenograft model for drug discovery 
Perhaps the most promising application of the zebrafish xenograft model is the ability to perform 
high-throughput drug screening on human cancer cells and samples in a way that is not possible using 
any other model organism. Larvae absorb drugs from the water through the skin and oral, enhancing 
the simplicity of drug administration [88]. Because embryos are maintained in 96-well plates, typically 
in 100−300 μL of water, screens require smaller drug quantities compared to mice. The efficacy of 
drugs can be quantified by live imaging of the tumour burden by fluorescence microscope [89,90]. 
Several research groups have also applied xenotransplantation methods to zebrafish, for the study of 
human cancer cell behavior, responses to therapy, within the context of the whole organism [91]. The 
different cell lines so far tested in xenotransplantation are cutaneous melanoma [92], conjunctival 
and uveal melanoma, colorectal cancer [93], breast cancer  [87], leukemia [94], ovarian cancer [95], 
neuroblastoma [96], pancreatic cancer [97], prostate cancer [51], and sarcoma [92]. Typically, cells 
are dye labeled to allow their identification within the living host and their growth, and to follow their 
infiltration into host tissues, monitored over two to five days. Treatment of engrafted embryos with 
drugs can result in graft stasis or regression, mirroring outcomes that can be observed in more costly 
and lengthier mouse xenograft experiments [98]. 
The technique of xenotransplantation into zebrafish can also be used with patient-derived tissues, 
which has been demonstrated previously for pancreatic adenocarcinoma, prostate cancer, and 
leukemia [87,99,100]. The total sample needed for this approach could be as little as 100 cells. The 
time for engraftment is between two and three days after fertilization. Given these characteristics, 
patient-derived xenografts (PDX) in zebrafish (zPDX) could be tools to predict patient responses to 
drug treatments. The valuable biopsy tissue from a patient could be injected into scores of zebrafish 
embryos potentially with different reporter constructs in the background and different treatments 
applied to select the most suitable clinical intervention. However, more proof-of-principle studies are 
needed to fully evaluate the value of zebrafish PDX models. Recently, development of 
immunodeficient zebrafish enabled the development of zPDX in adult zebrafish [100]. This approach 
is probably the most relevant when looking at it from a translational perspective and may in the near 
future provide fast and reliable assessments for personalized treatments and precision cancer 
therapy. Today, eight small molecules identified from zebrafish studies have been advanced into 
clinical trials, illustrating the ability to move fundamental discoveries from zebrafish to human [101]. 
Zebrafish embryonic tumour xenograft model for photodynamic dynamic therapy (PDT) and 
photoactivated chemotherapy (PACT) testing  
Another approach to treat cancer is to accumulate photosensitizers (PSs) in tumour tissue followed by 
the light-induced generation of cytotoxic reactive oxygen species (ROS) to kill the tumour cells. 
Photodynamic therapy (PDT) is a clinically-approved treatment in which the drugs only work after 





oxygen-dependent meaning that the energy of the excited photosensitizer PS*could be transferred 
into the O2 molecules in the irradiated tissues. Such energy transfer produces the excited state of O2 
called “singlet oxygen”, which is highly oxidative and leads to cell death via damage of DNA, proteins, 
and lipids (Fig. 2). Thus, PDT type II relies not only on light irradiation, but also on the local presence 
of dioxygen in the irradiated tumour tissue. Usually PDT type II ceases to work when the oxygen 
supply to the irradiated tissues is too low, for example in hypoxic tumours, or when the light intensity 
is too high [102].  
Type I PDT consists of the generation of radical species via electron transfer from the excited 
photosensitizer PS* to O2, which typically generates the superoxide radical O2●- and, by cascade 
reactions, other types of radical oxygen species (Fig. 2). Usually PDT type I is therefore also oxygen-
dependent, but in some cases electron transfer can happen directly from PS* to DNA or proteins to 
create radicals, without the involvement of dioxygen. In this case, PDT type I can also work in hypoxic 
conditions [103]. 
Photoactivated chemotherapy (PACT) relies on the oxygen-independent activation by light of a pro-
drug, turning a poorly toxic molecule into a much more toxic species. Metal-based PACT compounds 
are based on a heavy metal centre such as ruthenium (II) [82,104]. In some aspects, ruthenium (II) is 
similar to platinum (II), found for example in cisplatin, but it has photochemical properties: when 
coordinated to an appropriate ligand set, it can photosubstitute some of the ligands bound to it, ie. 
replace them by water molecules, as shown in the figure below. Water is poorly bound to heavy 
metal ions, so that biological molecules such as DNA, lipids, or proteins can bind to the aqua metal 
photoproduct, thereby creating metallated DNA or inhibiting proteins, which kill cancer cells. This 
metal binding of biomolecules cannot occur in the dark because the ligands protect the metal ion. 
Thus, the molecule is more toxic after light irradiation. A second form of PACT consists of using photo-
substitutional active ruthenium compounds where the liberated ligands bear the toxicity, rather than 
the metal-based photoproduct. This second form of PACT is sometimes called “photocaging”: the 
ruthenium complex appears as a “caging group”, and the ruthenium-ligand prodrug is called a 
“ruthenium-caged” cytotoxin [82].  
In PACT, whether the toxicity after light activation is due to the metal-containing photoproduct or to 
the ligand, the activation mechanism does not involve O2. Thus, PACT should be suitable for 
phototherapy of hypoxic tumours, where PDT usually fails. This idea has been demonstrated in vitro 
by the Bonnet group [105].  
For light-activated compounds (whether PDT or PACT) the photoindex, defined as PI = 
EC50(dark)/EC50(light), characterizes the enhanced toxicity upon irradiation in a given set of conditions 
(and with a given cell testing protocol). EC50(dark) and EC50(light) are cell growth inhibition effective 
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concentration values, ie concentrations that prevent 50% of cancer cell growth, compared to drug-
free control.  
 
Fig. 2 Scheme of PDT and PACT compound mechanisms.  
 
The zebrafish liver tumour model was used as an in vivo platform to investigate the biodistribution of 
fluorescent PS and the therapeutic efficiency of theranostic polymer-encapsulated nanoparticles to 
carry out PDT  [106].  The first photoswitchable inhibitor of human dihydrofolate reductase (DHFR) has 
been developed as a potent chemotherapy drug as determined in a zebrafish model [107]. In addition, 
this animal model has been increasingly utilized to assess the toxicity of nanoparticles. The acute and 
chronic toxic effects of metal nanoparticles, including Au, Ag, Cu, and metal oxide nanoparticles, such 
as TiO2, Al2O3, CuO, NiO and ZnO were measured [108]. Moreover, this model allowed assessment of 
off-target organ toxicities including immunotoxicity, developmental toxicity, neurotoxicity, reproductive 
toxicity, cardiovascular toxicity and hepatoxicity [109]. Wehmas et al used embryonic zebrafish to 
investigate the toxicity of engineered metal oxide nanoparticles [110]. 
 
A Zebrafish embryonic tumour xenograft model for nanomedicine optimization and delivery  
Recently, zebrafish stood out as a tool to develop and test new drug administration strategies of 
nanomedicines. Nanomedicine toxicity, biodistribution and systemic circulation, stability, functionality 
and targeting efficiency have all been successfully assessed within the complex biological, in vivo 
environment of living zebrafish larvae. The potential value of the zebrafish model for anti-cancer 
nanomedicine development has been demonstrated by many studies [111-113]. Most studies 
measured the toxicity and safety of blank nanoparticles (mostly liposomes) prior to drug 
incorporation. Taking advantage of the embryo’s transparency, biodistribution studies have also been 
performed to determine the ability of the nanocarriers to reach the target site, and to even pass the 





model has also been proven useful in the study of the interaction between drug-loaded nanocarriers 
and xenografted cells. For example, Yang and collaborators described the application of coiled coil 
peptides in liposomal anticancer drug delivery using the zebrafish xenograft model [111].  The work of 
Evensen and collaborators addressed the ability of PEGylated nanocarriers to avoid uptake by 
macrophages, a fact that translates in improved circulation time and increased accumulation into 
tumours [112]. The ultimate goal of nano-delivery methodologies is cell-specific targeting, yet on-
target uptake is approximately 1% of all injected nanoparticles [115] due to off-target interaction in 
the liver [116] and scavenger endothelial cells (SECs) of various tissues (e.g. kidney, heat and gills). 
Zebrafish whole-body 4D intravital imaging was applied to monitor the distribution of fluorescent 
liposomes with cellular resolution in near real-time [117]. The tested liposomes accumulated on 
endothelial cells. Dextran sulphate (a competitive inhibitor of stab-2 scavenger receptors) and stab2 
mutants led to a dramatic increase in the concentration of freely-circulating liposomes due to 
diminished stab-2 scavenger receptor binding. This study provided evidence that anionic liposomes 
are an ideal delivery system for targeting cells overexpressing stab-2 (such as SECs) and that inhibiting 




In this thesis, we will utilize embryonic zebrafish tumour models to understand the interaction 
between engrafted human cancer cells and macrophages from the host, test drug administration 
modalities and anti-cancer efficacies of newly-developed PDT and PACT compounds, and test a light-
triggered liposomal system for targeted drug delivery specifically to cancer cells in vivo.   
 
In chapter 2, we investigate the role of macrophages in tumour-induced angiogenesis. We show that 
macrophage-dependent angiogenesis is driven by macrophage recruitment to lactic acid secreted by 
glycolytic B16 melanoma cells. Chemical inhibition of macrophages and glycolysis blocks the initiation 
of angiogenesis in these models, suggesting that macrophages attracted to glycolytic melanoma cells 
contribute to the tumour-induced angiogenesis process.  
 
In chapters 3 and 4, we explore novel PDT and PACT compounds, respectively, for treatment of 
conjunctival melanoma in zebrafish. We inject conjunctival melanoma cells into the retro-orbital site 
to establish an orthotopic model and into the Duct of Cuvier to generate an ectopic model. Our 
results prove that zebrafish provides a fast vertebrate cancer model to test the optimal 
administration regimen of drugs, conditions of light irradiation, host toxicity and anti-cancer efficacy 
of PDT and PACT drugs against conjunctival melanoma.  
 
In chapter 5, we focus on modifying liposomes to be light triggered in order to deliver drugs 
specifically to cancer cells. We inject MDA231 breast cancer cells into the Duct of Cuvier at 2 days 
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post fertilization (dpf) to initiate metastasis to the CHT. We successfully demonstrate that light-
triggered, cell-specific delivery of liposome-encapsulated doxorubicin reduces the xenograft cancer 
cell burden without enhanced cytotoxicity of the zebrafish embryos. 
 
In chapter 6, we summarize the novel anti-cancer strategies, which we have developed using 
zebrafish xenograft models. In the same chapter, we frame our findings in the current scientific 
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Malignant melanoma is often linked to increased angiogenesis and a high infiltration with tumor-
associated macrophages (TAMs). TAMs influence various processes during tumor development, 
including immune responses, tumor growth, metastasis and angiogenesis. These immune cells may act 
as a local source of Vascular endothelial growth factor (VEGF), thereby stimulating neo-vascularization. 
However, the dynamic interactions between macrophages and the tumor environment, including 
melanoma and endothelial cells, remain elusive. We utilized a zebrafish allo- and xenograft model to 
understand the role of macrophages during melanoma progression and tumor- induced angiogenesis. 
Three red fluorescence-labeled melanoma cell lines (zebrafish ZMEL1, human SK-MEL28 and mouse 
B16.F10) were injected into transgenic reporter Tg(mpeg:GAL4:UAS:lifeact:GFP)  embryos with green 
fluorescent macrophages to study the interaction between melanoma cells and host macrophages. 
First, we compared the interactions between xeno- and allografted melanoma cells with macrophages, 
to ensure the response is not due to cross-species immune recognition. Next, the recruitment of 
macrophages to the primary tumor was analyzed. Additionally, the functional significance of these 
immune cells was studied by chemical ablation of macrophages in Tg (mpeg:GAL4:UAS:NTR:mCherry) 
embryos, using metronidazole (MTZ). The growth kinetics and angiogenic activity of each engrafted cell 
line were quantified in the presence and absence of macrophages. Finally, the function of lactic acid 
secreted by glycolytic B16.F10 melanoma cells was investigated after chemical inhibition of glycolysis.  
We observed that macrophages are attracted to lactic acid, secreted by glycolytic B16.F10 cells and 
subsequently promote their angiogenic potential.  
 
Introduction 
Cutaneous melanoma is an aggressive type of skin cancer which arises when pigment-producing skin 
cells, called melanocytes, become cancerous. Whereas healthy melanocytes respond properly to 
growth signals, melanoma cells proliferate, form blood vessels, invade the circulatory system and 
spread to distant tissues and organs. A high ability to metastasize makes melanoma one of the deadliest 
forms of cancers. Unfortunately, melanoma is becoming more common every year and is now the 
second most common cancer type in young people [1].  
 
The progression of cutaneous melanoma can be defined by a multi-phase model, from benign nevus, 
dysplastic nevus, radial growth phase, to vertical growth phase and metastatic melanoma [2]. The key 
driver behind its development is the accumulation of mutations in crucial genes which regulate cell 
growth, differentiation and survival. Mutations are primarily due to prolonged ultra-violet radiation 
(UVR) exposure. In the benign nevus stage, oncogenic mutations in the BRAF and N-RAS genes pave the 
way for melanoma development. After acquiring these mutations, a dysplastic nevus is shaped, which 
is characterized by molecular abnormalities that affect cell growth, DNA repair and survival. In this 
stage, loss of function mutations in tumor suppressor genes CDKN2A or PTEN are crucial for initiating 





(VGP) [3]. In the VGP, melanoma cells loose cell-cell contact and undergo epithelial to mesenchymal 
transition (EMT). Finally, vertical growth of the tumor through the basement membrane of the dermis 
is followed by periods of increased angiogenesis. As the tumor continues to expand into the dermis, 
the need for nutrients and oxygen increases. Through angiogenesis, the tumor stimulates the 
development of new blood vessels from existing ones. Additionally, these vessels provide a 
transportation route for nutrients and oxygen but also a route for the melanoma cells to the circulatory 
system [4]. Before homing of the disseminated melanoma cells (DMCs) at a secondary site, a pre-
metastatic niche is formed as a result of the accumulation of lysis oxidase, placental growth factor 
(PIGF) and exomes derived from the primary tumor. The pre-metastatic niche promotes metastatic 
colonization upon arrival of the DMCs [5]. The DMCs extravasate from the circulatory system into the 
tissue and begin to proliferate, resulting in the formation of a secondary tumor. 
 
It is generally accepted that the tumor microenvironment (TME) is an important factor in 
tumorigenesis. The TME is highly heterogeneous and is composed of various cell types which can either 
enhance or inhibit tumor growth [6]. Among these are immune cells such as macrophages, neutrophils, 
neutral killer cells and T cells. During development, cancers acquire hundreds or even thousands of 
mutations in coding exons, promoting the production of tumor specific- and tumor- associated 
proteins. These proteins, respectively, may serve as tumor-specific-antigens (TSAs) and tumor-
associated-antigens (TAAs) for recognition by the immune system [7,8]. Upon recognition of these 
antigens, attracted immune cells provide immunosurveillance and destroy malignant cells [9].  
In contrast, the host’s immune system can also promote tumor survival, growth and metastasis [10]. 
Some malignant cells are able to secrete molecules which change the cellular composition and function 
of the TME, thereby evading immunosurveillance [11]. The established TME shares many similar 
features with a chronic wound, inducing a wound-healing-like immune response. When immune cells 
are recruited to the TME,  they secrete inflammatory cytokines, growth factors and chemokines, which 
in turn stimulate tumor growth, angiogenesis and migration [12].  
 
One of the most abundant immune cells in the melanoma TME are macrophages, which are 
characterized by their plasticity and flexibility. Owing to their plasticity, macrophages alter their 
phenotype continuously, following environmental cues and intercellular interactions [13]. 
Conventionally, macrophage phenotypes have been classified in two main groups, namely the pro-
inflammatory type I macrophages (M1) and the anti-inflammatory type II macrophages (M2) [14]. 
However, these phenotypes should not be seen as binary, but as a spectrum where M1 and M2 
macrophages are at the opposite end [15,16]. M1 polarization is promoted by pro-inflammatory stimuli 
such as interferon gamma (IFNγ), tumor necrosis factor alpha (TNF-α) and toll-like receptor (TLRs) 
ligands. Many pro-inflammatory cytokines are secreted by M1 macrophages, including IL-1β, TNF-α, 
TNF-β and IL-6. Whereas M1 macrophages are involved in the initial tissue damage response, M2 
macrophages dominate later in repair [17,18]. Polarization towards an M2 phenotype is induced by IL-
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4, IL-13, the immune complex or glucocorticoids. M2 macrophages are characterized by their secretion 
of TGF-β, IL-10, VEGF and matrix metalloproteinases (MMPs), thereby assisting in the resolution of 
inflammation, and the promotion of tissue remodeling and repair [19].  
 
Melanoma cells secrete several factors that attract monocytes, including lactic acid, VEGF, and colony-
stimulating factor (CSF-1). Upon arrival at the tumor site, monocytes may differentiate into tumor-
associated macrophages (TAMs). In cutaneous melanoma, TAMs exhibit heterogeneous responses 
which can be pro- and antitumoral. It has been found that the function and phenotype of macrophages 
changes during melanoma progression. During the early neoplastic phase, macrophages play a 
proinflammatory role and provide immune surveillance, whereas macrophages in a malignant 
melanoma environment can promote angiogenesis and enhance tumor cell dissemination [20,21]. 
Therefore, pharmacological targeting of the macrophage activity depends on the stage of the disease. 
 
In melanoma, neovascularization is linked to high malignancy and metastasis, and is a crucial 
predictive factor in melanoma tumorigenesis [22]. Toriso H. et al. found that the number of infiltrating 
macrophages and blood vessels positively correlated with the depth of melanoma invasion. They 
suggest that activated macrophages are a local source of VEGF and that these immune cells 
upregulate pro-angiogenic factors IL-8 and VEGF in melanoma cells through secreting TNF-α and IL-1β 
[23]. How activated macrophages dynamically interact with melanoma cells and vascular endothelial 
cells remains unknown. However, using zebrafish as a model organism makes it possible to study these 
dynamic interactions in vivo. Over the last decade, zebrafish have emerged as a convenient in vivo 
model for cancer, immune and stem cell research. More than 70% of all human disease genes have a 
functional homolog in zebrafish [24]. Another advantage of this model is breeding efficiency. One 
zebrafish pair can produce up to 200 embryos per week, which develop ex vivo and are transparent, 
making them easy to study [25]. Additionally, the adaptive immune system is absent in early stage 
embryos, allowing tolerance for human tumor cell engraftment and exclusive study of the innate 
immune system [26] . In this research we aimed to microscopically trace macrophages in an allo- and 
xenograft zebrafish models and dissect their role in the tumor induced angiogenesis. The transgenic 
line, Tg(kdlr:GFP/mpeg:NTR:mCherry) with fluorescent blood vessels (green) and macrophages (red) 
was employed here to study the interaction between macrophages, vessels and engrafted melanoma 
cells (red and far red). Importantly, this transgenic line made possible to deplete macrophages in live 
embryos in the inducible fashion by adding metronidazol (MTZ) to the medium, which in turn was 
broken down by nitroreductase (NTR) enzyme to toxic compound, ablating macrophages [27]. 
Melanoma cells were engrafted into the Duct in Cuvier (DOC) or within the perivital space of two days 
old embryos, where they settled, formed a primary tumor and induced angiogenesis. Using these 
models, we observed attraction of macrophages to engrafted melanoma cells of different origin. 
Restrictively, macrophages attracted to lactic acid, secreted by glycolytic B16.F10 cells elevated their 







Transgenic Fish Lines 
The transgenic lines Tg(kdlr:GFP/mpeg:NTR:mCherry) and Tg(mpeg:GAL4:UAS:lifeact:GFP) were used 
in this study and were handled in compliance with local animal welfare regulations and maintained 
according to standard protocols (www.ZFIN.org). Zebrafish embryos were collected and treated with 
0.2 mM N-phenylthiourea at 24 hours post fertilization (hpf) to prevent melanization. To deplete 
macrophages, Tg(mpeg:GAL4:UAS:NTR:mCherry) fish were exposed to 2.5 mM metronidazol (MTZ) at 
48 hpf. The medium of 2.5 mM MTZ treated embryos was refreshed every two days.  
 
Melanoma Cell Lines 
Cell lines ZMEL1, a zebrafish melanoma cell line, kindly provided by dr. Richard M. White [28], SK-
MEL28, a human- cutaneous melanoma cell line, and B16.F10, a mouse melanoma cell line from the 
ATTC, were used. The cell lines were cultured in DMEM/F12 10% Fetal Calf Serum (FBS; Gibco). Stable 
fluorescent cell lines were created using lentiviral vectors expressing GFP or far red.   
 
Cell proliferation assay 
Sulforhodamine B (SRB) colorimetric assay was used to evaluate cell proliferation as described 
previously [29]. B16.F10 cells were seeded in a 96-well plate and left overnight. Cells were treated with 
different doses of 2-Deoxyglucose (2DG) for different times as indicated and then were fixed with 30 µL 
50% trichloroacetic acid (TCA, Sigma-Aldrich) for 1 h at 4 °C. Cellular proteins were stained with 60 µL 
0.4% SRB (Sigma-Aldrich) for 30 min and unbound SRB was removed by washing with 1% acetic acid 5 
times (VWR, Amsterdam, The Netherlands). Protein-bound SRB was dissolved in 200 µL 10 mM 
unbuffered Tris (Thermo Fisher) and solution absorbance was measured at 540 nm on an Infinite 
M1000 microplate reader (Tecan, Giessen, The Netherlands). Dose response curves and IC50 values 
were made in GraphPad Prism (version 8.1.1). 
 
ATP luciferase assay  
Following the manual’s instructions of the ATPlite 1 step Kit (PerkinElmer, the Netherlands), optimized 
number of cells were seeded on the black screen-star plate (Greiner, the Netherlands) and attached 
overnight in the incubator. After staining with Cells Hoechst for 45 mins, cells were treated with 
exposure medium. Prior to assay, the images of nucleai were captured on a Nikon Eclipse Ti microscope 
using a Plan Fluor 10 objective with 37 °C 5% CO2 incubator chamber, automated stage and perfect 
focus. At indicated measurement time, each plate well was replaced with 50 µL fresh medium and then 
50 µL of ATP substrate was added. After 2 mins mixture on the shaker, luminescence was measured 
with FLUO star plate reader (BMG Labtech, the Netherlands).  All graphs were plotted in Graphpad 
Prism. The numbers of cells were calculated by custom-made ImagePro macro. All values were 





Cells were cultured and treated with 100 µL indicated compound medium in 96 well plate.  At collection 
time, cells were removed by spinning down and supernatants were collected to a new 96-well plate. 10 
µL of supernatant was mixed with … of lactate assay regent (including 108 mM Triethanolamine HCl, 
10.7 mM EDTA.Na2, 42 mM MgCl2). After 7 mins incubation in the dark, absorbance was measured at 
wavelength of 490 nm on FLUO star plate reader (BMG Labtech, the Netherlands). Meantime, cells 
were stained with Hoechst and the images of nuclei were captured on a Nikon Eclipse Ti microscope 
using a Plan Fluor 10 objective with 37 °C 5% CO2 incubator chamber, automated stage and perfect 
focus. All graphs were plotted in Graphpad Prism. The numbers of cells were calculated by custom-
made ImagePro macro. All values were normalized to cell numbers. 
 
Embryo Preparation and Tumor Injection 
Zebrafish embryos at 2 days post fertilization (dpf) were anaesthetized with tricaine and translocated 
to a Petri dish coated with 1% agarose. Melanoma cells were trypsinized and collected as a single cell 
suspension in a 15ml collection tube. After 5 minutes centrifuging at 1200 rpm the supernatant was 
removed and the pellet was resuspended in phosphate-buffered saline (PBS). After second 
centrifugation the supernatant was removed, pellet was resuspended in 10µl 2% PVP and kept at room 
temperature before implantation. The cell suspension was transferred into glass capillary needles (nr 
99.) and the injections were performed with a Pneumatic Pico pump with a manipulator (WPI) within 2 
hours. ~50 ZMEL1 cells, ~300 SK-MEL28 or ~300 B16.F10 cells were injected above the ventral end of 
the Duct of Cuvier or within the perivital space [30,31]. As a negative control, 2% PVP was injected 
instead. ZMEL1 injected fish were maintained at 28°C, whereas SK-MEL28 and B16.F10 injected fish 
were kept at 34°C.  
 
Macrophages attraction assay 
1 nL of purified CCL2 protein (R&D Systems, The Netherlands) or lactic acid (Sigma Aldrich, The 
Netherlands) (10 ng/ml) were injected into the hindbrain ventricle of Tg(kdlr:GFP/mpeg:NTR:mCherry) 
larvae at 48 hpf [32]. 1 nL of PBS injected embryos were set as an injected control group. Samples were 
fixed with 4% PFA at 3 hours post injection (hpi), and macrophages were counted within the hindbrain 
ventricle under a Zeiss Observer 6.5.32 laser scanning confocal microscope (Carl Zeiss) by going through 
the z‐stacks, comprising the whole hindbrain ventricle.  
 
Microscopy and Analysis 
Before confocal live imaging, larvae were anaesthetized with tricaine and positioned on a glass cover 
plate before embedding them in 0.5% low melting agarose. The position of larvae was corrected after 
embedding with a toothpick to obtain a uniform view of all samples for confocal imaging. For stereo 
live imaging, anaesthetized larvae were positioned on a 1% agarose covered Petri dish. After stereo 





monitor tumor growth in each embryo at higher magnification.  A Leica TCS SPE confocal microscope 
and a Leica stereo microscope were used to acquire fluorescent images. Time-lapse movies and three-
dimensional images were reconstructed using ImageJ. The stereo xy and confocal xyz images were 
analyzed in ImageJ. The data generated in ImageJ was transferred to excel and Prism 6 software 
(GraphPad) for further analysis.  
 
Statistical Analysis 
The statistical analysis was performed using Prism 6 software. Comparisons between two groups were 
calculated with one-tailed non-parametric unpaired t-tests. Comparisons between more than two 
groups were performed with a multi-way ANOVA. Not significant (p > 0.05), *0.01 < p < 0.05, **0.001 




Zebrafish model to study melanoma growth and angiogenesis formation 
To study the interactions between macrophages and melanoma cells, we took advantage of the allo- 
and xenograft zebrafish model. Injecting fluorescence-labeled tumor cells into the Duct of Cuvier (DOC) 
of two-day old transgenic embryos allowed us to follow the growth kinetics of these cells in the 
presence of a microenvironment [30]. The head and tail, representing the primary tumor and the 
extravasation site, respectively, were imaged at various time points (Figure 1A). We tested three 
melanoma cell lines with BRAFV600E and p53-/- mutations, including zebrafish melanoma cell line ZMEL1, 
human cutaneous melanoma cell line SK-MEL28 and mouse melanoma cell line B16.F10. The number 
of melanoma cells that were injected was optimized by taking into account the survival of the embryos 
and tumor cells. We found that all cell lines formed a tumor at the injection site and migrated to the 
caudal hematopoietic tissue (CHT) (Figure 1B). ZMEL1 cells were highly proliferative at the injection site 
and formed a solid primary tumor surrounding the skin of the embryo at 6dpi. These cells showed low 
single cell extravasation from the vessel at the CHT without establishing a secondary tumor in the tail 
fin. We found that SK-MEL28 cells induced high extravasation and were more invasive, however they 
did not establish a solid primary tumor at the injection site. In contrast, these cells did form a secondary 
tumor at the CHT. B16.F10 cells induced a compact primary tumor on the skin, induced angiogenesis 
and established a secondary tumor, while SK-MEL28 induced a primary tumor without clear 
angiogenesis (Figure 2C). All cell lines were able to form primary tumors in the embryos, which allowed 





Figure 1 Experimental setup and melanoma growth dynamics in zebrafish embryos. An allo- and xenograft zebrafish 
model was used to study the role of macrophages on engrafted melanoma development. Around 300 tumor cells 
were injected into the Duct of Cuvier at 2 dpf. After injection of fluorescence-labeled tumor cells in the DOC, stereo 
and confocol images were taken at various time points of the head and tail respectively (A). Representative images 
show the ZMEL1, SK-MEL28 and B16.F10 primary tumor site and extravasation. The mCherry labeled macrophages 
are located throughout the entire embryo (B). Negative tumor angiogenesis formation (SK-MEL-28) and positive 
tumor angiogenesis formation (B16) at the primary site (C).  
 
Host macrophages recruited to injection site and interact with engrafted melanoma cells 
We next asked if host macrophages respond to engrafting of melanoma cells and whether interaction 
occurs between these cells. Injecting dTomato-labeled tumor cells into transgenic embryos with GFP- 
labeled macrophages allowed us to trace the migration and behavior of the tumor cells and 
macrophages for 10 hpi by using time lapse imaging (Figure 2A). The mock injection procedure induced 
accumulation of macrophages near the injection site. The macrophage population surrounding the 2% 
PVP injection resolved between 3-6hpi, indicating a resolution of inflammation. However, the 
macrophage population at the tumor injection site remained high and gradually increased until the 
termination of the experiment, suggesting that macrophages are attracted to the primary tumor and 
not the injection wound (Figure 2B). To ensure that there were close interactions between these cells, 
we reconstructed three-dimensional images of confocal z-stacks from the primary tumor. These images 
reveal that macrophages interacted closely with tumor cells and quickly infiltrated the engrafted tumor 







Figure 2 Tracking macrophage migration and their interactions with melanoma cells. Still images from the time 
lapse at 1hpi, 6hpi and 10hpi. Each row represents a single embryo, either non-injected or injected with 2% PVP, 
ZMEL1 or SK-MEL28. Images were taken with a 10x magnification. Macrophages accumulated near the injection 
site, which is marked in yellow (A). Quantification of the macrophage area at the injection site of each frame within 
the time lapse. A 175x175 pixels ROI was used to represent the injection site. The fluorescent signal in this ROI was 
normalized by dividing it by the total fluorescent expression in the same channel. Macrophages quickly respond to 
the injection, but only continued to accumulate near the injection site when tumor cells were present (B). 2D/3D 
reconstructed confocal z-stacks of the ZMEL1 and SK-MEL28 primary tumor at 1hpi, obtained with a 40x 
magnification. Right, the 3D image is shown of the 2D images, which is visualized on the left. Macrophages 
infiltrated the engrafted tumor at 1hpi (C). 
 
Macrophages continue to accumulate at the primary tumor site 
To verify whether engrafted melanoma cells continue to recruit macrophages during the timespan of 
our experiments, we analyzed and quantified three-dimensional images of the primary tumor at 1hpi, 
1dpi and 4dpi (Figure 3A). At 1hpi and 1dpi, SK-MEL28 had a significantly-larger tumor area than ZMEL1. 
However, ZMEL1 showed a trend to have a larger tumor area at 4dpi compared to SK-MEL28, suggesting 
that ZMEL1 proliferated more effectively. The number of macrophages in the field of view (FOV) of the 
injection site was similar between 2% PVP and tumor-injected embryos at 1hpi. The number of 
macrophages in the FOV of the primary tumor induced by ZMEL1 and SK-MEL28 injection gradually 
increased at 1dpi and 4dpi, whereas the population of macrophages at the 2% PVP injection site 
remained constantly small throughout the experiment (Figure 3B and 3C). The macrophages in 
proximity of the tumor showed a more rounded morphology, characterizing an inflammatory 
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phenotype. Occasionally, macrophages and melanoma cells showed overlap between their 
fluorescence signal, indicating that macrophages phagocytose tumor cells or debris (Figure 3D). These 
results suggest that macrophages are recruited to the engrafted tumor throughout and that these cells 
continuously interact with one another during the timespan of our experiments.   
 
   
Figure 3 Macrophages accumulate at the primary tumor site. Representative confocal images from the injection 
site of 2% PVP, ZMEL1 and SK-MEL28 injected embryos at 1hpi, 1dpi and 4dpi, obtained with a 40x magnification. 
Macrophages are labelled with lifeact:GFP and melanoma cells with dTomato (A). Quantification of the area of the 
ZMEL1 and SK-MEL28 primary tumor. The tumor area represents the z-stacked 2D area of each tumor. Each data 
point represents the average area at that time point. The error bars represent the ± SD. Non-parametric unpaired 
t-test was performed between each group (B). Quantification of the number of macrophages in the field of view 
(FOV) of the 2% PVP, ZMEL1 and SK-MEL28 injection site. An object larger than 10.000 voxels within the field of 
view (FOV) of the injection site was identified as a macrophage. Each point represents an average of 10 observations 
(n=10) and the error bars correspond to the mean ± SD. Non-parametric unpaired t-test was performed between 
each group. The number of macrophages gradually increased at the tumor site (3C). The characteristic morphology 
of macrophages at 4dpi under different circumstances was imaged. The macrophages outside tumor were more 
elongated, directional comparing to rounded macrophages inside the tumor. The white arrows mark macrophages 








Metronidazol (MTZ) effectively depletes macrophages in Tg(mpeg:GAL4:UAS:NTR:mCherry) embryos 
To study the functional significance of macrophages during melanoma development, we utilized the 
NTR/MTZ ablation system to deplete macrophages [33,34].  Embryos from 2dpf until 8dpf were 
exposed to various concentrations of MTZ to optimize the efficiency of the macrophage’s ablation 
without sign of toxicity. We observed that all MTZ concentrations successfully depleted macrophages 
in embryos from 3dpf until the termination of the experiment at 8dpf (Figure 4A). Furthermore, 
treatment with 2.5mM, 5mM and 7.5mM MTZ had no effect on the survival of embryos. Embryos 
treated with 10mM MTZ showed enhanced lethality, indicating that MTZ is toxic at higher 
concentrations (Figure 4B). Increasing the concentration affected the development of the embryos, as 
embryos treated with a higher concentration were significantly shorter (Figure 4C). Based on these 
findings, a concentration of 2.5mM MTZ was used throughout this study to successfully deplete 
macrophages.  
 
Figure 4 Efficiency and toxicity of NTR/MTZ Ablation System. We treated Tg(mpeg:NTR:mCherry) embryos with MTZ 
at 2dpf to deplete macrophages. Representative images of the macrophage population of untreated and 2.5mM 
MTZ treated embryos at 3dpf. Macrophages are labeled in mCherry (A). The macrophage area and survival rate of 
various treatments, including 2.5mM, 5mM, 7.5mM and 10mM were quantified. MTZ successfully depletes 
macrophages and is lethal at a concentration of 10mM (B). The effect of different MTZ concentrations on the length 
of the embryos. Increasing the concentration negatively correlated with the embryo length (C).  
 
B16.F10 ells rely on macrophages for tumor angiogenesis  
As macrophages are known to be crucial in angiogenesis, we asked whether macrophage depletion 
indirectly inhibits primary tumor growth through impairing neo-angiogenesis. To investigate the effect 
of macrophage ablation on vascularization induction by each engrafted cell line, we imaged the primary 
tumor and their vascular network at various time points in Tg(kdlr:GFP/mpeg:NTR:mCherry) embryos 
in the presence and absence of macrophages. After injection in the DOC, ZMEL1 and B16.F10 formed 
solid tumors at 6dpi. In line with previous data, SK-MEL28 cells formed no solid tumor, but invaded the 
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tissue where blood vessels were already located (Figure 5A). The neo-angiogenesis was quantified by 
calculating the percentage of embryos with a positive phenotype, which is characterized by having a 
solid primary tumor with a neo-vascular network. All SK-MEL28 injected embryos had a negative 
phenotype, as SK-MEL28 cells were unable to form a solid primary tumor. At 3dpi, all B16.F10 primary 
tumors induced neo-vascularization, whereas only 40% of ZMEL1 injected embryos had a positive 
phenotype. At 6dpi, B16.F10 had a higher percentage of neo-vascularized tumors compared to ZMEL1. 
We observed that macrophage ablation by MTZ severely lowered the percentage of neo-vascularized 
B16.F10 tumors at both timepoints. However, the percentage of positive phenotype of ZMEL1 injected 
embryos was not affected by macrophage depletion (Figure 5B). This data implies that B16.F10 
angiogenesis is macrophage dependent, while ZMEL1 cells initiate angiogenesis in the absence of 
macrophages (Figure 5B-D).   
 
Figure 5 B16.F10 primary tumor relies on macrophages for neo-vascularization. The angiogenesis of the primary 
tumor was visualized to investigate the effect of macrophage depletion on the vascular network. Representative 





The control group, kdlr:GFP, represents the vascular network in the absence of melanoma engraftment (A). The 
percentage of embryos with a solid primary tumor with a neo-vascular network. B16.F10 had the highest 
angiogenic activity. SK-MEL28 did not form a solid tumor, but invaded the surrounding tissue and nearby blood 
vessels. ZMEL1 neo-angiogenesis was not affected by macrophages depletion, whereas ablation of macrophages 
did inhibit neo-angiogenesis in B16.F10 primary tumors (B). Unfortunately, in the images depicted in B we are not 
able to distinguish macrophages from cancer cells as there were both labelled with red fluorescent marker, 
therefore we additionally conducted three colour experiments to confirm these results, using B16 iRFP670 cells 
expressing far- red fluorescence (C). The analysis was done by normalizing the blood vessel fluorescent intensity 
by tumor size at 2 dpi (D). 
 
Angiogenic activity of B16.F10 is macrophage dependent 
To further prove that B16.F10 induced angiogenesis is macrophage dependent, we performed another 
in vivo angiogenesis assay, which is used to measure the angiogenic activity of tumor cells in 18hpi [31]. 
In this assay, the growth of the blood vessels from the sub-intestinal vein plexus (SIV) is analyzed in the 
presence of tumor cells. Angiogenic cells are able to induce sprouting or remodel the SIV complex [31]. 
ZMEL1, SK-MEL28 and B16.F10 cells were injected in the perivitelline space of 48hpf 
Tg(kdlr:GFP/mpeg:NTR:mCherry) and macrophage-depleted embryos. Growth of the blood vessels 
from the sub-intestinal vein (SIV) was imaged at 1 dpi (Figure 6A). The percentage of positive SIV 
phenotypes, which is characterized by tumor induced sprouting or complete remodeling of the 
complex, was calculated for each cell line. B16.F10 had the highest percentage of positive phenotypes, 
followed by SK-MEL28 and thereafter ZMEL1. Injection of 2% PVP induced no sprouting. The number of 
positive phenotypes induced by B16.F10 cells was severely decreased in macrophage depleted embryos 
(Figure 6B, 6C). The elongation of the SIV was quantified by dividing the length of the SIV by the width 
of the SIV. This parameter gives information about the attraction and sprouting of the SIV, as both 
increase the length of the SIV. B16.F10 significantly enhanced elongation of the SIV complex, whereas 
ZMEL1 and SK-MEL28 did not. Macrophage ablation significantly reduced the B16.F10 induced 
elongated phenotype of the SIV complex (Figure 6D). Additionally, we found that macrophage depletion 
overall inhibited the formation of the SIV complex, implying that macrophages are essential in the 
establishment of this complex (Figure 6E). In conclusion, these results suggest that B16.F10 has the 




Figure 6 Macrophage ablation inhibits tumor-induced angiogenesis. An angiogenesis assay was performed to study 
the angiogenic activity of tumor cells. Tumor cells were injected in the perivitelline space of two-days old 
Tg(kdlr:GFP/mpeg:NTR:mCherry) embryos. 2% PVP was injected as a negative control. The SIV complex was imaged 
between 24-30hpi (A). Representative images of each injection and treatment groups. Blood vessels are labelled 
with GFP, macrophages and tumor cells lines with mCherry and dTomato therefore in these images we are not 
able to distinguish macrophages from cancer cells as there both are labelled with red fluorescent markers (B). The 
percentage of embryos with a positive phenotype, which is characterized by either attraction of the SIV or the 
formation of sprouts (C). Quantification angiogenic capability of tumor cells with (- MTZ) and without macrophages 
(+ MTZ). The elongation of the SIV complex was calculated by dividing the length by the width of the SIV complex. 
B16.F10, not ZMEL1 and SK-MEL28, induced elongation of the SIV complex towards the tumor, which was partly 
rescued through macrophage depletion (D). The total length of the SIV complex represents the total pixels of the 
skeletonized SIV complex. The error bars represent the standard error of each group (n=10). Macrophage depletion 








Lactic acid secreted by B16.F10 melanoma cells recruit macrophages to drive angiogenesis 
To address why macrophages are attracted to the tumor induced by engraftment of high glycolytic 
B16.F10 cells, we tested if lactic acid, product of glycolysis can attract macrophages in zebrafish model 
[35]. The lactic acid (10 µM) was injected into the zebrafish hindbrain at 2 dpf, which is free of 
macrophages at this developmental stage (Figure 7A). As positive control we used human cytokine 
hCCL2, as well known chemoattractant of macrophages in zebrafish [36]. To estimate macrophages 
response to the local inflammation generated by wound we injected PVP solvent and compared to un 
injected control (Figure 7B).  At 3hpi, the number of macrophages inside hindbrain was imaged and 
quantified (Figure 7B). Injection of hCC2 and lactic acid significantly increased number of accumulated 
macrophages in the hindbrain comparing to number of macrophages in the same area of control and 
PVP injected embryos (Figure 7C). In order to verify if lactic acid is secreted by tumor cells to attract 
macrophages, B16.F10 cells were pre-treated with glycolysis inhibitor 2-deoxyglucose (2DG). The 24h 
treatment of cells with 10 mM 2DG sufficiently inhibited lactic acid secretion, without influencing cell 
proliferation and cellular ATP production (Figure 7D). After 24h of 10 mM 2DG treatment, around 300 
far-red B16 cells were injected into DOC of 2 dpf embryos. Tumor size, macrophages infiltration, and 
blood vessels density inside tumor were analyzed at 2 dpi. The relative tumor area in 2DG group was 
not statistically reduced comparing to control group (Figure 7F). The fluorescence of macrophages and 
blood vessels was normalized by fluorescent tumor area in corresponding embryos and reveled that 
2DG treatment impaired the macrophages accumulation and blood vessel intensity (Figure 7F) 
suggesting that indeed lactic acid secreted by B16.F10 cells contributes to macrophages accumulation 




Figure 9 Lactic acid inhibition by 2DG in B16 tumor cells impairs macrophages accumulation and tumor 
angiogenesis formation. The macrophages attraction assay was performed here. 1 nL of lactic acid (10 µM), 2% 
PVP and hCCL2 (negative and positive controls) were injected into hindbrain of zebrafish at 2 dpf (A). After 3h, 
the images of macrophages in the hindbrain were taken by fluorescent microscope (B). The number of 
macrophages was calculated (C). B16 cells were treated with 2DG (0.1, 2, 3.16, 10 mM) for 24 h. After treatment, 
the cell proliferation, cellular ATP per 10000 cells and lactate per well were measured (D). Around 300 B16 cells 
treated with 10 mM 2DG for 24 h were injected into Duct of Cuvier of 2dpf embryos. After 2 dpi, the fluorescent 
images were taken (E) and relative tumor area, normalized macrophages infiltration and normalized blood vessel 




The malignancy of melanoma is often linked to increased angiogenesis and a high number of 
infiltrating TAMs [22,23]. Currently, many studies are aimed to understand the interplay between 
TAMs, melanoma and endothelial cells. However, the majority of these studies are conducted in vitro 
or in vivo using mouse models, which require complicated and invasive procedures to visualize 
dynamic interactions between tumor cells and their microenvironment. In contrast, the zebrafish 
xenograft model is a powerful platform to investigate dynamic cellular interactions within the tumor 
microenvironment, due to its transparency [25]. Injecting fluorescently labeled tumor cells into 
transgenic embryos with mCherry labeled macrophages allows us to study their interactions and 
behavior. In this work, we elucidated the functional significance of macrophages in primary tumor 





growth by promoting neo-angiogenesis. Thus, we put forth a model which serves as the foundation 
for further research aimed to discover the exact molecular mechanism by which macrophages 
enhance neo-angiogenesis in melanoma, and thereby contribute to its malignancy.  
Initially, we asked if macrophages interact and respond to engrafted tumor cells. Through time lapse 
imaging and confocal analysis of the primary tumor, we found no differences between the first 
response of macrophages to 2%PVP and tumor injections. Within six hours, we observed a gradual 
decrease of macrophages surrounding the 2% PVP injection site, which suggests that resolution of 
inflammation occurred after the wound was repaired. Inflammatory responses associated with wound 
healing and tumors are remarkably similar. Tumors have been found to behave as wounds that do not 
heal, in order to establish a favorable microenvironment [37]. Accordingly, in the presence of 
melanoma cells, no resolution phase was observed. Additionally, macrophages continued to 
accumulate at the primary tumor until four days after injection. These results suggest that the 
engrafted melanoma cells continuously induce an inflammatory response, thereby recruiting 
macrophages. This response was not simply due to cross-species immune recognition, as we observed 
similar inflammatory responses towards allografted zebrafish ZMEL1 and xenografted human SK-
MEL28 cells. The tumor fluorescent signals in macrophages suggest that these immune cells 
phagocytose components of the tumor. These components could be from alive tumor cells or from 
debris from dead tumor cells, as a result of phagocytosis. To further evaluate the function of 
macrophages during primary tumor growth, we depleted the entire macrophage population in 
embryos by utilizing the MTZ/NTR ablation system [33,34]. 
 
By comparing the growth kinetics of various melanoma cell lines in normal and macrophage depleted 
embryos, we found that macrophages promoted murine B16.F10 primary tumor growth, while 
inhibiting this process in ZMEL1 and SK-MEL28 tumors. We do not ignore the fact that macrophages 
could perform an anti-tumoral role during B16.F10 development at 6dpi. Hence, this could explain the 
marginal effect of macrophage depletion, as both the positive and negative functions of macrophages 
are abolished. The origin of each cell line was studied to find an explanation for the cell line 
dependent effect of macrophage depletion. The ZMEL1 cell line was obtained by Heilman S. et al. by 
harvesting in situ melanoma from transgenic mitfa-BRAFV600E; p53-/- zebrafish [38]. ZMEL1 cells are 
known to take advantage of the growth-promoting effect of the embryonic microenvironment, since 
these cells and the recipient are of the same species [28,39]. The xenografted cell line, SK-MEL28, was 
isolated from an axillary lymph node of a patient [40]. Involvement of the lymph nodes suggest that 
this melanoma has advanced to Stage III, implying that this cell line is highly malignant [41]. B16 cells 
were harvested from a tumor which developed naturally surrounding the ear of a C57BL/6 mouse. In 
this study we used the highly metastatic and aggressive variant B16.F10, which has classically been 
described as a non- or low-immunogenic tumor cell line [42]. No correlations were drawn between 
the origin of the cell line, its stage and the response to macrophage depletion, as we found that the in 
situ melanoma ZMEL1 and the highly malignant melanoma SK-MEL28 both progressed better in the 
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absence of macrophages, while a similar malignant melanoma B16.F10 showed impaired growth 
under the same circumstances. These results imply that only xenografted B16.F10 tumors profit from 
macrophages during development. Considering that B16.F10 is a low-immunogenic cell line, we 
decided not to focus on the immunosuppressive function of macrophages, but on their ability to 
promote angiogenesis.    
 
To assess the importance of macrophages in tumor-induced angiogenesis, we firstly proved that 
ZMEL1 and B16.F10 cells were able to form a solid tumor with neo-vascularization. Macrophage 
depletion severely impaired the neo-vascularization of the B16.F10 tumor. In previous research, it 
was found that the presence of pro-inflammatory macrophages leads to a significant increase in the 
amount and complexity of blood vessels. Pro-inflammatory macrophages, which can act as a local 
source of VEGF, are often associated with the vessel tips, thereby inducing vessel sprouting. Another 
mechanism by which macrophages support angiogenesis is through dislodging neutrophils from the 
vessel tips. Neutrophils were found to exhibit inhibitory angiogenic influences, and therefore require 
dislodging to promote angiogenesis [43]. Possibly, due to macrophage ablation, the angiogenetic 
switch of the B16.F10 tumor is tilted towards an anti-angiogenic outcome, resulting in severely 
impaired tumor vascularization, which in turn inhibited tumor growth [44]. In contrast, ZMEL1 neo-
angiogenesis was not affected by macrophage depletion. The ability of ZMEL1 to produce zebrafish 
VEGFA could explain why this tumor is capable of inducing angiogenesis in the absence of 
macrophages. Possibly, ZMEL1 tumors rely on their own production of VEGFA to tilt the angiogenic 
switch to a pro-angiogenic outcome. To strengthen this hypothesis, we assessed the ability of tumor 
cells to induce sprouting or attract blood vessels from the SIV. Consistent with our previous findings, 
B16.F10 showed the highest angiogenic activity. Ablation of macrophages impaired this activity, 
whereas ZMEL1 induced angiogenesis was not affected. These results strongly imply that the 
mechanism behind vascularization varies between each cell line. However, we found that cell lines 
which rely on macrophages for angiogenesis, also showed impaired growth in the absence of 
macrophages at 6dpi. 
 
In the end, we used zebrafish macrophages attraction assays to prove that lactic acid function as 
chemoattractant to recruit macrophages comparing to well-known cytokine, hCCL2. After chemical 
inhibition of glycolysis hence lactic acid secretion, less macrophages were attracted to the tumor site 
and tumor angiogenesis was impaired. Surprisingly the tumor burden at 2dpi was not significantly 
influenced by 2DG treatment presumably due to a short duration of the experiment. In future, genetic 
interference approach is required to further prove that angiogenesis induction by high glycolytic cells 
is indeed control by lactic acid dependent macrophages attraction.   
 
In summary, our findings demonstrate that macrophages can promote melanoma growth by inducing 





by which melanoma cell lines induce and rely on angiogenesis, but that this is cell line specific. We 
found that the growth of melanoma, which is able to induce angiogenesis in the absence of 
macrophages, was not promoted by macrophages. Similarly, macrophages did not promote growth of 
melanoma which did not induce neo-angiogenesis. Importantly, we found that macrophages are 
attracted by lactic acid to promote tumor angiogenesis in B16.F10 cells. 
In conclusion, this study has aided in the understanding of the interactions between macrophages and 
melanoma cells, and serves as a foundation for further research aimed to discover the exact 
mechanism by which macrophages induce neo-angiogenesis in melanoma with high glycolytic index. 
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The ruthenium-based photosensitizer (PS) TLD1433 has completed a phase I clinical trial for 
photodynamic therapy (PDT) treatment of bladder cancer. Here, we investigated a possible repurposing 
of this drug for treatment of conjunctival melanoma (CM). CM is a rare but often deadly ocular cancer. 
The efficacy of TLD1433 was tested on several cell lines from CM (CRMM1, CRMM2 and CM2005), Uveal 
Melanoma (OMM1, OMM2.5, MEL270), epidermoid carcinoma (A431) and cutaneous melanoma 
(A375). Using 15 minutes green light irradiation (21 mW/cm2, 19 J.cm-2, 520 nm), the highest 
phototherapeutic index (PI) was reached in CM cells, with cell death occurring via apoptosis and 
necrosis. The therapeutic potential of TLD1433 was hence further validated in zebrafish ectopic and 
newly-developed orthotopic CM models. Fluorescent CRMM1 and CRMM2 cells were injected into the 
circulation of zebrafish (ectopic model) or behind the eye (orthotopic model) and 24 hours later, the 
engrafted embryos were treated with the maximally-tolerated dose of TLD1433. The drug was 
administrated in three ways, either by i) incubating the fish in drug-containing water (WA), or ii) injecting 
the drug intravenously into the fish (IV), or iii) injecting the drug retro-orbitally (RO) into the fish. 
Optimally, four consecutive PDT treatments were performed on engrafted embryos using 60 min drug-
to-light intervals and 90 min green light irradiation (21 mW/cm2, 19 J.cm-2, 520 nm). This PDT protocol 
was not toxic to the fish. In the ectopic tumour model, both systemic administration by IV injection and 
RO injection of TLD1433 significantly inhibited growth of engrafted CRMM1 and CRMM2 cells. However, 
in the orthotopic model, tumour growth was only attenuated by localized RO injection of TLD1433. 
These data unequivocally prove that the zebrafish provides a fast vertebrate cancer model that can be 
used to test the administration regimen, host toxicity and anti-cancer efficacy of PDT drugs against CM. 
Based on our results, we suggest repurposing of TLD1433 for treatment of incurable CM and further 




Conjunctival melanoma (CM) is a rare but often deadly ocular disease that arises from mutated 
melanocytes, the melanin-producing cells in the conjunctiva [45]. Despite its rare occurrence, 
conjunctival melanoma is increasing [46]. Current treatment for CM is surgery combined with 
cryotherapy, brachytherapy, and/or topical chemotherapy. However, efficient treatment for this disease 
has not yet been developed and the side-effects caused by present treatments are severe [47]. 
Furthermore, lymph node metastases often develop in spite of a seemingly effective treatment of the 
local tumor, and may lead to further spreading [48-50]. Mutations in BRAF and NRAS genes lead to 
constitutive activation of the MAPK/ERK signalling pathway, which promotes CM proliferation and 
survival [50-53].  
 
New treatments for CM are being actively looked for, for example by knocking down the over-expressed 





drug testing [55], and by CM-specific gene discovery for targeted therapy [56]. However, cross-talk 
between different signalling pathways makes specific gene targeting approaches quite challenging 
[57,58]. In addition, cancer cells proliferate and mutate under single-treatment, often creating 
resistance against the common cancer drugs or gene-targeting therapies. Considering the superficial 
growth of CM and the widespread use of laser technology for curing eye diseases, photodynamic 
therapy (PDT), i.e. tumour ablation through visible light irradiation of a PS located inside the tumour 
[59-62], offers an interesting opportunity. 
 
PDT is used for a wide range of dermatological conditions, and for Barrett’s esophagus, bladder and 
prostate cancer [63]. Compared to surgery, PDT is less invasive, as tumour eradication can be obtained 
without creating a wound. PDT uses a PS molecule as a prodrug that under light irradiation generates 
an intense blast of reactive oxygen species (ROS) such as superoxides (O2−), hydroxyl radicals (HO−), 
and/or singlet oxygen 1O2, which eventually cause cytotoxic damage to biomolecules adjacent to the PS. 
ROS generation inside a malignant tissue may directly destroy cancer cells via ROS-induced cell death, 
as demonstrated with 5-aminolevulinic acid (5-ALA)-derived protoporphyrin IX (PpIX) [64]. However, 
indirect anti-tumour effects can also occur via ROS-induced damage to the tumour vasculature, as seen 
with TOOKAD®, mTHPC, or Photofrin® [65-69]. Besides tetrapyrole compounds and their precursors (5-
ALA), the metal-based PDT PS, in particular those containing ruthenium(II) (Ru), show a high potential 
for generating intracellular ROS [70]. These PS absorb in the visible region of the spectrum, which is 
critical for in vivo activation [71], and suffer less from photobleaching compared to many tetrapyrole 
compounds [72,73].  
 
Recently, the McFarland and Lilge research groups have actively developed TLD1433 (Figure 1, left), a 
Ru-based PS. A phase Ib clinical trial for intravesical PDT treatment of non-muscle invasive bladder 
tumours using this PS was successfully completed in 2018, [66,73] and a much larger Phase 2 study is 
underway. The compound has a low cytotoxicity in the dark and an exceptionally high phototoxicity with 
light activation when tested on a wide range of human cancer cells [73]. Its activation in cells is optimal 
in the green domain of the spectrum (520 nm), and although the mechanism of cell death by light-
activated TLD1433 is not completely clear, this PS generates 1O2 with near-to-unity quantum efficacy 
[66]. The outstanding type-II PDT properties of this compound involve initial population of metal-to-
ligand charge transfer excited states, which, after intersystem crossing, lead to triplet intra-ligand (3IL) 
or intra-ligand charge-transfer excited states (3ILCT, Figure 1, right) that are very sensitive to oxygen and 
other excited state quenchers. These remarkable results led us to investigate a possible repurposing of 
TLD1433 for the PDT treatment of conjunctival melanoma (CM). We analysed the in vitro and in vivo 
efficacy of this compound in different CM cells lines and zebrafish embryonic xenograft CM models using 






Figure 1 a) Chemical structure of the PDT photosynthesizer TLD1433. b) Jablonski diagram showing the formation 
of singlet oxygen (1O2) by irradiation of TLD1433 via initial population of metal-to-ligand charge transfer (MLCT) 
states and intersystem crossing to intra-ligand (IL, ILCT) states.  
 
Zebrafish (Danio rerio) are indeed increasingly used as an in vivo model to study cancer [74]. Benefits 
include large clutch size, ex utero development and easy manipulability of larvae [75]. Because there is 
high conservation of genes between zebrafish (ZF) and human, data collected in ZF are relevant for 
humans [76]. Notably, the histology of ZF tumours has been shown to be highly similar to tumours found 
in human cancers [77]. The adaptive immune system in ZF does not reach maturity until 4 weeks post-
fertilization, allowing circumvention of cell graft-host rejection by using ZF in early stages [78]. ZF larvae 
can absorb various small molecular weight compounds from the water they swim in, which is 
advantageous when screening for anti-cancer compounds. When assessing drug efficacy, ZF 
experiments require much less material than mouse models [79]. Routinely 1 mL (1 nM to 20 µM) of 
drug solution is enough for testing drug efficacy in 6 individual ZF embryos. Alternatively, (pro)drugs can 
also be injected in the animal in nL quantities, which further minimizes the amount of compound 
required for testing. Importantly, the use of transgenic lines with fluorescent vasculature, neutrophil 
granulocytes or macrophages, allows live, non-invasive imaging of proliferation, migration and tumour-
associated neo-angiogenesis, and interaction with the microenvironment at the single cell resolution in 
the entire organism within 1 week [80,81]. For PDT, the transparency of the animals allows for activating 
a PS in the entire organism by simple light irradiation. Overall, these combined advantages account for 
the increased experimental use of zebrafish cancer models in drug discovery during the last two decades 
[82,83].  
 
For cutaneous melanoma, a current phase I/II clinical trial of leflunomide combined with vemurafenib 
is the first to arise from initial screens in zebrafish [84]. Many ZF xenograft models have been established, 
and the choice of the best ZF model depends on the type of disease, but also on the type of treatment. 
Human tumour cells can be injected for example into the yolk sac [85], the Duct of Cuvier [30], the 
pericardial cavity [86], the perivitelline space [87], the swimming bladder [88], or the hindbrain [89]. 





PDT treatment strategy to combat CM growth. We hence developed a new orthotopic model for CM by 
RO injection of CM cells, mimicking primary tumour spread. We also investigated a previously-
developed ectopic model, generated by intravenous cell injection: circulating cancer cells usually form 
tumour lesions in the tail of the embryo [30,55]. Using three different treatment modalities of TLD1433 
in two different tumour models, we established a testing platform in which the anti-tumour efficacy of 
this PS can be observed. 
 
Materials and methods 
 
Photosensitizers 
For in vitro studies, TLD1433 was firstly diluted to 2 mM in autoclaved PBS and further diluted in media 
as required. For the in vivo studies, TLD1433 was directly diluted to autoclaved 2%PVP as required. 
 
Culturing Cell lines 
Human conjunctival malignant melanoma cell lines CRMM1 and CRMM2, isolated by Nareyeck et al [90], 
were cultured in F12 Kaighn’s modified medium (Hyclone, cat# SH30526.01) supplemented with 10% 
fetal bovine serum (FBS; Gibco, location). CM2005.1 established by Keijser et al [91] was cultured in 
RPMI 1640, Dutch Modified (Life Technologies, cat# 22409-015), supplemented with 10% fetal bovine 
serum (FBS; Gibco), 3 mM L-glutamine (1%, Life Technologies cat# 35050-038). Human uveal melanoma 
cell lines OMM1 (provided by Prof. Dr. G.P.M Luyten) [92], OMM2.5, MEL270 (provided by Dr. B.R. 
Ksander BR) [93] ) were cultured in Ham’s F12 medium (Sigma-Aldrich, cat# N3790) supplemented with 
10% FCS. Stable fluorescent CRMM1 and CRMM2 cell lines were generated using lentivirus expressing 
both tandem dimer (td)Tomato and Blasticidin-S, as previously described [94]. Human cancer cell lines 
A431 and A375 were distributed by the European Collection of Cell Cultures (ECACC), and purchased 
through Sigma Aldrich (Zwijndrecht). A375 and A431 cells were thawed and at least passaged twice 
before starting cytotoxicity and uptake experiments. A375 and A431 cells were cultured in Dulbecco’s 
Modified Eagle Medium with phenol red, supplemented with 10.0% v/v FCS, 0.2% v/v 
penicillin/streptomycin (P/S), and 0.9% v/v Glutamine-S (GM). Cells were cultured in either 25 cm2 or 75 
cm2 flasks and split at 70-80% confluence. The flasks were incubated in a normoxic incubator at 37 °C 
at 5.0% CO2 in a PHCbi O2/CO2 incubator, MCO-170M). The medium was refreshed twice a week. Cells 
used in all biological experiments were cultured for not more than eight weeks. Dulbecco’s Minimal 
Essential Medium (DMEM, high glucose, without glutamine), 200 mM Glutamine-S (GM), trichloroacetic 
acid (TCA), glacial acetic acid, sulforhodamine B (SRB), tris (hydroxylmethyl) aminomethane (tris base), 
and cis-diamineplatinum (II) dichloride (cisplatin) were purchased from Sigma Aldrich. (2R,3R,4R,5R)-
hexan-1,2,3,4,5,6-hexol (D-mannitol) was purchased from Santa Cruz Biotechnology via Bio-Connect. 
FCS was purchased from Hyclone. Penicillin and streptomycin were purchased from Duchefa and were 
diluted to a 100 mg/mL penicillin/streptomycin solution (P/S). Trypsin and Opti-MEM® (without phenol 
red) were purchased from Gibco® Life Technologies. Trypan blue (0.4% in 0.81% sodium chloride and 
48 
 
0.06% potassium phosphate dibasic solution) was purchased from Bio-Rad. Plastic disposable flasks and 
96-well plates were obtained from Sarstedt. Cells were counted using a Bio-Rad TC10 automated cell 
counter with Bio-Rad Cell Counting Slides. 
 
Cytotoxicity (SRB) assay 
At day 0, cells were detached using 1mL of trypsin, resuspended in 4 mL of media and transferred to a 
15 mL corning falcon tube. Cells were counted using trypan blue and BioRad® TC20™ automated cell 
counter (Figure 11). Dilutions of 6000 (CRMM1), 6000 (CRMM2), 8000 (CM2005.1), 6000 (OMM1), 6000 
(OMM2.5), 6000 (MEL270) 8000 (A431), and 4000 (A375) cells/well were calculated from each cell 
suspension at a final volume of 6 mL using the following formula: 
𝑉𝑐 = (𝑉𝑡 x 10𝐶)/𝐿𝑐 
Vc = volume of cell suspension to be diluted (mL) 
Vt = total volume of solution 
C = number of cells per well/per 100µL 
Lc = live cell count (cells/mL) 
 
The cell suspensions were transferred to a 50 mL reservoir and 100 µl of each cell line was seeded at 
the aforementioned cell densities in triplicate in six 96-well plates. Boarder wells were intentionally 
filled with PBS media to avoid boarder effects. After 24 h, the cells were treated with TLD1433 with six 
different concentrations ranging from 0.025 µM to 3.0 µM, followed by incubation in a normoxic 
incubator. After 24 h of post treatment the cells were exposed to the green light for 15 min (520 nm, 21 
mW/cm2, 19J/cm2). The dark control plate was kept under dark conditions. Cisplatin was used as a 
positive control in all cell types. Then cells were incubated for another 48 h before fixing them with 
trichloroacetic acid (10% w/w) solution. The fixed cells were kept at 4℃ for 48hrs, when TCA was 
washed out with distilled water before adding the sulphorhodamin B (SRB) (0.6 % SRB) dye. The SRB 
dye was washed out after 30 minutes and plates were air dried for overnight. Next day, the dye was 
dissolved using Tri-base (0.25%) and absorbance of SRB at 510 nm was recorded from each well using a 
Tecan plate reader. The SRB absorbance data was used to calculate the fraction of viable cells in each 
well (Excel and GraphPad Prism software). The absorbance data were averaged from triplicate wells per 
concentration. Relative cell viabilities were calculated by dividing the average absorbance of the treated 
wells by the average absorbance of the untreated wells. Three independent biological replicates were 
completed for each cell line (three different passage numbers per cell line). The average cell viability of 
the three biological replicates was plotted versus log(concentration) [μM], with the SD error of each 
point. By using the dose–response curve for each cell line under dark- and irradiated conditions, the 
effective concentration (EC50) was calculated by fitting the curves to a non-linear regression function 
with a fixed maximum (100 %) and minimum (0 %) (relative cell viability) and a variable Hill slope, which 






 Figure 2 Time line for the SRB assay. 
 
Cell irradiation setup 
The cell irradiation system consisted of a Ditabis thermostat (980923001) fitted with two flat-bottomed 
microplate thermoblocks (800010600) and a 96-LED array fitted to a standard 96-well plate. The λ=520 
nm LED (OVL3324), fans (40 mm, 24 V DC, 9714839), and power supply (EA PS 2042-06B) were obtained 
from Farnell as reported in our previous publication [95]. 
 
Flow Cytometry 
CRMM1 (10000/well) and CRMM2 (10000/well) cells were seeded into an 8-well chamber in Opti-
MEMTM (Gibco, Reduced Serum Medium, no phenol red) with 2.5% FBS (Gibco). After 24 h incubation, 
TLD1433 (0.0059 uM for CRMM1, 0.0048 uM for CRMM2) was added into the medium. 24h later, wells 
were washed and new drug-free medium was added. The cells were exposed to green light (520 nm, 21 
mW/cm2, 19 J/cm2) for 15 min and incubated for 48h. Medium of all wells was collected and wells were 
washed with PBS and lysed by 500 µl trypsin for 3 min. Collected medium was added to the wells with 
lysed cells, mixed and centrifuged for 2000 rpm, 3min. After washing, cells were resuspended in 200 µ 
of 1X binding buffer. Next, 5 µl of Annexin-V-FITC and 5 µl of Propidium Iodide was added to each well 
and incubated for 15 min at room temperature. 200µl of sample was added to 96-well plate, and used 
for FACS measurement. 
 
Zebrafish maintenance, tumour cells implantation and tumour analysis 
The Zebrafish (ZF) Tg(fli1: GFP/Casper) [80] were handled in compliance with local animal welfare 
regulations and maintained according to standard protocols (www.ZFIN.org). 
 
For cancer cell injection, two days post-fertilization (dpf), dechorionated zebrafish embryos were 
anaesthetized with 0.003% tricaine (Sigma) and plated on a 10cm Petri dish covered with 1.5% of 
solidified agarose. CRMM1 and CRMM2 cells were suspended in PBS containing 2% polyvinylpyrrolidone 
(PVP; Sigma-Aldrich) with a concentration of 50,000 cells/ul and loaded into borosilicate glass capillary 
needles (1 mm O.D. × 0.78 mm I.D.; Harvard Apparatus). In the ectopic model, 200 (td)Tomato 
fluorescent CM cells were injected into the Duct of Cuvier or at 2 dpf, which led to dissemination through 
the blood circulation and outgrowth in the head and tail. In orthotopic tumour model, 100 (td)Tomato 
fluorescent CRMM1 or CRMM2 cells were injected RO in 2 dpf embryos using a Pneumatic Picopump 
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acquired at 1-, 2-, 4- and 6-days post injection (dpi) with a Leica M165 FC stereo fluorescence 
microscope. Tumor growth was quantified by calculating the total fluorescence intensity and area with 
the ZF4 pixel counting program (Leiden). Each experiment was performed at least 3 times with a group 
size of >30 embryos.  
 
Light Toxicity assay for zebrafish embryos 
2 dpf embryos were transferred into 6-well plates (10 embryos/well). The embryos were exposed to 
green light (520 nm, 9.82 J.cm-2) for 0, 3, 6, 12 h. After irradiation, images were taken using a DFC420C 
camera coupled to a Leica MZ16FA fluorescence microscope. 
 
Maximum tolerated dose (MTD) for wild type zebrafish and tumour cells injected zebrafish 
For determining the MTD of the WA of the TLD1433 solution in wild type zebrafish, solutions of 2.3 nM, 
4.6 nM, 9.2 nM, 11.5 nM, 23 nM were made before the experiment. At 2.5, 3.5, 4.5, 5.5 dpf, TLD1433 
was added to the fish water and maintained for 12 h. At 3, 4, 5, 6 dpf, the fish water was refreshed and 
after 1 h, embryos were exposed to the green light for 90 min (520 nm, 21 mW/cm2, 19J/cm2). For the 
IV and RO administration, TLD1433 solution (1.15 mM, 2.3 mM, 4.6 mM, 9.2 mM, 11.5 mM) was made 
before the experiment. At 3, 4, 5, 6 dpf, 1nl of TLD1433 was injected via the dorsal vein or the RO site 
and maintained for 1 h. Embryos were exposed to the green light for 90 min (520 nm, 21 mW/cm2, 
19J/cm2). The images of treated and wild type embryos at 6dpf were taken using a DFC420C camera 
coupled to a Leica MZ16FA fluorescence microscope. In order to determine the The MTD of tumour cell 
bearing zebrafish, was performed according to the same procedure, after TLD1433 was delivered by WA, 
IV and RA administration as described above for the wild type embryos. 
 
TUNEL assay 
The zebrafish larvae were fixed overnight with 4% PFA at 4 C̊. Embryos were washed in PBST for five 
minutes and dehydrated by a graded methanol series until reaching 100% methanol. Embryos were 
stored at -20 C̊ for further use. Embryos were gradually rehydrated in PBST (25%, 50%, 75%), washed 
twice for 10 minutes with PBST and digested by proteinase K (Roche) solution in PBST (10 µg/mL) at 37 
C̊ for 40 minutes. After two washes in PBST, embryos were post-fixed in 4% PFA for 20 minutes. After 
twice washing in PBST for 10 minutes, 50 µl of TdT reaction mix (Roche) was added to the embryos. 
Embryos were overnight incubated with the TdT at 37 ̊C (in the dark). The reaction was stopped by three 
15 min washes with PBST at room temperature and embryos were used for high-resolution imaging. 
Embryos were placed on glass-bottom petri dishes and covered with 1% low melting agarose containing 
0.003% tricaine (Sigma). Imaging was performed using the Leica SP8 confocal microscope. The images 









Determination of the EC50 concentrations in vitro was based on a non-linear regression analysis 
performed using GraphPad Prism Software. Results are presented as means ± SD from three 
independent experiments. Significant differences were detected by one-way ANOVA followed by 
Dunnett’s multiple comparisons test implemented by Prism 8 (GraphPad Software, La Jolla, CA, USA). A 




TLD1433 is phototoxic in six eye melanoma cell lines 
TLD1433 is known to generate reactive oxygen species (ROS) with high quantum efficacy in many cancer 
cell lines. However, there is no report of the in vitro toxicity of this compound in eye melanoma cell 
lines. We determined the cell viability of three conjunctival melanoma cell lines (CRMM1, CRMM2 and 
CM2005.1), and three uveal melanoma cell lines (OMM1, OMM2.5, MEL270) in the presence of 
TLD1433, both in the dark or under green light irradiation (21 mW/cm2, 19 J/cm2, 520 nm, 15 min), and 
compared this viability to epidermoid carcinoma A431 and cutaneous melanoma A375 cell lines under 
the same conditions. The protocol used was based on previous work from the Bonnet group [96,97], 
and differed slightly from recommendations from McFarland et al [98]. Notably, the cell seeding time 
was 24 h instead of 3 h, and the drug-to-light interval (DLI) was 24 h instead of 16 h. The effective 
concentration (EC50) values, i.e. the concentration required to reduce cell viability by 50% compared to 
untreated wells, were assessed by fitting the dose-response curves with a Hill equation. The 
phototoxicity index (PI), defined as the ratio of the dark EC50 to the light EC50, was also calculated and 
represents the amplification of TLD1433 activity with a light trigger. In control A375 and A431 cells, the 
dark toxicity of TLD1433 was very low, with EC50 values higher than the highest concentration used in 
that assay (5 µM). PIs greater than 100, as previously reported for other cell lines [66], were observed. 
In eye melanoma cells, the dark toxicity of TLD1433 was relatively high, with EC50 values around 1 µM. 
Upon light activation, TLD1433 became significantly more potent (as observed with the A375 and A431 
cell lines), with EC50 values in the nanomolar regime. The lowest EC50 values were measured for CM cells, 
where the PI values were also the highest (>140). Due to the higher PI values for CM cells compared to 
uveal or cutaneous cancer cells, CM cells were chosen for later in vivo experiments (Figure 3, Table1). It 
should be noted that the PIs determined were somewhat lower than those reported for TLD1433 with 
other cell lines (>1000), which could be due either to a preferential toxicity toward uveal and CM 
melanoma lines or a difference in the in vitro PDT protocol used or both. Under the selected conditions, 
the dark toxicity observed for both uveal and CM cell lines was relatively high [73], which reduced the 
maximum PIs that can be obtained. In addition, the slightly lower PI could be due to the low light dose 
that we used, compared to other studies: typically, 100 J.cm-2 has been proposed by McFarland et al 
[98]. Regardless, we chose CM cells for further studies given that TLD1433 had the largest PI and was 




Table 1 Three conjunctival melanoma cell lines, three uveal melanoma cell lines and two control 
cell lines were tested in an SRB cell viability assay, after exposure to TLD1433 with or without 19 
J.cm-2 green light exposure for 15 minutes (21 mW/cm2, 19 J.cm-2). Cell growth inhibition effective 
concentrations (EC50, in µM) and 95% confidence intervals (95% CI, in µM) were obtained. The 
photo index (PI) was calculated as EC50, light divided by EC50, dark. 
 
  CRMM1 CRMM2 CM2005.1 OMM1 OMM2.5 MEL270 A431 A375 
EC50,dark (µM) 0.84 1.0 1.1 1.4 0.64 1.1 >5 >5 
95% CI (µM) 
-0.23 -0.17 -0.22 -0.48 -0.16 -0.092 n.a -0.020 
+0.27 +0.19 +0.25 +0.95 +0.19 +0.097 n.a +0.020 
EC50,light (µM) 0.0059 0.0048 0.0058 0.014 0.013 0.010 0.049 0.050 
95% CI (µM) 
-
0.00099 -0.00050 -0.00061 -0.0016 -0.0011 -0.0012 -0.025 n.a 
+0.0012 +0.00055 +0.00066 +0.0019 +0.0013 +0.0013 n.a n.a 
PI 140 210 190 100 49 110 >102 >100 
 
 
Figure 3 Cell viability after TLD1433 treatment of eight tumour cell lines (CRMM1, CRMM2, CM2005.1, OMM1, 
OMM2.5, MEL270, A431, A375). The green line shows TLD1433 activated by 520 nm light, 21 mW/cm2, 19 J.cm2 
(light-induced toxicity). The dark line shows TLD1433 treatment without light irradiation (dark toxicity). The tumour 
cells were treated with TLD1433 for 24 hours with concentrations ranging from 0.001 µM to 5 µM and kept in the 
dark, or ranging from 0.0001 µM to 0.025 µM and illuminated with a light dose of 21 mW/cm2, 19 J/cm2. SRB assay 
was carried out at 48 hours after light irradiation. The absorbance of Sulforhodamine B in solution was measured 
at 520 nm. Results are presented as means ± SD from three independent experiments with 95% confidence intervals.  
TLD1433 induces apoptosis and necrosis in CRMM1 and CRMM2 cells 
Depending on the nature and intracellular localization of a PS, the light dose, and the cell type, PDT is 
known to provoke either necrosis, apoptosis, or autophagy [99]. In order to investigate the death 
mechanism induced by green light-activated TLD1433 in CRMM1 and CRMM2 cells, the cells were 
stained with Annexin V and Propidium Iodide, and further analysed by fluorescence-activated cell 





the light-activated TLD1433 group, about half of the cells were found dead, either in the late apoptotic 
or necrotic quadrant (Figure 4A, 4B, 4C, 4D), but most importantly, very few early apoptotic cells were 
found. Overall, these results suggest that the CM cells treated with TLD1433 and light did not die via 
apoptosis, but probably by necrosis. 
 
 
Figure 4 Green light irradiation of TLD1433 induces apoptosis and necrosis in CRMM1 and CRMM2 cells. (A) CRMM1 
and (C) CRMM2 were stained with Annexin-V-FITC and Propidium Iodide. The percentages of live, early apoptotic, 
later apoptotic and necrotic cells in CRMM1 (B) and CRMM2 (D) were counted by FACS. Results are presented as 






Light toxicity and the maximum tolerated dose of TLD1433 by water, intra-venous and RO 
administration in zebrafish embryos 
In order to test the effectiveness of TLD1433-induced PDT in zebrafish CM cancer models, we first 
examined the effect of light irradiation on wild type, non-injected embryos. 2 days post fertilization (dpf) 
embryos (30 embryos per group) were exposed continuously to green light (21 mW/cm2, 520 nm) for 0, 
3, 6, and 12 h and cytotoxicity symptoms were monitored by stereomicroscope. Green light irradiation 
for 6h did not induce any toxicity or developmental defects in zebrafish embryos; the percentage of 
mortality, malformation (i.e. bent spine and pericardial edema) and fish length were the same as in the 








Figure 5 Light toxicity in zebrafish embryos. 2 dpf embryos (n=30) were exposed to green light (21 mW/cm2, 520 
nm) for 0, 3, 6, or 12 h. (A) Transmitted light images of the embryos after light irradiation. (B-D) The percentage of 
mortality, malformation and fish length after various time of light exposure. Results represents the means ± SD 





Next, we tried three different regimens of drug administration into zebrafish larvae and determined the 
maximum tolerated dose (MTD) of TLD1433 in dark and after light activation (Figure 6 and Table 2). 
Water administration (WA) of drugs by skin epithelial cell absorption and drinking is commonly used in 
zebrafish drug experiments [79]. Hence, different concentrations of TLD1433 were added into the egg 
water at 2.5, 3.5, 4.5, and 5.5 dpf embryos, followed by 12 h DLI and 90 min green light irradiation (21 
mW/cm2, 112.9 J.cm-2, 520 nm). In addition, we also tested IV of TLD1433 by direct injection into the 
dorsal vein, as well behind the eye injections for RO administration [41]. For IV and RO administration, 
the compound was injected four times into the embryos at 3, 4, 5 and 6dpf, followed by 60 min drug-
to-light interval and the same kinetic and irradiation regime as for the WA administration (Figure 6A). 
Zebrafish embryos tolerated light-activated TLD1433 without any effect on the mortality, malformation 
and fish length at an MTD of 9.2nM when delivered by WA administration and an MTD of 4.6mM when 
delivered by IV and RO administration, respectively (Figure 6 B-D). Considering that in the dark, even 
higher concentrations of TLD1433 (23 nM by WA, 11.5 mM by IV and RO) were not toxic to embryos, 
we conclude that this compound is activated by green light irradiation and very effective at low 







Figure 6 The maximum tolerated dose of TLD1433 in wild type zebrafish embryos administered through three 
different routes. (A) Schedule of TLD1433 treatment in wild type zebrafish. WA: TLD1433 (2.3nM, 4.6 nM, 9.2 nM, 
11.5 nM, 23 nM) were added to the water containing 10 embryos per well at 2.5, 3.5, 4.5, 5.5 dpf, for 12h (yellow 
box). After these treatments, the drug was removed and replaced by egg water followed by 90 min green light 
irradiation (21 mW/cm2, 112.9 J.cm-2, 520 nm), depicted as a green lightning bolt. IV or RO: 1 nl of TLD1433 (1.15 
mM, 2.3 mM, 4.6 mM, 9.2 mM, 11.5 mM) were injected into the embryos at 3dpf to 6dpf every morning, followed 
by 60 min drug-to-light interval (yellow box) and 90 min green light irradiation (21 mW/cm2, 112.9 J.cm-2, 520 nm), 
depicted as a green lightning bolt. (B) WA, (C) IV, (D) RO. (B-D) Images were made of irradiated (light) and non-
irradiated (dark) embryos (n=30) at 6dpf and the percentages of mortality, malformation and fish length were 
calculated (shown as means ± SD from three independent experiments). Representative images of embryos under 





The treatment of TLD1433 by WA, IV and RO in a zebrafish ectopic and orthotopic tumour model 
The zebrafish ectopic conjunctival melanoma tumour model has been described previously [30]. In this 
model, around 200 fluorescent CM cells are injected into the Duct of Cuvier at 2 dpf, and then 
disseminate through the blood circulation and grow in the head and tail. To establish the orthotopic 
tumour model, around 100 red, (td)Tomato fluorescent CRMM1 or CRMM2 cells were injected RO at 
2dpf into Tg(Fli:GFP/Casper), endothelial reporter transgenic zebrafish with green fluorescent 
vasculature and examined by fluorescent microscopy at day 1 and 4 after engraftment (Figure 
7A).Tumour expansion at the injection site was measured as fluorescence intensity and tumour area. 
Figure 6B shows that RO-engrafted CRMM1 and CRMM2 significantly proliferated at the site of injection 
and formed primary tumour lesions (Figure 7B, C).  
 
 
Figure 7 Development of a new conjunctival melanoma orthotopic tumour model in ZF. (A) Location of CM cell 
injection, (B) red fluorescent CRMM1 and (C) CRMM2 cells were injected RO into 2 dpf Tg(Fli:GFP/Casper) (n=10) 
and imaged by fluorescence microscopy at 1 and 4 days post injection (dpi). Relative tumour burden was calculated 







To engage both CM models for testing the efficacy of TLD1433 as a potential new PDT treatment strategy 
to combat CM growth, first, the MTD of TLD1433 delivered into zebrafish embryos engrafted with CM 
cells was measured (Table 2) following the same procedure as already described for wild type embryos 
(Figure 8 and Table 2). Engrafted embryos were more sensitive to light-activated TLD1433 than non-
engrafted embryos (Table 2). MTD concentrations of 4.6 nM and 2.3 mM were delivered by WA, IV and 
RO administration. Delivery of TLD1433 at the MTD by WA did not inhibit tumour burden in the ectopic 
or orthotopic tumour model after engraftment of CRMM1 and CRMM2 cells (Figure 8). Relative tumour 
burden, estimated as fluorescence intensity and tumour area, was not significantly different between 
the dark and light treatments, indicating that the low concentrations of TLD1433 added to the water of 
engrafted embryos were not sufficient to attenuate CM growth in either model (Table 3, 4). The 
TLD1433 concentration in these experiments was not increased further as the initial treatment was 
already at the pre-determined MTD.  
 
Table 2 The maximum tolerated dose (MTD) of TLD1433 in wild type zebrafish embryos and in the 
ectopic and orthotopic CM tumour model.  
TLD1433 administration type 
Maximum tolerated dose (MTD) 
Wild type 
embryos 
CM engrafted embryos  
Ectopic and orthotopic 
model  
Water  9.2 nM 4.6 nM 
Intravenous  4.6 mM 2.3 mM 





Figure 8 Treatment of zebrafish ectopic and orthotopic CM models with TLD1433 through WA. (A) Schedule of 
tumour injection and TLD1433 administration in zebrafish embryos. Fluorescent CRMM1 and CRMM2 cells were 
injected at 2 dpf into the Duct of Cuvier (ectopic model) and behind the eye (orthotopic model) and TLD1433 was 
administered with or without a light treatment following the schedule presented in A. Relative tumour burden 
estimated as fluorescence intensity and tumour area was calculated by Image J. (B) CRMM1 tumour burden in 
ectopic model (n≈30). (C) CRMM1 tumour burden in orthotopic model (n≈15). (D) CRMM2 tumour burden in 
ectopic model (n≈30). (E) CRMM2 tumour burden in orthotopic model (n≈15). Results are presented as means ± 
SD from three independent experiments. Representative images show CM tumour burden in the head and tail 
regions in the ectopic model and a localised tumour in the orthotopic model. 
 
Next, the effect of IV administration of TLD1433 was determined in both CM models. Figure 9 indicates 
that light activation of TLD1433 significantly reduced the tumour burden in the CRMM1 and CRMM2 
ectopic model but not in the orthotopic model. In the ectopic model, light activation with the MTD (2.3 





area (41%, 31%, 54%, and 50%) (Figure 9 B, D and Table 3, 4). The CRMM1 and CRMM2 tumour burden 
was not changed in the orthotopic model (Figure 9 C, E and Table 3, 4). This clearly shows that CRMM1 
and CRMM2 tumour cells received a sufficient amount of activated TLD1433 in the ectopic model but 
not in the orthotopic model, suggesting that IV administration allows the compound to reach and inhibit 
CM cells in the ectopic model but is not effective to attenuate localized CM growth behind the eye in 
orthotopic model. 
 
In contrast, delivery of the same concentration of TLD1433 (2.3 mM) by RO administration toward 
CRMM1 and CRMM2-induced tumours diminished the fluorescence intensity and tumour area in both 
ectopic (47%, 40%, 64%, 52%) and orthotopic models (35%, 55%, 69%, 71%) upon green light activation 
(58.3 J.cm-2, 520 nm) (Figure 10 and Table 3, 4). We propose that TLD1433 remained longer in the 
interstitial fluid at the injection site after RO injection, reaching a higher effective concentration to 





Figure 9 TLD1433 treatments by IV administration in the zebrafish ectopic and orthotopic CM model. (A) Schedule 
of tumour injection and TLD1433 administration in zebrafish embryos. Relative tumour burden was calculated as 
described in Figure 7. (B) CRMM1 tumour burden in the ectopic model (n≈30). (C) CRMM1 tumour burden in the 
orthotopic model (n≈15). (D) CRMM2 tumour burden in the ectopic model (n≈30). (E) CRMM2 tumour burden in 
the orthotopic model (n≈15). Results are presented as means ± SD from three independent experiments. 
Representative images show CM tumour burden in the head and tail regions in ectopic model and localised tumours 







Figure 10 TLD1433 treatments by RO administration in the zebrafish ectopic and orthotopic CM model. (A) Schedule 
of tumour injection and TLD1433 administration in zebrafish embryos. Relative tumour burdens were calculated as 
described in Figure 7. (B) CRMM1 tumour burden in the ectopic model (n≈30). (C) CRMM1 tumour burden in the 
orthotopic model (n≈15). (D) CRMM2 tumour burden in the ectopic model (n≈30). (E) CRMM2 tumour burden in 
the orthotopic model (n≈15). Results are presented as means ± SD from three independent experiments. 
Representative images show CM tumour burden in the head and tail regions in ectopic model and localised tumour 











Table 3 Relative tumour burden quantified by fluorescence intensity in zebrafish embryonic models 
after treatment with TLD1433, delivered by three different administration routes. The fluorescence 
intensity is calculated as percentage, compared to the control dark group (100%).  
 
    Relative tumour burden as measured by Fluorescence Intensity 
 
Route of TLD1433 
administration  
Ectopic Model Orthotopic Model 
  Light dose (J.cm-2) 
PI 
Light dose (J.cm-2) 
PI 
    0 19 0 19 
CRMM1 
Water  91% 89% 1.0 96% 96% 1.0 
Intravenous 94% 59% 1.6 91% 111% 0.82 
Retro-orbital 85% 53% 1.6 120% 65% 1.8 
CRMM2 
Water  90% 96% 0.93 96% 104% 0.92 
Intravenous 97% 69% 1.4 98% 95% 1.0 
Retro-orbital  93% 60% 1.6 100% 45% 2.2 
 
Table 4 The relative tumour burden quantified by tumour area in zebrafish embryonic models after 
treatment with TLD1433 delivered by three different administration routes. The tumour area is 
calculated as percentage, compared to the control dark group (100%). 
 
    Tumour area 
 
Route of TLD1433 
administration  
Ectopic Model Orthotopic Model 
  Light dose (J.cm-2) 
PI 
Light dose (J.cm-2) 
PI 
    0 19 0 19 
CRMM1 
Water  103% 99% 1.0 90% 89% 1.0 
Intra venous  102% 46% 2.2 109% 126% 0.87 
Retro orbital  85% 36% 2.4 125% 31% 4.1 
CRMM2 
Water  92% 102% 0.90 104% 95% 1.1 
Intra venous  99% 50% 2.0 97% 93% 1.1 
Retro orbital  94% 48% 2.0 99% 29% 3.4 
 
 
TLD1433 by retro orbital administration induces apoptosis of CRMM1 and CRMM2 cells in zebrafish 
orthotopic model 
In situ TUNEL assay on fixed embryos was used to detect TLD1433 induced apoptosis in zebrafish 
CRMM1 and CRMM2 orthotopic tumour models at 4 dpi after light activation of 2.3 mM TLD1433, 
administrated by retro orbital injection. The DNA strand breaks in apoptotic tumour cells were stained 
with fluorescein and visualized as a green signal. In control dark, control light, TLD1433 dark groups 
there was no positive green signal detected, which co-localized with red signal of CRMM1 and CRMM2 





induced CRMM1 and CRMM2 cell apoptosis in the zebrafish orthotopic model. After light irradiation, 
the red signal representing engrafted CM cells was reduced, however some of the reaming cells stained 
positive for apoptotic cells and turned green (yellow in overlay), indicating that PDT-driven anti-tumour 





Figure 11 TUNEL assay of in CRMM1 and CRMM2 orthotopic model after RO of TLD1433. Red 
fluorescent CRMM1 (A) and CRMM2 (B) cells were injected at 2dpf behind the ZF eye and divided 





performed as described in Figure 10C, E. After dark or light exposure embryos were fixed and TUNEL 
staining was performed. Representative images of embryos are shown in this figure. (A, B) In 
TLD1433 light groups nuclear DNA fragmentation by nucleases is detected by co-localization of 
green (DNA fragments) and red signal of engrafted CM cells, depicted as yellow signal and marked 
by white arrows. In control dark, control light, TLD1433 dark, there are no positive green apoptotic 
tumour cells observed. Background green signal in TLD1433 light groups, does not co-localized with 
cytosolic red signal, which is diminished in degraded cells and TUNEL stains only the DNA breaks in 




 Developing new ocular PDT treatments often depends on a limited number of rabbit studies, due to 
lack of other animal models. To overcome this, we previously generated an ectopic CM model, and now 
developed an orthotopic CM model in zebrafish. Zebrafish xenograft models are particularly 
straightforward for testing compound toxicity and efficacy in vivo, as one can examine on the one hand 
adverse effects on developing phenotypes or animal survival, and on the other hand tumour burden by 
fluorescence microscopy. For PDT in zebrafish, one should note that the PI can either be defined as the 
total tumour fluorescence or the total tumour area (as detected in confocal microscopy) in the light-
activated group, divided by the tumour fluorescence or tumour area in the dark group. These definitions 
are quite different from the definition of the PI in vitro, where it is usually defined as the ratio between 
the EC50 values in the dark and in light-irradiated conditions. As a consequence, in vitro and in vivo PIs 
cannot be directly compared. For example, the PI obtained by fluorescence spectroscopy in the 
orthotopic CRMM1 model and using RO injection of TLD1433 was 1.85, while that obtained by 
measuring the tumour area was 4.1; the PI measured by the ratio of EC50 values in vitro was 140. The 
only PIs that can be compared are the ones defined identically in the same cancer model.  
 
Here, our results demonstrate not only activity of TLD1433 in a broad range of different CM and UM 
cells in vitro, but also anti-tumour activity in a zebrafish embryo tumour models of CM. Interestingly, 
the in vitro results on 6 different eye melanoma cell lines are not significantly different, which means 
that TLD1433 shows a broad range of photoactivity, independently of the genetic background of the 
different cell lines. For the in vivo part of this work, we focussed on CM because TLD1433 induced the 
highest PIs in these cell lines. However, future experiments may further analyse UM, as good activity 
was also observed in the UM cell lines. Clearly, the excellent photodynamic properties of the Ru-based 
TLD1433 sensitizer make it phototoxic in most cell lines, including cutaneous melanoma and non-
melanoma cell lines. When testing it in vivo, it is hence particularly important to optimise the mode of 
administration, compound dose, and light dose, in order to minimise side effects. 
 
The main limitation for PDT of the zebrafish embryo tumour model is that due to the small size of the 
animal, light irradiation occurs on the whole organism, while in mice (or patients) prodrug activation 
occurs locally by light irradiation of the tumour. Global toxicity after local light activation in larger 
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animals is less likely to occur than upon full-body activation of a sensitizer in a small zebrafish embryo. 
Hence, higher toxicity is expected in zebrafish models, compared to mice models, which is why our 
results included an MTD study. On the other hand, zebrafish embryo are transparent and the engrafted 
CM cells are fluorescent, which allows for following in time and space the outcome of anti-tumour 
treatment, particularly in the primary tumour.  
 
Despite such advantages, the relationship between the method of implanting the tumour and the mode 
of administration of the compound has to be established for each particular disease. For CM, our results 
clearly demonstrate that when the route of administration did not fit with the chosen tumour model, 
the activity in zebrafish was abrogated. This result is very important considering the notoriously 
excellent ROS generation properties of TLD1433 and its excellent PDT properties in mice tumour models 
[98]. In other words, activity in fish only appeared when the proper administration route was used. 
Clearly, the best model for tumor growth and drug testing was the orthotopic one, combined with local 
injection of TLD1433, i.e. injection behind the eye. Such a mode of administration turns out to be 
reminiscent of that used in bladder cancer patient, where TLD1433 is injected in the bladder and taken 
up very selectively by the tumour cells. Our results open the door for further zebrafish testing of not 
only TLD1433 (to assess on its toxicity, activity, and mode of action), but also of other phototherapeutic 
compounds, for which no activity in vivo has ever been reported.  
 
Last but not least, clinical PDT in intraocular melanoma has up to now been limited not only by the lack 
of clinically approved PS, but also by interferences by the ocular and tumour pigment with light 
absorption. Most approved PDT sensitizers are porphyrin compounds, which offer a quite narrow (~20 
nm) excitation wavelength range. If the pigment of the tumour absorbs too much of that light, PDT 
activity may be compromised. TLD1433, like most Ru polypyridyl compounds, shows broad absorption 
bands (Δλ ~ 150 nm) between the blue and red regions of the spectrum, thereby allowing to fine-tune 
the excitation wavelength and optimise light absorption by the sensitizer vs light absorption by the 
pigment [100]. These effects could not be tested here, as the CM and uveal melanoma cell lines have 
lost their pigments. Rutherrin, a new formulation of TLD1433 and transferrin, is now being proposed to 
improve the target specificity and water solubility of the PS [101-103]. Rutherrin was proven to cross 
the blood brain barrier (BBB) and is now under clinical investigation for glioblastoma multiforme (GBM) 
and non-small-cell lung cancer (NSCLC) [98]. However, this obstacle should be taken into account in any 




Our work supports three main conclusions. First, the Ru-based PDT sensitizer TLD1433 is very active in 
eye melanoma cell lines, where green light activation provokes cell death via apoptosis and necrosis. 
Second, this paper is one of the rare examples of testing PDT in a zebrafish tumour model. It could hence 





Due to the excellent ROS generation properties of this PDT sensitizer, it appears of utmost importance 
to fine-tune the way of administration of the prodrug to the tumour model. For two different models 
of conjunctive melanoma, i.e. an ectopic and an orthotopic model, we have tested three ways of 
administration of TLD1433. The WA, which is often chosen to test compounds in zebrafish, did not give 
good results: the phototoxicity to the zebrafish was high, and the anti-tumour efficacy low. When the 
compound was injected IV or RO, however, the toxicity became much lower and, when injected IV or 
RO, excellent anti-tumour properties were observed. We hence propose, as a third and last conclusion 
of this work, that TLD1433 can be repurposed as a treatment against conjunctival melanoma. 
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In vivo data are very rare for ruthenium-based photoactivated chemotherapy (PACT) compounds, a new 
family of phototherapeutic drugs that are activated via ligand photosubstitution. Here a novel 
trisheteroleptic ruthenium complex ([2](PF6)2) was generated and its light-activated anticancer 
properties were validated in vitro and in embryonic zebrafish cancer models. The dark toxicity of 
[2](PF6)2 was optimized by combining three different ligands with different hydrophobicities, each 
bound in a bidentate fashion to the metal centre. Upon green light irradiation, one of these ligands, 2-
methylthiomethylpyridine (mtmp), was selectively photosubstituted by solvent molecules, thereby 
releasing the phototoxicity of the heavy metal photoproduct. Fifteen minutes of green light irradiation 
(21 mW.cm-2, 19 J.cm-2, 520 nm) led to high phototherapeutic indexes (PI) for this compound, in 
particular in prostate cancer cells (PC3Pro4) and conjunctival melanoma cells (CRMM1 and CRMM2). 
The therapeutic potential of [2](PF6)2 was further evaluated in zebrafish ectopic and orthotopic tumour 
models of these cell lines. The ectopic model consisted of fluorescent PC3Pro4-, CRMM1-, or CRMM2-
mCherry cells, injected intravenously (IV) into zebrafish, that formed perivascular metastatic lesions 
within four days at the posterior ventral end of caudal hematopoietic tissue (CHT). By contrast, in the 
orthotopic model, CRMM1- and CRMM2-mCherry cells were injected behind the eye where they 
developed metastatic lesions. After 24 hours, the engrafted embryos were treated at the maximally-
tolerated dose of [2](PF6)2, which was determined for three different modes of administration: i) 
incubating the fish in drug-containing water (WA); ii) injecting the compound intravenously (IV) into the 
fish; or iii) injecting the compound retro-orbitally (RO) into the fish. Optimally, four consecutive PACT 
treatments were performed on engrafted embryos using 60 min drug-to-light intervals and 90 min 
green light irradiation (21 mW.cm-2, 114 J.cm-2, 520 nm). Most importantly, this PACT protocol was not 
toxic to the zebrafish. In all three ectopic tumour models, [2](PF6)2 did not significantly diminish the 
formation of metastatic lesions. However, in both conjunctival melanoma orthotopic tumour models, 
retro-orbitally administered [2](PF6)2 significantly inhibited growth of the engrafted cells. Overall, this 
study represents the first demonstration in zebrafish cancer models of the clinical potential of 
ruthenium-based photoactivated chemotherapy against conjunctival melanoma. 
 
Introduction 
Cisplatin was the first metal-based chemotherapy drug approved by the Food & Drug Administration 
for the treatment of testicular tumours and ovarian adenocarcinoma, and with the development of 
carboplatin and oxaliplatin (two derivatives of cisplatin) the use of platinum-based drugs has expanded 
to the treatment of many different malignancies [1-3]. Although the exact mechanism of action of 
platinum(II) (Pt) complexes is still debated, it is generally accepted that the ultimate event that induces 
apoptosis in cancer cells is the binding of the heavy metal centre to DNA after hydrolysis of one or two 
labile ligand(s) of the metal complex [4]. DNA binding to Pt inhibits DNA replication and transcription, 




leads to severe side effects  in patients treated with platinum drugs, for example hepato- and 
nephrotoxicity, which limits the clinical efficacy of these compounds and the patients’ quality of life [8-
10]. Therefore, other metal-based compounds have been considered as anticancer chemotherapy 
candidates, including those based on ruthenium(II) (Ru) [11]. Although several of these compounds 
have reached the stage of clinical trials, the general toxicity of metal-based compounds, due to 
spontaneous activation of a metal-ligand bond before the drug reaches the tumour, remains an issue.  
Ruthenium-based PhotoActivated ChemoTherapy (PACT) is a new anticancer phototherapy modality 
that uses visible light irradiation as an external trigger [12,13]. PACT primarily aims at limiting the 
biological action of the anticancer drug to the location of the tumour by localized, light-induced 
activation at the tumour site [14]. Unlike photodynamic therapy (PDT), a clinically-approved 
anticancer phototherapy method based on the photochemical activation of dioxygen by an excited 
photosensitizer, PACT relies on an oxygen-independent photochemical bond cleavage reaction. This 
process generates a molecular species that is more cytotoxic than the (non-activated) prodrug kept in 
the dark [15-17]. Many examples of PACT agents have been reported in the literature, among which 
are molecules based on ruthenium [18-20]. Ru-based PACT compounds make use of the versatile and 
well-understood photochemistry of polypyridyl ruthenium compounds, which, next to energy transfer 
and electron transfer, comprises light-induced photosubstitution reactions [21]. When 
photosubstitution occurs, one of the organic ligands bound to the metal is replaced by loosely-bound 
solvent molecules. In the dark, the ligand to be photosubstituted serves as a protecting group towards 
the coordination of biomolecules present in cells. After light irradiation, photosubstitution produces 
an “uncaged” metal compound that, by analogy with cisplatin, acts as an activated drug, as it can bind 
to biomolecules and induce cell death (Figure 1) [22-24]. For example, blue light-induced 
photosubstitution of the non-toxic ligand 2-methylthiomethylpyridine (mtmp) in compounds 
[Ru(dpp)2(mtmp)]2+ ([1]2+, dpp = 4,7-diphenyl-1,10-phenanthroline) and [Ru(bpy)2(mtmp)]2+ ([3]2+, bpy 
= 2,2’-bipyridine), has recently been demonstrated [25]. These two compounds belong to a wide 
family of complexes [Ru(N-N)2(L-L)]2+, where N-N are non-photocleavable “spectator” polypyridyl 
ligands, and L-L is a photocleavable chelate [25-29]. Although the photochemistry of this type of 
complexes is relatively well-understood, two major challenges in their development are on the one 
hand minimizing the difference between dark and light toxicity, and on the other hand, understanding 
how the molecular structure relates to the dark toxicity in vivo, i.e. the toxicity before 
photosubstitution takes place. In [1]2+ and [3]2+, both challenges are not met: [1]2+ bears two very 
hydrophobic dpp chelates that make the complex taken up by cells in large amounts and generate high 
cytotoxicity before light activation, while [3]2+ bears the much less hydrophobic bpy spectator ligands, 
as a result of which this compound is too hydrophilic to penetrate significantly into cancer cells, which 
prevents this compound to show any toxicity even after light activation [24].   
We set out to resolve both challenges. First, we designed a new ruthenium complex, 
[Ru(dpp)(bpy)(mtmp)]2+ ([2]2+, Fig. 1), as a compromise between [1]2+ and [3]2+. A single dpp chelate is 
78 
 
expected to alleviate the excessive hydrophobicity and dark toxicity of [1]2+, while it should increase 
the cellular uptake and photoinduced anticancer activity of [3]2+. Second, after demonstration of the 
excellent phototherapeutic properties of [2]2+ in vitro, this compound was subjected for the first time 
to in vivo efficacy testing and determination of the maximum tolerated dose using zebrafish ectopic 
and orthotopic tumour models. Zebrafish tumour models are advantageous for anticancer compound 
development as they allow for fast compound screening in vivo with low amounts of compound, 
compared to rodents, and with better statistics [30-33]. As zebrafish are transparent it is especially easy 
to activate a phototherapeutic compound by light in the whole body of the animal by simply shining 
light onto the aqueous solution containing the embryos [34-40]. The transparency of the embryo makes 
it easy to quantify the relative tumour burden, using engraftment of human cancer cells which stably 
express red fluorescent protein (RFP). This property has been used for studying PDT [41], as well as 
photoswitchable inhibitors, allowing analysis before and after light activation [37]. Zebrafish provide a 
particularly useful animal model for assessing drug toxicity: acute and chronic toxic effects of metal 
nanoparticles have been measured, with special focus on immunotoxicity, developmental toxicity, 
neurotoxicity, reproductive toxicity, cardiovascular toxicity, or hepatoxicity [42,43]. Systemic drug 
toxicity to zebrafish embryos has been well described [44-46]. Th zebrafish model allowed us to 
investigate for the first time the toxicity of photosubstitutionally active ruthenium compounds in 
different in vivo models of cancer while respecting the 3Rs principles (Reduction, Refinement, 
Replacement). As zebrafish embryo had not been used for PACT yet, we tested different protocols of 
compound administration, to find a mode of administration to test anti-cancer efficacy and toxicity. 
Critically, this work highlights that similarly high efficacies of a PACT compound in vitro do not 
necessarily translate into similarly high efficacies in vivo, where the mode of administration of the 





Fig. 1 Activation mechanism of the ruthenium-based PACT compound [2]2+. Upon green light irradiation, the 
protecting, non-toxic mtmp ligand is photosubstituted by solvent molecules, which recovers the biomolecule-





Method and Materials 
Synthesis 
General: the ligands 2,2’-bipyridine (bpy) and 4,7-diphenyl-1,10-phenanthroline (dpp), and the 
precursor cis-[Ru(DMSO)4Cl2], were purchased from Sigma-Aldrich. Potassium hexafluorophosphate 
(KPF6) was purchased from Alfa-Aesar. All reactants and solvents were used without further 
purification. The synthesis of [1]Cl2 was described previously [47]. The ligand 2-
(methylthiomethyl)pyridine (mtmp) was prepared according to the literature [48]. Electrospray mass 
spectra (ES MS) were recorded by using a Thermoquest Finnagen AQA Spectrometer and a MSQ Plus 
Spectrometer. All 1H NMR spectra were recorded on a Bruker DPX-300 or DMX-400 spectrometers. 
Chemical shifts are indicated in ppm relative to the residual solvent peak.  
[Ru(dpp)(DMSO)2Cl2] [4]: cis-[Ru(DMSO)4Cl2] (500 mg, 1.03 mmol) and bathophenanthroline (343 mg, 
1.03 mmol) were heated at reflux in ethanol (35 mL) for 2 h. The reaction was then cooled to room 
temperature and the solvent volume reduced to ca. 10 mL in vacuo. The precipitate that formed upon 
cooling was filtered, washed with minimal cold ethanol and copious amounts of hexane/diethyl ether, 
and dried under vacuum. Yield: light-brown solid, 347 mg (0.52 mmol, 51%). 1H NMR (400 MHz, CDCl3) 
δ 10.19 (d, J = 5.4, 0.9 Hz, 1 H), 10.00 (d, J = 5.6, 0.9 Hz, 1 H), 8.03 (dd, 2 H), 7.89 (d, J = 5.5, 0.9 Hz, 1 H), 
7.72 (d, J = 5.6, 0.9 Hz, 1 H), 7.65 – 7.51 (m, 10 H), 3.67 (s, 3 H, 1), 3.62 (s, 3 H, 2), 3.27 (s, 3 H), 2.70 (s, 
3 H). 13C NMR (101 MHz, CDCl3) δ 155.72, 152.34, 149.95, 148.98, 135.93, 135.79, 129.81, 129.68, 
129.13, 128.73, 128.27, 125.49, 125.36, 125.30, 125.23, 47.15, 46.52, 45.49, 44.37. 
 
[Ru(dpp)(ox)(mtmp)] [5]: [4] (300 mg, 0.45 mmol) and sodium oxalate (84.5 mg, 0.65 mmol) were 
heated at reflux in water (15 mL) for 1 h. The reaction was then cooled to room temperature and added 
to a hot (60 °C) solution of 2-[(methylthio)methyl]pyridine (63 mg, 0.45 mmol) in ethylene glycol (15 
mL). The resulting mixture was heated at reflux for 3 h, cooled to room temperature and then added 
dropwise to 50 mL of stirring water. After 30 minutes, the precipitate was filtered through a 1 μm 
Micropore membrane. The solids were washed with copious amounts of water and minimal acetone 
before drying thoroughly under vacuum. Mixture of isomers was separated in silica column (Rf = 0.3) in 
DCM/ CH3OH (2-20% CH3OH). Only one isomer was isolated. Yield: dark red powder, 144 mg (0.21 mmol, 
71%). 1H NMR (400 MHz, CDCl3) δ 9.63 (d, J = 5.6, 0.9 Hz, 1H), 9.34 (d, J = 5.4, 0.9 Hz, 1H), 8.08 (dd, J = 
9.4, 0.9 Hz, 2H), 7.81 (d, J = 5.3 Hz, 1H), 7.64 – 7.47 (m, 11H), 7.43 – 7.36 (m, 2H), 6.81 (d, 1H), 6.59 (t, J 
= 6.1, 2.4 Hz, 1H), 4.66 (dd, 2H), 2.45 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 168.86, 167.83, 163.08, 153.42, 
152.04, 151.05, 149.48, 148.15, 145.53, 136.37, 136.29, 134.29, 129.96, 129.78, 129.53, 129.35, 129.21, 
129.17, 129.03, 128.39, 125.91, 125.48, 124.44, 123.14, 122.34, 45.79, 16.12. Anal. Calcd for 
C33H25N3O4RuS·3H2O: C, 55.45; H, 4.37; N, 5.88 Found: C, 56.08; H, 4.56; N, 5.46. 
[Ru(dpp)(bpy)(mtmp)](PF6)2 [2](PF6)2: [5] (140 mg, 0.211 mmol) was suspended in acetonitrile (3 mL) 
and then perchloric acid 1 M (3 mL) was added. After refluxing for 1 h, a red-brown solution of the Ru-
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solvate was obtained and after cooling it was poured on 15 mL stirring water. The solid that precipitated 
was filtered and dried to yield the crude orange [Ru(dpp)(mtmp)(CH3CN)2](ClO4)2 complex. The 
intermediate was dissolved in an ethylene glycol solution (15 mL) containing the bpy ligand (33 mg, 
0.211 mmol) and heated at 100 °C for 6 h. The deep red mixture was cooled to room temperature and 
poured on stirring aqueous potassium hexafluorophosphate to precipitate the crude complex as the 
hexafluorophosphate salt. Configurational isomers were resolved by column chromatography on silica 
DCM/CH3OH 95:5. Three fractions were obtained from a long orange band (Rf ~ 0.5), from which only 
the last fraction contained a pure isomer (3.2 mg, 1.5%) (Isomer B, [2b](PF6)2). A mixture of isomers A/B 
in a ration 0.23:1 has been used for photochemical analysis and biological testing, further referred to 
as [2](PF6)2 (60 mg, 28%). 1H NMR (400 MHz, CD3CN) δ 9.63 (d, J = 5.5 Hz, 1HB), 9.39 (d, J = 5.7 Hz, 1HA), 
8.61 (d, J = 8.2 Hz, 1HB), 8.58 – 8.51 (m, 2HA), 8.43 (d, J = 8.1 Hz, 1HB), 8.31 (dd, J = 8.0, 1.5 Hz, 1HB), 
8.29 – 8.23 (m, 1HB + 1HA), 8.22 – 8.14 (m, 2HB + 2HA), 8.14 – 8.03 (m, 3HA), 8.02 (d, J = 5.5 Hz, 1HB), 
7.99 (d, J = 5.5 Hz, 1HB), 7.93 (ddd, J = 7.8, 6.5, 1.5 Hz, 1HB), 7.86 (td, J = 7.8, 1.6 Hz, 1HA), 7.81 – 7.51 
(m, 15HB + 15HA), 7.48 (dd, J = 5.9, 1.5 Hz, 1HA), 7.32 (ddd, J = 7.1, 5.6, 1.3 Hz, 1HA), 7.24 (d, J = 5.5 Hz, 
1HB), 7.17 (td, J = 7.2, 5.6, 1.4 Hz, 1HB + 1HA), 6.98 (ddd, J = 7.7, 5.8, 1.6 Hz, 1HB), 4.82 (d, J = 16.5 Hz, 
1HB), 4.74 (d, J = 16.7 Hz, 1HA), 4.28 (dd, J = 16.6, 4.8 Hz, 1HB + 1HA), 1.59 (s, 3HB), 1.32 (s, 3HA). 13C 
NMR (101 MHz, CD3CN) δ 162.96, 162.63, 158.56, 157.73, 153.51, 153.33, 153.09, 152.90, 151.98, 
150.77, 150.61, 150.05, 149.66, 148.72, 139.46, 138.67, 138.55, 136.62, 136.53, 130.79, 130.70, 130.13, 
130.06, 129.20, 127.78, 127.26, 127.19, 127.12, 126.92, 125.86, 125.59, 125.55, 124.93, 45.36, 17.04. 
High Resolution ES MS m/z (calcd): 364.57519 (364.57446, [2]2+). Anal. Calcd for C41H33F12N5P2RuS: C, 
48.34; H, 3.26; N, 6.87 Found: C, 48.21; H, 3.41; N, 6.82.  
 
Photochemistry: determination of the photosubstitution and singlet oxygen generation quantum 
yields 
When monitoring photoreactions with UV-vis and mass spectrometry, a Cary 50 Varian spectrometer 
equipped with temperature control set to 298 K and a LED light source (λex = 521 nm, with a Full Width 
at Half Maximum of 33 nm) with a photon flux of 6.21·10−8 mol·s−1 was used. The irradiation 
experiments were performed in a quartz cuvette containing 3 mL of solution. A stock solution of the 
desired complex was prepared in CH3CN, which was then diluted in the cuvette to a working solution 
concentration (36 μM). The sample was deaerated 15 min by gentle bubbling of dinitrogen and the 
atmosphere was kept inert during the experiment by a gentle flow of dinitrogen on top of the cuvette. 
A UV-vis spectrum was measured every 30 s for the first 10 min, every 1 min for the next 10 min, and 
eventually every 10 min until the end of the experiment. Data were analysed with Microsoft Excel and 
Glotaran as follows: Upon light irradiation, a complex RuL converts into a complex RuY by 
photosubstitution of a ligand (L) by a solvent molecule (Y). Considering that both metal complexes are 
thermally stable, the quantum yield of the photosubstition reaction ΦPR can be calculated by 




[49], when the irradiation is performed at a wavelength that is not an isosbestic point, the ΦPR can be 
obtained from the slope of a plot of the number of mol of RuL (nRuL) vs. the total number of mol of 
photons absorbed by RuL from t0 till ti (Qi). Qi is calculated according to Equation 1:  
Qi(t) = ∑ qi
i
t=0    Equation 1 
where qi is the moles of photons absorbed by RuL between two consecutive UV-vis measurements at 






∙ (1 − 10−3∙(Ae)ave) ∙ φ ∙ ∆t Equation 1 
where (ARuL)ave is the average of the absorbance due to RuL between two consecutive UV-vis 
measurements, (Ae)ave is the average of the absorbance of the solution at the irradiation wavelength 
between two consecutive UV-vis measurements, (1 − 10−3∙(Ae)ave) is the probability of absorption of 
a photon when the irradiation comes from the top of the quartz cuvette and goes through 3 cm 
pathlength, while all absorbances are measured perpendicularly through a 1 cm pathlength, and φ is 
the photon flux of the irradiation source at the irradiation wavelength.  
The value of (ARuL)ave, and by extension nRuL, was calculated by modelling the evolution of the UV-vis 
spectra vs. time using the Glotaran software. We fitted hence the time-dependent evolution of the UV-
vis spectroscopy data to a kinetic model based on first-order laws, obtaining two output data sets that 
can be used for the calculation of ΦPR. The first dataset is a collection of globally fitted absorption 
spectra of the starting complex and the photoproduct, which makes possible the calculation of the 
molar extinction coefficient of all the species from that of the starting reagent (Fig. S1a). The second 
dataset is the modelled evolution of the relative fractions of the two ruthenium species vs. irradiation 
time, here as well according to global fitting (Fig. S1b). From the time evolution of these fractions and 
the molar absorption coefficient of all species, the time evolution of nRuL can be calculated, as well as 
Qi. The slope of the plot of nRuL vs. Qi (Fig. S1c) gives the quantum yield of the reaction. 
Singlet oxygen quantum yield measurements were performed by direct spectroscopic detection of the 
1275 nm emission, as described by Meijer et al [25]. 
 
Attached cell culture 
Human conjunctival malignant melanoma cell lines CRMM1 and CRMM2, isolated by Nareyeck et al 
[50], were cultured in F12 Kaighn’s modified medium (Hyclone, cat# SH30526.01) supplemented with 
10% fetal bovine serum (FBS; Gibco). CM2005.1 established by Keijser et al [51] was cultured in RPMI 
1640, Dutch Modified (Life Technologies, cat# 22409-015), supplemented with 10% fetal bovine serum 
(FBS; Gibco), 3 mM L-glutamine (1%, Life Technologies cat# 35050-038). Human uveal melanoma cell 
lines OMM1 (provided by Prof. Dr. G.P.M Luyten) [52], OMM2.5, and MEL270 (provided by Dr. B.R. 
Ksander) [53] were cultured in Ham’s F12 medium (Sigma-Aldrich, cat# N3790) supplemented with 10% 
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FCS. Stable fluorescent CRMM1 and CRMM2 cell lines were generated using lentivirus expressing both 
tandem dimer (td)Tomato and Blasticidin-S, as previously described [54]. PC3Pro4 (provided by Dr. 
Gabriel van der Pluijm) was cultured in DMEM (Sigma-Aldrich, cat# 32160801) supplemented with 10% 
FCS. Human lung carcinoma A549 was distributed by the European Collection of Cell Cultures (ECACC), 
and purchased from Sigma Aldrich, cultured in DMEM (Sigma-Aldrich, cat# 32160801) supplemented 
with 10% FCS. Cells were cultured in either 25 cm2 or 75 cm2 flasks and split at 70-80% confluence. The 
flasks were incubated in a normoxic incubator at 37 °C at 5.0% CO2 in a PHCbi O2/CO2 incubator, MCO-
170M). The medium was refreshed twice a week. Cells used in all biological experiments were cultured 
for not more than eight weeks. Trypsin and Opti-MEM® (without phenol red) were purchased from 
Gibco® Life Technologies. Trypan blue (0.4% in 0.81% sodium chloride and 0.06% potassium phosphate 
dibasic solution) was purchased from Bio-Rad. Plastic disposable flasks and 96-well plates were 
obtained from Sarstedt. Cells were counted using a Bio-Rad TC10 automated cell counter with Bio-Rad 
Cell Counting Slides.  
 
Spheroids cell culture and CellTiter-Glo 3D cell viability assay 
A549 (500 cells/well) within 100 µL OptiMEM (Gibco® Life Technologies, cat# 11058021) were seeded 
in the low-attachment 96 well plates (Corning Spheroid microplate 4515) and incubated in normoxia 
(21% O2). After 24 h, 100 µL/well of diluted [2](PF6)2 with six different concentrations in OptiMEM or 
OptiMEM for control was added into each well and the cells were further incubated for another 24 h 
(drug-to-light interval).  100 μL of medium was pipetted out from each well and 100 μL/well of new 
OptiMEM was added. Then, the plates for [2](PF6)2 treatment with light activation and vehicle with light 
activation groups were irradiated with green light (21 mW.cm-2, 15 min, 19 J.cm-2, 520 nm) and the 
plates for [2](PF6)2 treatment with no light activation and vehicle with no light activation groups were 
put in the dark box. After treatment, all plates were put back in the incubator for 48 h. Before the 
CellTiter-Glo 3D cell viability assay, the plates were taken out from the incubator and left out for 20 min 
to reach the room temperature. 100 μL medium was taken out from each plate and 100 μL of CellTiter 
Glo 3D was added per well. The plates were put on the shaker for 5 min and left the plates at room 
temperature without shaking for 25 min. The luminescence of the plates was read by Tecan reader.   
 
Cellular uptake 
Cell uptake studies for complexes [1]Cl2 and [2](PF6)2 were conducted on A549 lung cancer cells. 1.6·106 
cells were seeded at t = 0 h in Opti-MEM complete (10 mL) in a 75 cm2 T-flask. At t = 24 h the media 
was aspirated and cells were treated with solutions of [1]Cl2, [2](PF6)2 to give a final concentration at 
the EC50 in the dark (3.4 and 65µM, respectively) in a total volume of 10 mL. After 24 h of drug 
incubation at 37 ºC and 21% O2, the medium was aspirated and the cells were washed twice with PBS 




rpm, 4 min). After aspiration of the supernatant, the cells were re suspended in PBS (1 mL) and counted. 
After a second centrifugation, the supernatant was discarded. For metal and protein quantification, the 
pellets were resuspended in demineralized water (250 µL) and lysed for 30 min by ultrasonication. The 
protein content of lysates was determined by the Bradford method, and the ruthenium content was 
determined by Atomic Absorption Spectroscopy.  
 
A contrAA 700 high-resolution continuum-source atomic absorption spectrometer (Analytik Jena AG) 
was used. Pure samples of the respective complex were used as standard and calibration was done in 
a matrix-matched manner (meaning all samples and standards were adjusted to the same cellular 
protein concentration of 1.0 mg/mL by dilution with distilled water if necessary). Triton-X 100 (1%, 10 
μL) as well as nitric acid (13%, 10 μL), were added to each standard sample (100 μL). Samples were 
injected (25 μL) into coated standard graphite tubes (Analytik Jena AG) and thermally processed as 
previously described by Schatzschneider et al.[55] Drying steps were adjusted and the atomization 
temperature set to 2400 °C. Ruthenium was quantified at a wavelength of 349.90 nm. The mean 
integrated absorbances of double injections were used throughout the measurements. The data from 
two independent biological replications were used to obtain the uptake values shown in Table 2. 
 
Cell irradiation setup 
The cell irradiation system consisted of a Ditabis thermostat (980923001) fitted with two flat-bottomed 
microplate thermoblocks (800010600) and a 96-LED array fitted to a standard 96-well plate. The λ=520 
nm LED (OVL3324), fans (40 mm, 24 V DC, 9714839), and power supply (EA PS 2042-06B) were obtained 
from Farnell as reported in our previous publication [56]. 
 
Cytotoxicity assay  
At day 0, cells were detached using 1 mL of trypsin, resuspended in 4 mL of media and transferred to a 
15 mL corning falcon tube. Cells were counted using trypan blue and BioRad® TC20™ automated cell 
counter (Figure 11). Dilutions of 6000 (CRMM1), 6000 (CRMM2), 8000 (CM2005.1), 6000 (OMM1), 6000 
(OMM2.5), 6000 (MEL270) 6000 (A549), and 6000 (PC3Pro4) cells/well were calculated from each cell 
suspension at a final volume of 6 mL. The cell suspensions were transferred to a 50 mL reservoir and 
100 µL of each cell line was seeded at the aforementioned cell densities in triplicate in six 96-well plates. 
Boarder wells were intentionally filled with PBS media to avoid boarder effects. After 24 h, the cells 
were treated with [2](PF6)2 with six different concentrations. After 24 h of post treatment the cells were 
exposed to the green light for 15 min (21 mW/cm2, 19 J.cm-2, 520 nm). The dark control plate was kept 
under dark conditions. Then cells were incubated for another 48 h before fixing them with 
trichloroacetic acid (10% w/w) solution. The fixed cells were kept at 4℃ for 48h, when TCA was washed 
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out with distilled water before adding the sulphorhodamin B (SRB) (0.6 % SRB) dye. The SRB dye was 
washed out after 30 minutes and plates were air dried overnight. Next day, the dye was dissolved using 
Tri-base (0.25%) and absorbance of SRB at 510 nm was recorded from each well using a Tecan plate 
reader. The SRB absorbance data was used to calculate the fraction of viable cells in each well (Excel 
and GraphPad Prism software). The absorbance data were averaged from triplicate wells per 
concentration. Relative cell viabilities were calculated by dividing the average absorbance of the treated 
wells by the average absorbance of the untreated wells. Three independent biological replicates were 
completed for each cell line (three different passage numbers per cell line). The average cell viability of 
the three biological replicates was plotted versus log(concentration) [μM], with the SD error of each 
point. By using the dose–response curve for each cell line under dark- and irradiated conditions, the 
effective concentration (EC50) was calculated by fitting the curves to a non-linear regression function 
with a fixed maximum (100 %) and minimum (0 %) (relative cell viability) and a variable Hill slope [57]. 
 
Flow Cytometry 
CRMM1 (10000/well) cells were seeded into an 8-well chamber in Opti-MEMTM (Gibco, Reduced 
Serum Medium, no phenol red) with 2.5% FBS (Gibco). After 24 h incubation, 4.3 µM of [2](PF6)2 was 
added into the medium. 24h later, wells were washed and new drug-free medium was added. The cells 
were exposed to green light (21 mW/cm2, 19 J.cm-2, 520 nm) for 15 min and incubated for 48 h. Medium 
of all wells was collected and wells were washed with PBS and lysed by 500 µL trypsin for 3 min. 
Collected medium was added to the wells with lysed cells, mixed and centrifuged for 2000 rpm, 3 min. 
After washing, cells were resuspended in 200 µL of 1X binding buffer. Next, 5 µL of Annexin-V-FITC and 
5 µL of Propidium Iodide were added to each well and left for 15 min at room temperature. 200 µL of 
each sample was added to a well in a 96-well plate, and used for FACS measurement. 
 
Zebrafish maintenance, tumour cells implantation and tumour analysis  
Zebrafish lines were kept in compliance with the local animal welfare regulations and European 
directives. The study was approved by the local animal welfare committee (DEC) of Leiden University 
(Project: “Anticancer compound and target discovery in zebrafish xenograft model”. License number: 
AVD1060020172410). The Zebrafish Tg(fli1: GFP/Casper) [58] were handled in compliance with local 
animal welfare regulations and maintained according to standard protocols (www.ZFIN.org). 
For cancer cell injection, two days post-fertilization (dpf), dechorionated zebrafish embryos were 
anaesthetized with 0.003% tricaine (Sigma) and plated on a 10cm Petri dish covered with 1.5% of 
solidified agarose. PC3Pro4, CRMM1 and CRMM2 cells were suspended in PBS containing 2% 
polyvinylpyrrolidone (PVP; Sigma-Aldrich) with a concentration of 50,000 cells/µl and loaded into 
borosilicate glass capillary needles (1 mm O.D. × 0.78 mm I.D.; Harvard Apparatus). In the ectopic 




Duct of Cuvier at 2 dpf, which led to dissemination through the blood circulation and outgrowth in the 
head and tail. In orthotopic tumour model, 100 (td)Tomato fluorescent CRMM1 or CRMM2 cells were 
injected retro-orbitally in 2 dpf embryos using a Pneumatic Picopump and a manipulator (WPI). After 
injection, the embryos were incubated in a 34 ˚C incubator. Images were acquired at 1-, 2-, 4- and 6-
days post injection (dpi) with a Leica M165 FC stereo fluorescence microscope. Tumour growth was 
quantified by calculating the total fluorescence intensity and area with the ZF4 pixel counting program 
(Leiden). Each experiment was performed at least 3 times with a group size of >30 embryos.  
 
Maximum tolerated dose (MTD) for wild-type zebrafish and tumour cell-injected zebrafish 
For determining the MTD of the water administration (WA) of the [2](PF6)2 solution in wild type 
zebrafish, solutions of 0.1 µM, 0.25 µM, 0.5 µM, 1 µM, 2 µM were made before the experiment. At 2.5, 
3.5, 4.5, 5.5 dpf, [2](PF6)2 was added to the fish water and maintained for 12 h. At 3, 4, 5, 6 dpf, the fish 
water was refreshed and after 1 h, embryos were exposed to green light for 90 min (21 mW.cm-2, 114 
J.cm-2, 520 nm). For the IV and RO administration, [2](PF6)2 solution (50 µM, 100 µM, 200 µM, 300 µM, 
500 µM) was made before the experiment. At 3, 4, 5, 6 dpf, 1nl of [2](PF6)2 was injected via the dorsal 
vein or the RO site and maintained for 1 h. Embryos were exposed to green light for 90 min (21 mW.cm-
2, 114 J.cm-2, 520 nm). The images of treated and wild type embryos at 6dpf were taken using a DFC420C 
camera coupled to a Leica MZ16FA fluorescence microscope. In order to determine the MTD of tumour 
cell-bearing zebrafish, 90 min green light activation (21 mW.cm-2, 114 J.cm-2, 520 nm) was performed 
according to the same procedure, after [2](PF6)2 was delivered by WA, IV and RA administration as 
described above for the wild type embryos. 
 
The antitumour efficacy of [2](PF6)2 by WA, IV and RO in zebrafish ectopic and orthotopic tumour 
models 
Fluorescent PC3Pro4 cells were injected at 2 dpf into the Duct of Cuvier (ectopic model) and [2](PF6)2 
was delivered by WA and IV administration with or without light treatment as described in 5.9. 
Fluorescent CRMM1 or CRMM2 cells were injected at 2 dpf into the Duct of Cuvier (ectopic model) and 
behind the eye (orthotopic model) and [2](PF6)2 was delivered by WA IV and RO administration with or 
without light treatment as described in 5.9. For the WA administration, the 0.5 µM [2](PF6)2 solution 
was added to the tumour cells-injected zebrafish at 2.5, 3.5, 4.5, 5.5 dpf and maintained for 12 h. At 3, 
4, 5, 6 dpf, the fish water was refreshed, and after 1 h, embryos were exposed to green light for 90 min 
(21 mW.cm-2, 114 J.cm-2, 520 nm). For the IV and RO administration, 1 nL of 200 µM [2](PF6)2 solution 
was injected via the dorsal vein or the RO site at 3, 4, 5, 6 dpf. After 1 h interval, the embryos were 
exposed to green light for 90 min (21 mW.cm-2, 114 J.cm-2, 520 nm). After treatment, the embryo 
images were acquired with a Leica M165 FC stereo fluorescence microscope. Tumour growth was 
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quantified by calculating the total fluorescence intensity and area with the ZF4 pixel counting program 
(Leiden). Each experiment was performed at least 3 times with a group size of >30 embryos. 
 
TUNEL assay 
The zebrafish larvae were fixed overnight with 4% PFA at 4 ˚C. Embryos were washed in PBST for five 
minutes and dehydrated by a graded methanol series until reaching 100% methanol. Embryos were 
stored at -20 ˚C for further use. Embryos were gradually rehydrated in PBST (25%, 50%, 75%), washed 
twice for 10 minutes with PBST and digested by proteinase K (Roche) solution in PBST (10 µg/ml) at 37 
˚C for 40 minutes. After two washes in PBST, embryos were post-fixed in 4% PFA for 20 minutes. After 
washing them again twice in PBST for 10 minutes, 50 µl of TdT reaction mix (Roche) was added to the 
embryos. Embryos were overnight incubated with the TdT at 37 ˚C (in the dark). The reaction was 
stopped by three 15 min washes with PBST at room temperature and embryos were used for high-
resolution imaging. Embryos were placed on glass-bottom petri dishes and covered with 1% low melting 
agarose containing 0.003% tricaine (Sigma). Imaging was performed using the Leica SP8 confocal 
microscope. The images were processed with ImageJ software. Each experiment was performed 3 times 
with a group size of 10 embryos.  
 
Statistical analysis 
Determination of the EC50 concentrations in vitro was based on a non-linear regression analysis 
performed using GraphPad Prism Software. Results are presented as means ± SD from three 
independent experiments. Significant differences were detected by one-way ANOVA followed by 
Dunnett’s multiple comparisons test implemented by Prism 8 (GraphPad Software, La Jolla, CA, USA). 
A p-value < 0.05 was considered statistically significant, *: p <0.05, **: p<0.01, ***: p<0.001. 
 
Results and discussion 
 
Synthesis and photoreactivity 
The synthesis of [2]2+ is more challenging than that of complexes such as [1]2+ or [3]2+ because [2]2+ is a 
tris-heteroleptic compound, i.e. it bears three different bidentate ligands that need to be coordinated 
to the metal in a controlled fashion (Fig. 2). With most generic synthetic routes, ligand scrambling 
occurred, i.e. [2]2+ was obtained with traces of [Ru(dpp)(mtmp)2]2+, [Ru(bpy)(mtmp)2]2+, [1]2+, or [3]2+, 
that were very difficult to remove. The synthesis of [2](PF6)2 was hence adapted from a novel method 
developed by Keyes et al [59] that involved the sequential coordination, in this order, of dpp, mtmp, 
and bpy. The novelty of this method relies on the use of an intermediate oxalate ligand (ox2−) during 
the coordination of the second (mtmp) chelate. This negatively-charged chelate prevents the formation 




used. After purification of the [Ru(dpp)(mtmp)(ox)] ([5]) intermediate complex, oxalate was removed 
selectively by HClO4 treatment in acetonitrile, after which the last chelate (bpy) was reacted to afford, 
after counter anion metathesis, [2](PF6)2. Due to the dissymmetry of mtmp and the tri-heteroleptic 
nature of the final complex, two configurational isomers are expected: one having the sulfur donor 
atom trans to bpy and another having the sulfur donor atom trans to dpp. These isomers were detected 
by 1H NMR and initially separated by column chromatography. Isomer [2a](PF6)2 was slightly 
contaminated with [Ru(dpp)(bpy)2](PF6)2, while isomer [2b](PF6)2 was pure according to 1H NMR but 
obtained in a low yield (<2%). Later on, as no difference in reactivity could be observed between both 
isomers, mixtures of [2a](PF6)2 and [2b](PF6)2 deprived of any other impurities were prepared and 
further used in biological studies; it is designated below as [2](PF6)2. 
 
Figure 2 Synthesis of tris-heteroleptic compound [Ru(dpp)(bpy)(mtmp)](PF6)2 ([2](PF6)2). Conditions: i) 1.0 eq. dpp, 
EtOH, reflux 2 h, Y = 51%. ii) a) 1.5 eq. Na2C2O4; water, reflux 1 h; b) 1.0 eq. mtmp, ethylene glycol, reflux 3 h; c) 
water; Y = 71%. iii) a) 1 M HClO4(aq)/CH3CN 1:1, reflux 1 h, b) 1.0 eq. bpy, ethylene glycol, 100 °C, 6 h; 3) aqueous 
KPF6; Y = 28%. 
 
The photoreactivity of [2](PF6)2 was studied by UV-vis spectroscopy in CH3CN. The spectrum of a 
solution of [2](PF6)2 irradiated for 20 minutes with green light (521 nm, 14 mW.cm-2) showed an 
increase of the intensity of the metal-to-ligand charge-transfer (MLCT) band between 400-430 nm, and 
a decrease in the valley at 344 nm with clear isosbestic points at 363 and 440 nm (Fig. 3). After 15 
minutes, when the reaction reached the steady state, mass spectrometry showed peaks at m/z = 140.3 
and 336.3, corresponding to the free caging ligand {mtmp+H}+ (calcd m/z = 140.1) and 
[Ru(bpy)(Ph2hen)(CH3CN)2]2+ (calcd m/z = 336.1). No traces of bpy, dpp, or of any ruthenium complex 
resulting from the photosubstitution of one of the two bis-imine ligands, was observed by mass 
spectrometry. There was also no trace of the starting complex [2]2+, confirming the selective and 
complete photosubstitution of mtmp upon light irradiation in deaerated CH3CN, to produce 
[Ru(dpp)(bpy)(MeCN)2]2+ as sole photosubstitution product. The photosubstitution quantum yield, 
measured by UV-vis spectroscopy was found to be 0.111 in these conditions (Fig. S1). The excited states 
of [2]2+ do not necessarily deactivate only via photosubstitution and non-radiative decay; reaction with 
ground state oxygen to produce singlet oxygen (1O2) may happen, too, as described in PDT type II [60-
62]. Hence, the quantum yield for the generation of 1O2 (ΦΔ) was experimentally determined by direct 
detection of the 1274 nm near-infrared phosphorescence of 1O2 in an air-equilibrated CD3OD solution 
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of [2](PF6)2. Under blue light irradiation (450 nm) using [Ru(bpy)3]Cl2 as reference (ΦΔ = 0.73) [63], a ΦΔ 
value of 0.096 was found for [2]2+, which is slightly higher than for [1]2+ (ΦΔ = 0.020 in the same 
conditions), but much lower than PDT sensitizers such as Photofrin (0.90) [64], Foscan (0.43) [65], or 
TLD-1433 (1.0) [66]. Overall, the low ΦΔ value and a rather high photosubstitution quantum yield make 
of [2]2+ a promising PACT agent, provided it can enter cancer cells before light irradiation take place. 
 
Figure 3 Evolution of the UV-vis spectrum of an acetonitrile solution of [2](PF6)2 (36 μM) upon green light irradiation 
(521 nm, 14 mW.cm-2, photon flux 6.2×10-8 mol.s-1) under inert atmosphere. Insert: black and red dots represent 
the evolution of the absorbance at 460 nm and 430 nm, respectively (dashed lines in the spectrum), vs. irradiation 
time. 
 
Cellular uptake and cytotoxicity in vitro 
Considering the good photosubstitution properties of [2]2+, its cytotoxicity was first tested in the dark 
and upon green light activation in a human lung cancer cell line (A549) where the two known analogues 
[1]2+ and [3]2+ had already been evaluated [47]. The protocol is detailed in Hopkins et al. [67]. The 
effective concentrations (EC50), defined as the compound concentration (in µM) that reduces cell 
viability by 50% compared to untreated cells, are shown in Table 1. In the dark, the EC50 value was 59 
µM for [2]2+, which is intermediate between that found, in the same conditions, for [1]2+ (3.4 µM) and 
for [3]2+ (>100 µM) [14]. After 15 minutes green light irradiation (520 nm, 21 mW.cm-2, 19 J.cm-2), the 
EC50 value decreased to 6.5 µM or [2]2+, respectively, which is also intermediate between the 0.62 µM 
and >150 found for [1]2+ and [3]2+, respectively (Fig. 4). As suggested by Lameijer et al, validating a 
compound as either a PACT agent or a PDT agent requires comparing the photoindexes (PI), rather than 
the EC50 values [68]. The photoindexes (PI) value for [2]2+ (9.1) was twice higher than for [3]2+ (5.5), 
which suggested that the compound design was successful. Qualitatively, cytotoxicity is closely related 




prodrug [69]. Typically, the presence of more phenyl groups results in an increase of lipophilicity [70]. 
The intermediate lipophilicity of [2]2+ obtained by balancing the number of dpp and bpy ligands, 
significantly decreased its dark toxicity, compared to [1]2+, while keeping its cytotoxicity after light 
activation much higher than for [3]2+. To verify quantitatively that this effect was related to drug uptake, 
A549 cells were treated for 24 h with [1]Cl2 and [2](PF6)2 at their EC50 concentrations (3.4 and 65 μM, 
respectively), counted, lyzed, after which the ruthenium content was measured using ICP-MS (Table 1). 
In such conditions, the cellular uptake of [2]2+ was found almost equal to that of [1]2+, although the 
concentration used for treatment was 20 times higher. Similar experiments with [3]2+ had 
demonstrated that this compound was not taken up by A549 cells because of its too high hydrophilicity 
[14]. Thus, the intermediate lipophilicity of [2]2+, between that of [1]2+ and [3]2+, indeed allowed for 
moderating cellular uptake, which kept the dark toxicity low while not jeopardizing the toxicity after 
light activation (Table 2). Such balanced lipophilicity also allowed the compound to penetrate 3D 
multicellular tumour spheroids of the same cell line (A549). In such conditions, the activity of [2]2+ 
remained significantly improved upon light irradiation, with EC50 values in the dark and after light 
irradiation (520 nm, 21 mW.cm-2, 19 J.cm-2) of 172.9 and 70.9 µM, respectively. Most importantly, the 
viability of the tumour spheroid was almost eradicated at 300 µM upon light irradiation, which 
highlights the excellent phototoxicity of this compound also in a 3D environment.  
Table 1 Cytotoxicity expressed as cell growth inhibition effective concentrations (EC50 with 95% confidence 
intervals, in μM) of [1]Cl2, [2](PF6)2 and in lung (A549) and prostate (PC3Pro4) cancer cell lines, in the dark and upon 
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Figure 4 Dose-response curves for A549 cells treated with [2](PF6)2, and irradiated with green light (520 nm, 15 
min, 21 mW.cm-2, 19 J.cm-2) 24 h after treatment (green data points) or left in the dark (black data points). a) A549 
cells were cultured in 2D cell monolayers. SRB assay was carried out at t=96 h. The absorbance of Sulforhodamine 
B in solution was measured at 520 nm. b) A549 cells were cultured as 3D multicellular tumour spheroids in ultra-
low attachment flask. The spheroids were treated with [2](PF6)2 at day 4, irradiated at day 5 (520 nm, 15 min, 21 
mW.cm-2, 19 J.cm-2), and their viability assayed at day 7 by a CellTiter-Glo 3D cell viability assay. Results are 
presented as means ± SD from three independent experiments with 95% confidence intervals. 
 
Encouraged by these results, the cytotoxicity of [2](PF6)2 was further assayed in a wider range of 2D 
cell monolayer models, i.e. using the PC3Pro4, CRMM1, CRMM2, CM2005.1, OMM1, OMM2.5 and 
MEL270 human cancer cell lines (Fig. S2). PC3Pro4 is a cancer cell line derived from a bone metastasis 
obtained after injection of PC3 human prostate cancer cells into nude mice [71], while CRMM1, 
CRMM2 and CM2005.1 are conjunctival melanoma cell lines and OMM1, OMM2.5 and MEL270 are 
uveal melanoma cell lines. The EC50 values are listed in Table 2 and 3. Interestingly, [2](PF6)2 exhibited 
higher toxicity in PC3Pro4, CRMM1 and CRMM2 cells upon light irradiation, and less toxicity in the 
dark, resulting in very high PI values of 45, >47, and >59, respectively (Table 3). In order to investigate 
the cytotoxic mechanism induced by light activated [2](PF6)2, CRMM1cells were treated with 4.3 µM 
for 24 h, stained with Annexin V and propidium iodide, and analysed by fluorescence-activated cell-
sorting (FACS). While the fraction of early apoptotic vs. necrotic cells in the cells treated with [2](PF6)2 
but not irradiated were almost identical to that of the vehicle control, almost half of the cells treated 
with [2](PF6)2 and activated by light were found to be either necrotic (PI+, Annexin–) or in the late 
apoptotic/dead cell quadrant, while the number of early apoptotic cells decreased to almost zero (Fig. 
S3). These results come in strong contrast with the almost exclusively apoptotic cell death mode 
observed with another ruthenium-based PACT compound, [Ru(bapbpy)(dmso)Cl]Cl, showing that the 
cell death mode with such compounds highly depends on the structure of the complex [72]. Overall, 
the excellent in vitro results observed in PC3Pro4, CRMM1, and CRMM2 cells, led us to selecting these 





Table 3 Cytotoxicity expressed as effective concentrations (EC50 with 95% confidence intervals, in μM) of [2](PF6)2 
in conjunctival melanoma (CRMM1, CRMM2, CM2005.1) and uveal melanoma (OMM1, OMM2.5, MEL270) cell 
lines, in the dark and upon green light irradiation (21 mW.cm-2, 15 min, 19 J.cm-2, 520 nm). 
Cell line Light dose (J.cm-2) 
[2](PF6)2 
EC50 95%CI PI 
CRMM1 
0 >200 















































Maximum tolerated dose of [2](PF6)2 in zebrafish ectopic and orthotopic cancer models 
To investigate the in vivo anti-cancer efficacy of [2](PF6)2, we utilized prostate (cell line PC3Pro4) and 
eye (CRMM1, CRMM2, CM2005.1) zebrafish embryonic cancer models, previously established in our 
group [73,74]. For prostate, androgen-independent osteotropic red-emitting PC3Pro4-mCherry cells 
(100-400 cells) were intravenously injected into the Duct of Cuvier (DoC) of Tg(Fli:GFP) endothelial 
reporter transgenic zebrafish line with green fluorescent vasculature (GFP) at 2 days post fertilization 
(dpf) (Fig. 5). The DoC is an open blood circulation channel connecting the heart and the trunk 
vasculature of the embryo [75]. Immediately after injection, cells haematogenously disseminated 
through the whole circulation. Most of the circulating cells regressed without extravasation or initiating 
tumour growth. However, within 1 day, some cells were able to extravasate exclusively at the posterior 
ventral end of caudal hematopoietic tissue (CHT), and invade into the tail fin where they developed 
perivascular metastatic lesions within 4 dpf (Fig. 5). CHT is an intermediate site of haematopoiesis 
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during zebrafish embryogenesis and is the functional analogue of the foetal liver during mammalian 
development [76]. Metastatic tumours grew around CHT at 6dpf, as detected by red fluorescence 
(excitation: 587 nm, emission: 610 nm) that can be quantified, either in terms of emission intensity, or 
by the relative tumour area in microscopy images; both quantifications are referred below as “relative 
tumour burden”. This tumour model is called “ectopic” as the CHT site does not represent the organ of 
origin of these cancer cells. For conjunctive melanoma (CM), we used an orthotopic model recently 
developed in our group for PDT treatment [57,77]. In short, the CM tumours were generated by 
injection of 200 CRMM1-mCherry or CRMM2-mCherry cells into the retro-orbital site of the embryo at 
2 dpf (Fig. 6). From 2 to 6 dpf, the CRMM1 or CRMM2 cells formed local lesions at the injection site 
behind the eye. This tumour model is called “orthotopic” as the site for tumour growth, i.e. the eye, 
does represent the organ of origin of these cancer cells.  
 
Table 4 The maximum tolerated dose (MTD) of [2](PF6)2 in wild type zebrafish embryos and in the ectopic and 
orthotopic CM tumour models.   
[2](PF6)2 
Maximum tolerated concentration  
Wild Type 
Embryos 
Tumour cells engrafted Embryos 
Ectopic and Orthotopic Model 
Water Administration 1 µM 0.5 µM 
Intravenous Administration 300 µM 200 µM 
Retro-orbital Administration a 300 µM a 200 µM a 
a for CRMM1 and CRMM2 xenografts only.  
 
 
In terms of drug treatment modalities, the embryos were subjected to three different protocols (Fig. 5 
and 6). For the ectopic model, treatment with [2](PF6)2 was performed either by water administration 
(WA) or by intravenous injection (IV), while for the orthotopic model, treatment was performed either 
by WA, IV, or retro-orbital (RO) injections. Before testing the anti-tumour efficacy, it was necessary to 
evaluate the toxicity of the phototherapy treatment. The toxicity of green light alone (520 nm) was 
recently reported [57]. At an intensity of 21 mW.cm-2, the zebrafish embryos could tolerate light 
irradiation until 6 h without any toxicity or visible developmental defects [57]. The toxicity of [2](PF6)2 
was then evaluated by measuring its maximum tolerated dose (MTD) for the different administration 
modes,  both for tumour-free embryos and tumour cell-injected embryos (Table 4 and Fig. S4). For 
treatment via water administration, different concentrations (0, 0.1 0.25, 0.5, 1, 2 µM) of [2](PF6)2 were 
added to the egg water (i.e., the water in which the zebrafish embryo were swimming) at 2.5, 3.5, 4.5 
and 5.5 dpf, and incubation was continued overnight for a drug-to-light interval of 12 h. At 3, 4, 5, 6 dpf, 
excess [2](PF6)2 was washed by drug-free water and the embryos were further irradiated with green 
light (21 mW.cm-2, 90 min, 114 J.cm-2, 520 nm). In such conditions, an MTD of 0.5 μM for embryos 
engrafted with PC-Pro4-mCherry tumours, and of 1 μM for tumour-cell free embryos, was obtained. For 
treatment via intravenous or retro-orbital administration, 1 nL with different concentrations (0, 50, 100, 




5, 6 dpf. After a shorter drug-light interval of 1 h, the zebrafish embryos were irradiated with the same 
dose of green light (21 mW.cm-2, 90 min, 114 J.cm-2, 520 nm). The lethality, aberrant morphology and 
fish length were measured at 6 dpf. Zebrafish embryos tolerated, without any effect on mortality, 
malformation and fish length, injection of [2](PF6)2, followed by light activation, at a MTD of 200 µM for 
embryos engrafted with PC-Pro4-mCherry, CRMM1, CRMM2 cells and of 300 µM for tumour-free 
embryos (see Fig. S4). These MTD values of 0.5 µM (WA) and 200 µM (IV and RO) were further used for 
assessing the anti-tumour efficacy in the zebrafish tumour models. 
 
Effect of [2](PF6)2 on PC3Pro4 tumour growth by water and intravenous administration in zebrafish 
ectopic prostate cancer model 
In the PC3Pro4-mCherry zebrafish ectopic model, both WA (0.5 µM) and IV administration (1 nL, 200 
µM) of [2](PF6)2 were tested using the previously determined MTD. At 6 dpf, images of the PC3Pro4-
mCherry tumours were taken using a stereo microscope. Quantification of the relative tumour burden 
was performed by measuring either the relative fluorescence intensity or the relative tumour area (Fig. 
5). Using a 12 h (WA) or 1 h (IV) drug-to-light interval, green light activation (21 mW.cm-2, 90 min, 114 
J.cm-2, 520 nm) did not change the tumour burden, compared to the dark groups, even when the 
treatment on each embryo was repeated 4 times (Fig. 4). Usually, WA in zebrafish is acknowledged to 
mimic the oral route in human patients. Indeed, the compound will first go into the enterohepatic 
circulation and then disseminate through the blood circulation. The fact that no anti-tumour activity 
was observed for [2](PF6)2 administered by WA in the prostate cancer zebrafish model, while it showed 
excellent activity in PC3Pro4 cell monolayers in vitro (Table 2), suggested that in the embryo, the 
compound may simply not be taken up into the blood circulation. Another possibility is that it was 
excreted within the 90 min irradiation time. In contrast, IV injection delivers the compound directly into 
the blood circulation, but this had no effect either. However, compound [2](PF6)2 may distribute 
anywhere in the embryo during the 1 h drug-to-light interval, or be excreted. To obtain anti-tumour 
efficacy upon light activation requires that the prodrug reaches the tumour in sufficiently high 
concentrations, which clearly did not happen here. Alternatively, engrafted prostate cancer cells might 
have gained chemotherapy resistance in vivo, which they did not have in vitro [78]. Overall, these results 
most probably suggest that more specific targeting strategies would be needed to achieve proper 






Fig. 5 Efficacy of [2](PF6)2 in PC3Pro4 prostate cancer zebrafish ectopic model. a) Schedule of tumour cells injection 
and treatment with [2](PF6)2 by water administration (WA). Around 300 PC3Pro4 cells were injected into Duct of 
Cuvier at 2dpf. 0.5 µM of [2](PF6)2 was added into water at 2.5, 3.5, 4.5, 5.5 dpf. At 3, 4, 5, 6 dpf, the compound 
was washed away, the embryos were irradiated with green light (21 mW.cm-2, 114 J.cm-2, 520 nm) for 1.5 h. b) 
Water administration of [2](PF6)2 into 6-well plates containing engrafted embryos. c) The images of PC3Pro4 
tumour burden at CHT site at 6 dpf. d) The relative fluorescence intensity of PC3Pro4 tumour burden at 6 dpf.  e) 
The relative tumour area of PC3Pro4 tumour burden at 6 dpf) Schedule of tumour cells injections and treatment 
with 200 µM of [2](PF6)2 by intravenous administration. g) The injection site of intravenous administration (IV). h) 
The images of PC3Pro4 tumour burden at CHT site at 6 dpf. i) The relative fluorescence intensity of PC3Pro4 tumour 
burden at 6 dpf. j) The relative tumour area of PC3Pro4 tumour burden at 6dpf. Results are presented as means ± 
SD from three independent experiments. 
 
[2](PF6)2 effect on CRMM1 and CRMM2 tumour growth by retro-orbital administration in the 
zebrafish orthotopic conjunctival melanoma model 
When both the tumour cells and the prodrug are injected into the general blood circulation of the 
embryo, it should not be taken for granted that the drug properly biodistributes to reach the inside of 
a tumour at a sufficiently high concentration. One way to address this issue is to use a model where the 
prodrug is injected near the tumour. The efficacy of [2](PF6)2 was hence examined in the orthotopic 




in the back of the eye, near the location of the cancer cell injection, and the prodrug is also injected at 
the same place. A shorter drug-to-light interval is used (1 h) to avoid prodrug diffusion away from the 
tumour prior to light activation. In a sense, this model may better mimic local PDT treatments 
performed in human cancer patients. Following our treatment strategy as developed for the PDT 
sensitizer TLD-1433 [57], the MTD of [2](PF6)2 (1 nL, 200 µM) was injected retro-orbitally at 3, 4, 5, 6 
dpf. After 1 h drug-to-light interval, the embryos in both light-irradiated groups (vehicle, [2](PF6)2) were 
irradiated with green light (520 nm, 90 min, 21 mW.cm-2, 114 J.cm-2), while the two dark groups (vehicle, 
[2](PF6)2) were kept in the dark. During the experiment, the egg water of engrafted embryos was 
refreshed before injection and after irradiation. At 6 dpf and 4 consecutive treatments, quantification 
of the CRMM1 and CRMM2 relative tumour burden was performed by measuring either the relative 
fluorescence intensity or the relative tumour area using a stereo microscope (Fig. 6). In the group 
treated with [2](PF6)2 and green light (21 mW.cm-2, 114 J.cm-2, 520 nm), the CRMM1 tumour burden 
was significantly inhibited by 57% (fluorescent intensity) and 78% (tumour area) compared with the 
dark group, while the CRMM2 tumour burden was inhibited by 52% (fluorescence intensity) and 88% 
(tumour area), compared with the dark group. When comparing these excellent results with the 
absence of efficacy of the same compound in the ectopic model for prostate cancer, we envision that 
local RO administration of [2](PF6)2 generates a higher concentration of the inactive compound in the 
proximity of the tumour, and therefore that green light activation generates sufficient amounts of the 
activated ruthenium molecules, to attenuate localized CM development in the light-irradiated group 
(Fig. 6c-h). These results represent the first experimental demonstration that ruthenium-based PACT 
treatment can inhibit CM growth in an animal tumour model. They also suggest that compound [2](PF6)2 





Fig. 6 Efficacy of the PACT compound [2](PF6)2 in the Tg(Fli:GFP/casper) zebrafish orthotopic model of conjunctival 
melanoma (CRMM1 and CRMM2 cell lines) by retro-orbital administration (RO). a) Scheme showing the injection 
site of retro-orbital administration. b) Time flow of [2](PF6)2 treatment with RO administration. Around 200 CRMM1 
or CRMM2 cells were injected into the RO site of zebrafish embryos at 2 dpf. [2](PF6)2 was injected into RO site at 
3, 4, 5, 6 dpf, and after 1 h drug-light interval, the embryos were irradiated with green light (520 nm, 21 mW.cm-2, 
90 min, 114 J.cm-2). c) The images of CRMM1 or CRMM2 tumour burden (in red) at CHT site at 6 dpf. Green 
represents vessels in zebrafish embryos. d, g) The relative red fluorescence (excitation: 554 nm, emission: 581 nm) 
intensity of CRMM1 or CRMM2 tumour burden at 6 dpf.  e, h) The relative tumour area (pixel2) of CRMM1 or 
CRMM2 tumour burden at 6dpf. Results are presented as means ± SD from three independent experiments. ****: 
P < 0.0001. 
 
[2](PF6)2 induces CRMM1 cell apoptosis in the zebrafish orthotopic model 
To monitor whether the observed inhibition of CM growth in the zebrafish orthotopic model by [2](PF6)2 
was occurring via apoptosis, an in situ TUNEL assay was conducted on fixed embryos bearing CRMM1 
tumours at 4 dpi (days post injection), which were either kept in the dark or irradiated with green light 
(520 nm, 90 min, 21 mW.cm-2, 114 J.cm-2), and treated by RO injection at the MTD (1 nL, 200 μM) either 
with vehicle control or [2](PF6)2 (Fig. 6 and 7). In the TUNNEL assay, the DNA strand breaks in apoptotic 




dark vehicle group, light vehicle group, and group treated with [2](PF6)2 but not irradiated, no positive 
green signal was detected (Fig. 7a). Only in the group treated with [2](PF6)2 and irradiated with green 
light (520 nm, 21 mW.cm-2, 90 min, 114 J.cm-2), a significant number of cancer cells (Fig. 7b) stained 
positive for apoptotic signal and turned green, which co-localized with red signal of CRMM1 cells 
(yellow in overlay, Fig. 7a). This result indicated that the anti-tumour efficacy of [2](PF6)2 in this PACT 
regime was at least partially apoptosis-dependent, which significantly differs from the FACS analysis in 
vitro. It should also be noted that there was no apoptotic signal detected in the tissue surrounding the 
tumours, pointing out that light activated [2](PF6)2 attacked CM tumours but not healthy tissues, which 




Figure 7 TUNEL assay in the CRMM1 orthotopic tumour model after RO injection of [2](PF6)2. a) Red fluorescent 
CRMM1 cells were injected behind the eye of the embryo at 2dpf, and the embryos were divided into four groups 
for drug treatment. RO administration of vehicle control and [2](PF6)2 was performed as described in Fig. 6. After 
dark or light exposure, embryos were fixed and TUNEL staining was performed. a) Representative overlay images 
of embryos are shown. In the group treated with [2](PF6)2 and light, nuclear DNA fragmentation in nucleases is 
detected by co-localization of green (DNA fragments) and red (CM tumour cell) signal, depicted on the overlay as 
yellow signal marked by white arrows. In the dark control group, light control group, and group treated with 
[2](PF6)2 and left in the dark, there were no positive green apoptotic tumour cells. The background green signal in 
the [2](PF6)2 light groups did not co-localize with cytosolic red signal, which is diminished in degraded cells and 
TUNEL stains only the DNA breaks in these CM apoptotic cells. b) Quantification of the number of apoptotic tumour 






In conclusion, we have synthesized the new tris-heteroleptic ruthenium-based PACT prodrug [2](PF6)2 
which is characterized by a well-balanced hydrophobicity in the dark. The toxicity of this chemical is 
obtained by green light activation, which triggers photosubstitution of the non-toxic mtmp ligand and 
liberates a ruthenium-based activated photoproduct. This activated photoproduct can bind to many 
biomolecules, which ultimately leads to cell death. Of course, [2](PF6)2 has not been designed for 
specific targets in tumour cells, which may be seen as a potential sources of side-effects. On the other 
hand, this lack of specificity ensures that single mutations in cancer cells would not quench the cytotoxic 
activity of the light-activated compound, as confirmed by the large range of unrelated cancer cell lines 
(lung, prostate, eye) in which [2](PF6)2 remained photoactive. Still, differences in photoindexes existed 
between cell lines, which pointed at PC3Pro4, CRMM1, and CRMM2 cell lines, for further in vivo 
evaluation. We do not know why the uveal melanoma cell lines did not show a better response to the 
treatment with [2](PF6)2, but we decided to use the conjunctival cell lines when we saw how much more 
sensitive these were. Zebrafish embryos allowed us to demonstrate the efficacy of ruthenium-based 
PACT in conjunctival melanoma xenografts in vivo [48]; this provided the first MTD values for a 
photosubstitutionally active ruthenium compound administered either via water, intravenous 
injection, or retro-orbital injection. More than this, our results also highlight the difference between 
ectopic and orthotopic in vivo models for photoactivated drugs: while the photoindexes in vitro were 
high both in prostate cancer cells (PC3Pro4) and conjunctival melanoma cells (CRMM1, CRMM2), in vivo 
there was no activity in the ectopic model of prostate cancer, while activity was excellent in the 
orthotopic model of conjunctival melanoma. Such a difference underscores the interaction between 
the type of tumour model as well as the mode of compound administration in tumour xenografts, which 
cannot be modelled in vitro but dramatically influence both (pro)drug biodistribution, drug uptake by 
the tumour, and hence the final anti-tumour efficacy of the treatment. Overall, the present validation 
of the anti-tumour efficacy of retro-orbitally administered ruthenium compound [2](PF6)2 in zebrafish 
conjunctival melanoma orthotopic models suggests that further pre-clinical development of this new 
PACT drug should be considered in larger models (rodents) for conjunctival melanoma, where light 
irradiation can be limited to the tumour. 
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QUANTUM YIELD DETERMINATION 
 
 
Figure S1 Kinetic data for the second step of the photosubstitution of [2](PF6)2 in CH3CN under N2. a) Globally 
fitted absorption spectra of the mono-aqua intermediate [Ru(dpp)(bpy)(η1-mtmp)(CH3CN)] ([2-CH3CN] , black) and 
[Ru(dpp)2(CH3CN)2]
2+ (grey) according to modeling using the Glotaran software. b) Modeled evolution of the 
relative concentrations of [2- CH3CN]
2+ (squares) and [Ru(dpp)2(CH3CN)2]
2+ (circles) vs. irradiation time according 
to global fitting using Glotaran. c) Plot of the amount of [2-CH3CN]
2+ (mol) vs. total amount of photons absorbed 
by [2-CH3CN]
2+ (mol). The slope of the obtained line is the opposite of the quantum yield of the formation of the 
bis-aqua complex. Conditions: 0.036 mM solution of [2](PF6)2 in CH3CN irradiated at 298 K under N2 using a 521 






DOSE-RESPONSE CURVES IN CONJUNCTIVE MELANOMA, 
UVEAL MELANOMA AND PROSTATE CANCER CELL LINES 
 
 
Figure S2 Dose-response curves for CRMM1, CRMM2, CM2005.1, OMM1, OMM2.5, MEL270 and PC3Pro4 cells 
treated with [2](PF6)2 and irradiated with green light (520 nm, 21 mW/cm2, 19 J.cm-2) 24 h after treatment (green 
data points) or left in the dark (black data points). SRB assay was carried out at t=96 h. The absorbance of 















Figure S3 Green light irradiation of [2](PF6)2 induces apoptosis and necrosis in CRMM1 cells. 4.3 µM of [2](PF6)2 was 
added into the medium of CRMM1 cells. After 24 h, [2](PF6)2  was washed by new free-drug medium and 15 min of 
green light (21 mW/cm2, 19 J.cm-2, 520 nm) was performed. After treatment, the cells were incubated for another 
48 h. a) CRMM1 cells were stained with Annexin-V-FITC and Propidium Iodide. b) The percentages of live, early 
apoptotic, later apoptotic and necrotic cells in CRMM1 were counted by FACS. Results are presented as means ± 


























Figure S4 The maximum tolerated dose of [2](PF6)2 in wild type zebrafish embryos administered through three 
different routes. a) Schedule of [2](PF6)2 treatment in wild type zebrafish. Water administration (WA): [2](PF6)2 (0 
µM, 0.1 µM, 0.25 µM, 0.5 µM, 1 µM, 2 µM) were added to the water containing 10 embryos per well at 2.5, 3.5, 
4.5, 5.5 dpf, for 12h (yellow box). After these treatments, the drug was removed and replaced by egg water followed 
by 90 min green light irradiation (21 mW/cm2, 114 J.cm-2, 520 nm), depicted as a green lightning bolt. Intravenous 
injection (IV) or retro-orbital injection (RO): 1 nL of [2](PF6)2 (0 µM, 50 µM, 100 µM, 200 µM, 300 µM, 500 µM) 
were injected into the embryos at 3 dpf to 6 dpf every morning, followed by 60 min drug-to-light interval (yellow 
box) and 90 min green light irradiation (21 mW/cm2, 114 J.cm-2, 520 nm), depicted as a green lightning bolt. b) WA, 
c) RO, d) IV. b-d) Images were made of irradiated (light) and non-irradiated (dark) embryos (n=30) at 6dpf and the 
percentages of mortality, malformation and fish length were calculated (shown as means ± SD from three 







Light triggered, cancer cell-specific targeting and 
liposomal drug delivery in a zebrafish xenograft 
model 
Li Kong1⊥, Quanchi Chen2⊥, Frederick Campbell1, Ewa Snaar-Jagalska2* and Alexander Kros1* 
 
 
⊥ Authors contributed equally 
1Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 
CC Leiden, The Netherlands 
2Institute of Biology, Leiden University, Leiden 2311 EZ, The Netherlands 























Cell-specific drug delivery remains a major unmet challenge for cancer nanomedicines. Here, we 
demonstrate light-triggered, cell-specific delivery of liposome-encapsulated doxorubicin to xenograft 
human cancer cells in live zebrafish embryos. Our method relies on light triggered dePEGylation of 
liposome surfaces to reveal underlying targeting functionality. To demonstrate general applicability of 
our method, we show light triggered, MDA-MB-231 breast cancer cell specific targeting in vivo 
(embryonic zebrafish) using both clinically relevant, folate-liposomes, as well as an experimental 
liposome-cell fusion system. In the case of liposome-cell fusion, delivery of liposomal doxorubicin direct 
to the cytosol of target cancer cells resulted in enhanced cytotoxicity, compared to doxorubicin delivery 
via either folate-liposomes or free doxorubicin, as well as a significant reduction in xenograft cancer cell 




The majority (5 of 7) of clinically approved, targeted nanomedicines are liposomal formulations used 
to treat various human cancers [1,2]. All function through passive targeting of solid tumors via the 
enhanced permeability and retention (EPR) effect – a phenomenon characterized by the ill-defined 
(“leaky”) vasculature and poor lymphatic drainage of select solid tumors [3,4]. To maximize passive 
targeting to solid tumors, PEGylation of nanoparticle surfaces is a long-standing strategy to reduce 
serum protein absorption, limit nanoparticle recognition and clearance by the reticulo-endothelial 
system (RES) in the liver and spleen, and prolong circulation lifetimes [5,6]. Once passively accumulated 
within the target tumor, however, drugs must be released from a nanoparticle at effective therapeutic 
concentrations (typically cytotoxic concentrations). In the case of Doxil® (PEGylated liposomal 
doxorubicin) – the first clinically approved, targeted cancer nanomedicine – extracellular drug release 
relies on passive diffusion of doxorubicin across the liposome membrane. To maximise free drug 
concentrations within targeted tumors, methods to actively load very high concentrations of 
doxorubicin within liposomes have been developed [7]. Despite this, the superiority of clinically 
approved liposomal doxorubicin formulations, over administered free doxorubicin, remains 
contentious. It is now generally accepted that improved toxicological profiles, rather than improved 
efficacy, constitute the main pharmacological benefit of liposomal-doxorubicin formulations (over 
administration of the free drug).  
 
A potentially more effective strategy to treat cancer is to promote cellular uptake of drug-filled 
nanomedicines within cancer cells. This is most commonly attempted through the display of active 
targeting moieties (e.g. RGD, folate) from a nanoparticle surface [8,9]. However, active targeting 
strategies to promote cellular uptake of nanoparticles typically conflict with strategies employed to 
prolong circulation lifetimes. Most notably, the extremely limited cellular uptake of PEGylated 




dilemma, stimuli-responsive dePEGylation of nanoparticles within the target tumor has been 
investigated [11,12]. In the majority of cases, dePEGylation is triggered by an endogenous stimuli (low 
pH [13], matrix metalloproteinases [14]), exploiting pathophysiological differences between healthy 
and tumor tissues. However, suboptimal cleavage conditions/rates – common pH-sensitive groups (e.g. 
hydrazones, acetals and benzoic imines) are optimally sensitive at pH <6, whereas the tumor 
microenvironment is generally pH >6.5 [15]– typically lead to inefficient drug release profiles. 
Alternatively, dePEGylation of a nanoparticle can be triggered by an external stimuli, e.g. light [12]. In 
this way, nanoparticle activation can be localized with very high spatiotemporal resolution, including 
deep within tissue. Two photon excitation sources, for example, can be used to focus light within 
femtoliter (fL) volumes at tissue depths of up to 1 cm [16,17], while deeper tissues/pathologies can be 
accessed using fibre optic LEDs or injectable microLEDs [18-20]. Although the use of light to dePEGylate 
nanomedicines has mainly been used to trigger extracellular drug release from a nanocarrier [21-26], 
enhanced tumor targeting and active cellular uptake of dual responsive polymersomes following light 
activation has recently been reported [27]. In this case, near-infrared (NIR) light was used in 
combination with upconverting nanoparticles (UCNPs) to achieve efficient nanoparticle dePEGylation 
deep within a murine xenograft tumor. 
 
Herein, we show light-triggered and cell specific targeting of doxorubicin-filled liposomes to xenograft 
breast cancer cells in live embryonic zebrafish. Our method relies on responsive dePEGylation of a 
liposome surface, in situ and in vivo, to reveal underlying, active targeting functionality tethered to the 
liposome surface. To demonstrate the general applicability of this approach, we show light-triggered 
targeting of liposomal-doxorubicin formulations to cancer cells using both clinically relevant, folate-
decorated liposomes (F-liposomes, targeting the overexpressed folate receptor on xenograft MDA-MB-
231 cells [28,29]), as well as an experimental, two component (peptide E and K) fusion system that 
promotes direct fusion of liposome and cell membranes, with concurrent cytosolic delivery of 
encapsulated liposomal content (Figure 1) [30]. For the fusion system, liposome-cell interactions rely 
on the recognition and binding of two coiled-coil forming peptides – peptide E (amino acid sequence: 
(EIAALEK)n) and peptide K (amino acid sequence: (KIAALKE)n) – tethered to opposing lipid membranes 
[31]. For this system to work, target cancer cell membranes must, therefore, first be enriched with the 
synthetic lipopepetide CPK (cholesterol-PEG4-peptide K, see Scheme S1 for chemical structure) to form 
K-funtionalised cells. Once engrafted in vivo, these cells can recognize, bind to and fuse with circulating 
liposomes whose membranes are enriched with the complementary lipopepetide, CPE (cholesterol-
PEG4-peptide E, see Scheme S1 for chemical structure). Crucially, prior to light-triggered dePEGylation, 
both PEGylated E- and PEGylated F-liposomes freely circulated throughout the vasculature of the 







Figure 1 Light-triggered, cancer-cell specific liposome-cell fusion in xenograft zebrafish embryos. Human cancer 
cells are first pre-functionalised with cholesterol-peptide K4 in vitro. Functionalised cancer cells are then injected 
into the circulation (via the Duct of Cuvier) of 2-day old zebrafish embryos. Xenograft cancer cells quickly 
accumulate within the caudal hematopoietic tissue (CHT) of the embryo. One hour after cancer cell injection, EPEG-
liposomes are injected into circulation via the posterior caudal vein (PCV). Prior to light triggered dePEGylation, 
liposomes are confined to the vasculature of the fish and freely circulate. Following UV irradiation and in situ 
dePEGylation, liposomes rapidly and selectively bind to and fuse with xenograft cancer cells. This interaction is 
mediated through the recognition of fusogenic peptides E and K displayed from opposing lipid membranes. 
Liposome-encapsulated cargos (eg. cytotoxic drugs) are delivered directly to the cytosol of the recipient cell. 
 
Materials  
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (DOPE-
NBD), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DOPE-LR), 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(6-((folate)amino)hexanoyl) (DPPE-FolateCap) 
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] 
(ammonium salt) (DSPE-PEG5000) were purchased from Avanti Polar Lipids. 1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine-Atto633 was purchased from ATTO-TEC GmbH (Germany). Cholesterol, 
doxorubicin hydrochloride (DOX), propidium iodide (PI) and all other chemical reagents were purchased 
at the highest grade available from Sigma Aldrich and used without further purification. All solvents 
were purchased from Biosolve Ltd. Phosphate buffered saline (PBS): 5 mM KH2PO4, 15 mM K2HPO4, 150 
mM NaCl, pH 7.4. Lipopeptide constructs – E4 and K4 – were synthesized as previously reported [30]. 
Photolabile cholesterol-PEG constructs – PEG2000 and PEG5000 – were synthesized as previously reported 
[32].  
Light source 
A 375-nm LED (Maximum measured wavelength = 370 nm, FWHM = 13.4 nm; H2A1-H375-S, Roithner 
Lasertechnik, Vienna, Austria), driven by a custom-built LED driver (I = 350 mA), was used as UV light 




light actinometry) and light doses (for cell and zebrafish experiments) are reported for individual 
experiments. For monitoring the photolysis of EPEG-liposomes (Figure S2), UV lamp (SUNON lamp 
SF9225AT; 56.8 W, 50-60 Hz) was used as UV light source. 
 
Liposome formulation and biophysical characterisation 
Phospholipids (DOPC:DOPE:cholesterol; 2:1:1), as a stock solution (10 mM) in chloroform, and either 
lipopeptide E4 or K4, as a stock solution (100 µM) in chloroform:methanol (1:1), or DPPE-Folate as a 
stock solution (100 µM) in chloroform,  were mixed to the desired molar ratios and dried to a film, first 
under a stream of N2 and then >1h under vacuum. The lipid film was then re-hydrated in PBS and 
sonicated (Branson 2510 Ultrasonic Cleaner) for 5 min at 55oC to yield E-liposomes, K-liposomes or F-
liposomes respectively (1 mol% E/K/folate in all cases).   
Post-modification of E- and F-liposomes with photolabile cholesterol-PEG constructs was carried out as 
previously described [32].  Briefly, for lipid mixing experiments involving E-liposomes, hydrated and 
sonicated solutions of cholesterol-PEG (2-20 µM) in PBS were added in equal volumes to E-liposomes 
(200 µM total [lipid]) in PBS and incubated for 30 min to yield E-liposomes (100 µM total [lipid]) with 
varying mol% cholesterol-PEG displayed from the outer membrane leaflet. For lipid mixing 
experiments, fluorescent lipid probes (DOPE-NBD and DOPE-LR, 0.5 mol% each) were included within 
E-liposome formulations. 
Hydrodynamic diameters of all liposomes, as measured by dynamic light scattering (DLS; 
Zetasizer Nano ZS, Malvern Instruments, UK) were approx. 100 nm and polydispersities <0.2. DLS 
measurements were made at room temperature and at a total lipid concentration of 100μM. For zeta 
potential measurements (Zetasizer Nano ZS, Malvern Instruments, UK), liposomes were formulated in 
ddH2O and diluted in salt (NaCl) solution. Zeta potentials were measured at room temperature, at 500 
μM total lipid concentration and 10mM NaCl concentration. All reported DLS measurements and zeta 
potentials are the average of three measurements. For DLS and zeta potential experiments monitoring 
changes following light activation, liposomes were irradiated (370 ± 7 nm, 202 mW/cm2) for 15 mins in 
quartz cuvettes with the LED mounted 1 cm from the sample.  
 
For transmission electron microscopy (TEM) images of EPEG-liposomes and FPEG-liposomes, a drop of 
liposome solution (1 mM) was placed on a lacey carbon covered TEM copper grid for 3 mins before 
dabbing dry through the underside of the grid with a tissue.  The sample was then washed three times 
with ddH2O, Finally, a drop of phosphotungstic acid (TPA, 1% w/v) in H2O was added and the sample left 






Propidium iodide encapsulation within E-liposomes 
Propidium iodide (PI) was loaded into E-liposomes via passive encapsulation. Briefly, lipid films (1 mM 
total lipids) were hydrated in PBS containing 15 mM PI and sonicated for 2−3 min in a sonication bath 
at 55 °C. Un-encapsulated PI was removed through size exclusion chromatography (illustraTM NAPTM 
SephadexTM G-25, GE-Healthcare, USA) according to the manufacturer’s guidelines. Final concentration 
for cell experiments: liposomes (400 µM total lipids); encapsulated PI (75 µM). 
Doxorubicin encapsulation within E- and F-liposomes 
Active loading of doxorubicin hydrochloride (DOX) was carried out as previously reported [7]. Briefly, 
liposomes (10mM total lipid) were formulated (sonication) in sodium citrate buffer (pH 3.5) before 
being passed through a size exclusion column (illustraTM NAPTM SephadexTM G-25, GE Healthcare, USA) 
using PBS buffer (pH 7.4) as eluent to set up a pH gradient across the liposome membrane. Next, DOX 
(powder) was added to the liposomal solution at a final concentration of 1 mg/mL and incubated 
overnight at 4 °C. Finally, free DOX was removed by size exclusion chromatography (illustraTM NAPTM 
SephadexTM G-25, GE Healthcare, USA). The entrapment efficiency (EE) and drug loading content (DL) 
of DOX was determined using UV−vis spectrophotometry (Cary 300 UV-Vis, Agilent). Briefly, liposomes 
were solubilized by addition of Triton X-100 (0.5% v/v), absorption measured at 480nm, and [DOX] 
calculated against a predetermined DOX calibration curve (free DOX in PBS containing Triton X-100 




∗ 100%  
DL =
Weight of DOX
Weight of liposomes 
∗ 100%  
 
Where C DOX in liposomes is the concentration of DOX determined in the liposomes, Ctotal is the total added 
concentration of DOX, ‘Weight of DOX’ is the weight of DOX encapsulated in the liposomes and ‘Weight 
of liposomes’ is the weight of liposomes. Unfortunately, active loading of DOX, in this case, did not yield 
the high reported encapsulation efficiencies (typically >85%) as expected. After final size exclusion 
column chromatography, EPEG-liposomes (4 mM total lipid concentration) contained 200 µM DOX (5% 
EE, 4.02% DL), whereas FPEG-liposomes (4 mM total lipid concentration) contained 195 µM DOX (4.8% 
EE, 3.92% DL).  
DOX concentrations for WST in vitro experiments: liposomal-DOX formulations either diluted or 
concentrated (spin column) to desired [DOX] – ie. 200 µM DOX = 4 mM total lipids; 50 µM DOX = 1mM 




NOTE: For F-liposomes, total lipid concentrations (and therefore [folate]) are 2.5% higher than for E-
liposomes (and [peptide E]) at identical [DOX] to compensate for the slight variation in EE between E- 
and F-liposomes.  
NOTE: where [DOX] <25 µM and [total lipid] <500 µM, the concentration of peptide E (1mol%, displayed 
from the liposome surface) is less than the concentration of peptide K (5 µM, displayed from the cell 
membrane).  
Final DOX concentrations for in vivo (zebrafish embryo xenograft) experiments: 200 µM DOX; 4 mM 
total lipids (40 µM peptide E). 
 
In vitro DOX release 
To monitor the release of DOX from liposomes, 1 mL of DOX loaded liposomes (200 µM DOX; 4 mM EPEG 
liposomes or 4.1 mM FPEG liposomes) in PBS were placed in dialysis tubing (MWCO: 3.5 KDa) and 
dialyzed against 20 mL PBS at 37oC. At various time intervals, 3.0 mL of dialysis buffer was removed and 
replaced with fresh buffer. The amount of released DOX was quantified by flurescence emission at 595 
nm (Ex = 480 nm) against a predetermined calibration curve (DOX in PBS). The cumulative release was 
calculated according to the following equation: 




where Ccumulative release is the cumulative released concentration of DOX in dialysis buffer and Ctotal is the 
total added concentration of DOX. At each successive timepoint, Ccumulative release was corrected to account 
for the removed and replaced dialysis buffer of previous timepoints (eg. Ccumulative release (at the 4th time point) = 
3(CDOX at the 1st time point + CDOX at the 2nd time point + CDOX at the 3rd time point)  +  20(CDOX at the 4th time point)). To monitor 
light activated release of DOX, liposomes were irradiated (370 ± 7 nm, 202 mW/cm2) for 15 mins in 
quartz cuvettes, with the LED mounted 1 cm from the sample, before adding to the dialysis tube. 
 
Photolysis of EPEG-liposomes 
A solution of EPEG-liposomes (total lipid = 5 mM, 4 mol% PEG5000, 1 mol% of lipopeptide E4) in PBS was 
irradiated under the UV lamp (SUNON UV lamp SF9225AT; 56.8 W, 50-60 Hz), for 5 min, followed 
immediately by acquisition of the UV-visible absorption spectra. The same sample was then re-
irradiated and this cycle repeated for cumulative irradiation time points of 10, 20, 30, 40 and 60 min.  
 
Lipid mixing assay 
For lipid mixing assays, NBD fluorescence (excitation: 465 nm emission: 530 nm) was measured upon 
mixing fluorescent EPEG-liposomes and non-fluorescent K-liposomes every 20 s for 3500 s (TECAN Plate 
Reader Infinite M1000). The 0% value was determined by measuring NBD emission of EPEG-liposomes 
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to which an equal amount of PBS (in place of K-liposomes) was added. The 100% value was determined 
using liposomes containing half the fluorescent probe (DOPE-NBD and DOPE-LR) concentrations ie. 0.25 
mol%. The percentage of lipid mixing (%F(t)) was calculated as:  
%F(t) =
F(t) −  F0
Fmax −  F0
 
where F(t) is the fluorescence intensity measured, F0 is the 0% fluorescence intensity and Fmax is the 
100% fluorescence intensity. For measuring the effects of UV irradiation on the rate of lipid mixing, 
EPEG-liposomes were irradiated liposomes were irradiated (370 ± 7 nm, 202 mW/cm2) for 15 mins with 
the LED mounted at a distance of 1 cm from the sample, prior to the addition of K-liposomes. 
 
Cell culture, WST and in vitro assays  
HeLa cells and MDA-MB-231 breast cancer cells (ATCC), stably expressing GFP (Plasmid #106172; 
Addgene.org) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)/F12, supplemented with 
10% fetal calf serum (FCS, iron supplied), 2% L-glutamine. Cells were cultured in an atmosphere of 5% 
CO2 at 37°C. Medium was refreshed every two days and cells passaged at 70% confluence by treatment 
with trypsin-EDTA (0.05% trypsin).  
For in vitro assays (Figure 2b), HeLa cells (1x105 mL-1) were transferred to 8-well cell culture plates (300 
µL, µ-Slide 8 Well, Ibidi GmbH) and cultured for a further 24 h. A solution of lipopeptide K4 (5 µM in 
DMEM + 10% FCS; prepared by sonication, 5 min, 55oC, Branson 2510 Ultrasonic Cleaner), was added 
(300 μL) to cells and incubated for 2 h at 37 °C. The lipopeptide K4 solution was carefully removed and 
cells washed (3 x PBS). EPEG-liposomes (300 μL, 400 µM, 8 mol% PEG2000 or 4 mol% PEG5000, 1mol% DOPE-
NBD) in PBS, with encapsulated PI (75 µM), were then added to cells and incubated at 37 °C for 20 min. 
Cells were then washed (3 x DMEM+FCS) and immediately imaged by confocal microscopy 
(Leica TCS SP8, Solms, Germany; wavelengths: NBD-DOPE: Ex/Em: 455/530 nm (Ex laser: 488 nm), 
propidium iodide: Ex/Em: 535/617 nm (Ex laser: 543 nm). For light triggered membrane fusion, EPEG-
liposomes (300 μL, 400 mΜ, 4 mol% PEG5000) were added to cells and irradiated (15 mins, 370 ± 7 nm, 
50.6 mW/cm2, light dose = 45.5 J/cm2) from directly above (2cm) the well plate. Following irradiation, 
cells were incubated for a further 20 min, washed (3 x DMEM+FCS) and imaged. To demonstrate spatial 
control over liposome-cell membrane fusion, EPEG-liposomes (300 μL, 400 µΜ, 4 mol% PEG5000) were 
added cells, the well plate half covered with aluminum foil and irradiation applied as above. Following 
incubation at 37 °C for 20 min, cells were carefully washed (3 x DMEM+FCS) and confocal imaging 
performed across the boundary of the (now removed) aluminium foil.  
For WST cell proliferation assays, MDA-MB-231 cells were seeded in 96-well plates (10,000 cells per 




DMEM+FCS) was added to cells, incubated for 2 h and washed away (3 x PBS). For F-liposomes, cells 
were simply washed with PBS prior to addition of liposomes. To the cells were then added either 
solutions of free DOX (100 μL, varying concentrations in 1:1 PBS:DMEM+FCS), EPEG-liposomes or FPEG-
liposomes, both containing DOX (100 μL varying liposome/DOX concentrations in 1:1 PBS:DMEM+FCS) 
and incubated for 2 h. For the ‘+UV’ liposome samples, cells were irradiated (15 mins, 370 ± 7 nm, 50.6 
mW/cm2, light dose = 45.5 J/cm2) immediately after sample addition to cells. Following incubation, cells 
were washed (3 x DMEM+FCS), re-suspended in DMEM+FCS and incubated for a further 24 h. Cell media 
was then removed and 100 μL Cell Proliferation Reagent, WST-1 (Sigma) added to each well. Cells were 
incubated for a further 3 h, according to the supplier guidelines. To determine cell viability, absorbance 
at 450 nm was measured. All experiments were carried out in quadruplicate. 
 
Zebrafish experiments 
Zebrafish (Danio rerio, strain AB/TL) were maintained and handled according to the guidelines from the 
Zebrafish Model Organism Database (http://zfin.org) and in compliance with the directives of the local 
animal welfare committee of Leiden University. Fertilization was performed by natural spawning at the 
beginning of the light period, and eggs were raised at 28.5 °C in egg water (60 µg/mL Instant Ocean sea 
salts). At 24 hours post-fertilization (hpf), 0.2 mM N-phenylthiourea was added to the egg water to 
prevent malanization. At 2 days post-fertilisation (dpf), embryos were anaesthetized with 0.01% tricaine 
and embedded in 0.4% agarose containing tricaine prior to microinjection. In addition to WT embryos, 
the established zebrafish line Tg(kdrl:GFP/mpeg1:GAL4gl24/UAS-E1b:nfsB-mCherryi149) [33] was also 
used (Figure 3a).  
 
For biodistribution studies in zebrafish embryos, MDA-MB-231 cells (2 x 106) were suspended in 
(PBS/EDTA), pelleted (5 min, 1200 rpm), washed (PBS), pelleted again and finally re-suspended in 2% 
PVP in PBS (10 µL) ready for injection. Suspended cells were loaded in a glass capillary needle, prepared 
using a Flaming/Brown micropipette puller (model P-99, HEAT=496, PULL=95, VEL.=60, TIME=90, Sutter 
Instrument Co.) Forceps were used to cut the end of the needles and the exposure time and gas pressure 
were adjusted in order to inject around 300 cells. Cells were engrafted into the circulation of a 2-day 
old embryo, via the Duct of Cuvier. In the case of E-liposome experiments, MDA-MB 231 cells were 
pretreated with lipopeptide-K, as for in vitro assays. One hour after engraftment, EPEG- or FPEG-liposomes 
(1 mM, 3 nL, 4mol% PEG5000, 1mol% DOPE-LR) in PBS were injected into circulation via the posterior 
cardinal vein. Embryos were kept at 34 °C. For in situ UV irradiation (15 mins, 370 ± 7 nm, 13.5 mW/cm2, 
light dose = 0.45 J/embryo), the LED light source was positioned directly above (3 cm) the embryo in 
agarose. Images were taken 45 min after liposome injection using either a Leica MZ16FA fluorescent 
microscope coupled to a DFC420C camera or Leica TCS SPE confocal microscope. Wavelength settings 
for GFP Ex: 488 nm, Em: 500-550 nm and for rhodamine Ex laser: 552 nm, Ex laser: 570-650 nm. Images 
were processed and quantified using the Fiji distribution of ImageJ [34].  
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For doxorubicin delivery in zebrafish embryos, 3 nL doxorubicin-filled EPEG-liposomes (4 mM total lipids, 
4 mol% PEG5000, 200 µM DOX) in PBS were injected into the circulation of 2-day old xenograft zebrafish 
embryos (K-functionalised MDA-MB-231 cells, generated as described above) via the posterior cardinal 
vein. Embryos were kept at 34 °C throughout the course of the experiment. Where applicable, UV 
irradiation (15 mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 J/embryo) was performed immediately 
following liposomes injection. The LED light source was positioned directly above (3 cm) the embryo in 
agarose. Four days post-injection (4 dpi), fluorescent images were obtained, using a Leica MZ16FA 
fluorescent microscope coupled to a DFC420C camera and Leica TCS SPE confocal microscope, and 
cancer cell mass, within the tail invasive site, quantified based on the green fluorescent signal of 
xenograft MDA-MB-231 cells (Image analysis software: ImageJ 1.51n, National Institutes of Health, 
USA). One-way ANOVA tests were performed to compare means of the three groups of data. 
Statistical Analysis  
Data presented as mean values ± SD. No pre-processing of data was performed. Data was analysed by 
one-way ANOVA (non-parametric and mixed) statistical test using GraphPad Prism 8.0.1. Significance is 
shown as P value (****, p < 0.0001; NS, not significant). Sample sizes for each statistical analysis are 
individually reported and no statistical methods were used to predetermine sample size.  
 
Results and Discussion  
We have previously shown the interaction between fusogenic peptides E and K, displayed from 
opposing membranes, can be sterically shielded through PEGylation of E-functionalized liposomes (EPEG-
liposomes) [35]. Furthermore, through incorporation of a photocleavable linker, we have shown precise 
spatiotemporal control of liposome-liposome fusion and liposome-cell docking through light triggered 
dePEGylation of EPEG-liposomes in vitro [32]. In this case, PEG2000 was sufficient in length to sterically 
shield the interaction between complementary, three heptad (21 amino acid) E and K peptides (E3 and 
K3). However, to achieve full fusion of liposome and cell membranes, E and K peptides must be extended 
to four heptad repeats (E4/K4, 28 amino acids) [30].  
 
To assess the optimal PEG length necessary to sterically shield the E4/K4 peptide interaction, lipid mixing 
experiments between E4- and K4-liposomes were, therefore, first performed in vitro (Figure 2a). For 
this, photolabile cholesterol-o-nitrobenzyl-PEG constructs (PEG2000 and PEG5000, see Scheme S1 for 
chemical structure) were incorporated (via post-modification), at varying mol% (0-10 mol%) within E4-
liposome formulations (see Supporting Information for size and zeta potentials of all liposomes, Figure 
S1 for TEM images of EPEG- and FPEG-liposomes). As photocleavable functionality, methoxy-
functionalised o-nitrobenzyl groups were selected as: 1) they have  been successfully used as photocage 
of a variety of bioactive compounds and biomolecules in complex biological solutions, 2) they have 
rapid photolysis kinetics, and 3), as the methyl substituted variant (at the benzylic position), the evolved 




tetrameric E4 and K4 peptides displayed from liposome surface, PEG2000 was shown ineffective at 
shielding the interaction between complementary peptides, as evidenced by significant lipid mixing of 
E- and K-liposome membranes even at high incorporated mol% of PEG. In contrast, >2 mol% 
cholesterol-PEG5000 incorporated within the E-liposome membrane was sufficient to completely shield 
the E4/K4 interaction. Furthermore, upon UV irradiation (15 mins, 370 ± 7 nm, 202 mW/cm2, see Figure 
S2 for dePEGylation efficiency) of an equimolar solution of K-liposomes and EPEG-liposomes (4 mol% 
photolabile cholesterol-PEG5000), complete restoration of lipid mixing of K- and E-liposome membranes 
(Figure 2a) and a concomitant increase in liposome size, due to the fusion of two or more distinct 
liposomes (Figure S3), was observed. Given the significantly smaller molecular size of folate, we 
assumed 4 mol% PEG5000 would be amply sufficient to sterically mask displayed folate functionality from 
the F-liposome surface. EPEG-liposomes (containing 4 mol% photolabile cholesterol-PEG5000) were stable 
in aqueous media (+ 10% serum) for at least 20h at room temperature (Figure S4).   
 
Next, light induced liposome-cell interactions, mediated through E/K complexation, were assessed in 
vitro (Figure 2b-d). For these experiments, HeLa cells were pre-functionalised with lipopeptide K4 
constructs (to form K-functionalised cells), as previously described [37]. EPEG-liposomes (400 µM, 4 
mol% PEG2000 or PEG5000) – containing a fluorescent lipid probe (1 mol% DOPE-NBD, green) and 
encapsulated propidium iodide (PI, a turn-on intercalator, 75 µM, red) – were incubated with K-
functionalised cells, washed and imaged, both before and after UV irradiation (15 mins, 370 ± 7 nm, 
50.6 mW/cm2, light dose = 45.5 J/cm2). Under analogous irradiation conditions and experimental 
setups, no photocytotoxicity was observed [24]. Supporting lipid mixing experiments, EPEG-liposomes 
(PEG2000, 4 mol%), prior to light irradiation, interacted with K-functionalised HeLa cells (Figure 2b), 
confirming PEG2000 is an insufficient steric shield in blocking E4/K4 interactions in both liposome-
liposome and liposome-cell fusion experiments. In contrast, prior to light triggered dePEGylation, EPEG-
liposomes (PEG5000, 4 mol%) showed no interaction with cells nor intracellular PI delivery (Figure 2c). 
However, subsequent in situ UV irradiation (15 mins, 370 ± 7 nm, 50.6 mW/cm2, light dose = 45.5 J/cm2) 
resulted in HeLa cell membranes homogenously labelled with liposome-associated lipid probes (DOPE-
NBD) and PI clearly dispersed within the cell cytosol (Figure 2d). Analogous localization and 
homogenous dispersion of lipid probes throughout target plasma cell membranes (rather than punctae 
within cells, indicative of endosomal uptake) was previously observed in E4/K4 mediated liposome-cell 
fusion experiments, including in the presence of various endocytosis inhibitors [30]. From these 
experiments, 4 mol% PEG5000 displayed on the surface of E4-liposomes was deemed sufficient to inhibit 
putative E4/K4 mediated liposome-cell fusion and, by using photolabile lipid-PEG constructs, precise 




Figure 2 Optimisation of required PEG length. A. Lipid mixing experiments of E- and K-liposomes incorporating 
varying mol% cholesterol-nitrobenzyl-PEG2000 (left) or cholesterol-nitrobenzyl-PEG5000 (right) within E-liposome 
formulations. 0 mol% (black), 2 mol% (red), 4 mol% (blue), 8 mol% (pink) and 10 mol% (green), 4mol% following 
UV irradiation  (15min, 370 ± 7 nm, 202 mW/cm2) (orange). Liposome-cell fusion of EPEG-liposomes (4 mol% PEG2000, 
– before UV, (B); 4 mol% PEG5000 before (C) and after (D) applied UV light (15 mins, 370 ± 7 nm, 50.6 mW/cm2, light 
dose = 45.5 J/cm2). EPEG-liposomes contained 1 mol% DOPE-NBD (lipid probe, green) and encapsulated PI (75 µM, 
turn-on intercalator, red), scale bars = 30 μm. 
 
Next, light triggered, active targeting of liposomes to xenograft MDA-MB-231 breast cancer cells was 
assessed within live embryonic zebrafish (Figure 3). Both F-liposomes, targeting the overexpressed 
folate receptor on MDA-MB-231 cells [28,29], and E-liposomes, targeting K-functionalised MDA-MB-
231 cells, were independently tested. Zebrafish embryos are small (2-3 mm in length) and transparent 
enabling fluorescence imaging of specific biological events across entire living organisms in real time 
[38]. Zebrafish are increasingly used as model organisms to study fundamental processes such as 
embryogenesis, cell migration, sleep and disease pathogenesis [39,40]. This includes the development 
of embryonic zebrafish xenograft models to study the pathogenesis of human cancers [41-43], including 




microinjected into the circulation of 2-day old zebrafish larvae via the duct of Cuvier and quickly 
accumulated (<1 hours post injection (hpi)) within the caudal hematopoietic tissue (CHT) [46]. One hour 
after injection of cancer cells, either fluorescently labelled EPEG- or FPEG-liposomes (4 mol% PEG5000, 1 
mol% DOPE-LR probe) were injected (1 mM, 3 nL) into circulation via the posterior cardinal vein (PCV). 
Prior to UV irradiation, both EPEG- and FPEG-liposomes freely circulated, were confined within the 
vasculature of the embryo, and no co-localization of liposomes with either xenograft cancer cells or key 
RES cell types of the embryonic zebrafish (e.g. scavenging endothelial cells (SECs) or blood resident 
macrophages) [47], was observed (Figure 3).  
 
Following in situ UV irradiation (15 mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 J/embryo) of the 
embryonic fish, however, both E- and F-liposomes rapidly and selectively co-localised with xenograft 
cancer cells (<30 min, i.e. prior to first image acquisition) (Figure 3). Under these irradiation conditions, 
embryos continued to develop normally (up to 6 days post-fertilisation (dpf)) and no phenotypic 
abnormalities were observed (Figure S6). Under identical conditions, the biodistribution of FPEG-
liposomes containing non-cleavable PEG5000 (DSPE-PEG5000, Avanti) remained unchanged before and 
after in situ light irradiation, demonstrating the targeting requirement of both liposomes containing 
photocleavable PEG as well as UV light (Figure S7). In the case of E-liposomes, E/K specificity was 
confirmed by repeating the experiment in the absence of peptide K (displayed from xenografted cancer 
cells). In this case, no E-liposome accumulation with cancer cells was observed following UV irradiation, 
confirming the requirement and selectivity of E4/K4 recognition and complexation for cell specific 




Figure 3 Cancer cell-specific, light triggered liposome-cell interactions in vivo. A. Biodistribution of EPEG-liposomes 
(1 mM, 4 mol% PEG5000, containing 1 mol% DOPE-Atto 633, far red) in Tg(kdrl:GFP/mpeg:RFP) zebrafish embryos (2 
dpf), following i.v. injection. Liposomes are confined within the vasculature of the embryo and freely circulate. No 
liposome co-localisation with either endothelial cells (green) or (blood resident) macrophages (blue) is observed 
indicative of the ability of EPEG-liposomes to evade key RES cell types. Confocal z-stacks acquired at 1hpi.  B,C. MDA-
MB-231 human breast cancer cells, stably expressing GFP, were injected into the circulation of a 2-day old zebrafish 
embryo and quickly accumulated in the caudal hematopoietic tissue (CHT). In the case of E-liposomes, cells were 




containing 1 mol% DOPE-LR, red) were injected into circulation. Prior to UV irradiation, both EPEG- or FPEG-liposomes 
were freely circulating, confined within the vasculature of the fish (left image panels). Following UV irradiation (15 
mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 J/embryo) and photolytic dePEGylation, both E- and F-liposomes 
selectively bound to xenograft cancer cells within the CHT (right image panels). Data are representative of three 
independent experiments (each n=5). Field of view = boxed region in embryo cartoon. Scale bars = 100 μm. 
 
Extending our approach to liposome mediated, intracellular drug delivery, we first measured the in vitro 
cytotoxicity (MDA-MB 231 cells, WST assay) of doxorubicin-filled EPEG- and FPEG-liposomes (4 mol% 
PEG5000), before and after light activation, and compared this to the toxicity of free doxorubicin (Figure 
4a). Again, for experiments involving EPEG-liposomes, cells were first pretreated with lipopeptide K. For 
both EPEG- and FPEG-liposomes, cell viability was unaffected in the absence of applied UV light, and, in 
the case of EPEG-liposomes, no intracellular DOX delivery was observed (Figure 4b, FPEG-liposomes were 
not analyzed under the fluorescence microscope). Upon light triggered dePEGylation, however, both E- 
and F-liposome mediated delivery of doxorubicin led to enhanced cytotoxicity (IC50 approx. 100 µM and 
200 µM, respectively for E- and F-lipo-DOX) compared to free DOX (IC50 approx. 300 µM). Interestingly, 
under these experimental conditions, the most potent cytotoxicity was observed for E/K mediated 
liposomal delivery of DOX. This suggests DOX delivery direct to the cell cytosol, following liposome-cell 
membrane fusion, is a potentially potent method of drug delivery. Importantly, freshly prepared DOX-
loaded liposomes used in all cases, as significant DOX leakage (30-40%) from the liposome core was 
observed for all formulations during prolonged storage and would affect the efficiency of liposomal 
DOX delivery over time (Figure S9).  
 
Next, doxorubicin-filled EPEG-liposomes (4 mol% PEG5000, 250 µM doxorubicin) were intravenously 
microinjected into embryonic zebrafish xenografts (K-functionalised MDA-MB-231 breast cancer cells) 
(Figure 4c) and the efficacy in reducing tumor burdens assessed (Figure 4d and 4e). For this, relative 
cancer cell proliferation was quantified by measuring total GFP fluorescence of xenograft cancer cells. 
Here, significantly (p<0.0001) reduced cancer cell proliferation (46.9% reduction) was only observed in 
the ‘+UV’ group. In the absence of light, tumor proliferation was unaffected and no significant 
difference in cancer cell numbers was measured compared to the untreated controls. Again, using 
cancer cells unfunctionalized with peptide K, no reduction in cancer cell proliferation was observed 





Figure 4 Delivery of liposome-encapsulated doxorubicin to MDA-MB 231 cells both in vitro and in vivo. a. MDA-MB-
231 breast cancer cell viability in vitro (measured by WST assay) following 2 h incubation with either DOX-filled EPEG-
liposomes (4 mol% PEG5000), before (red) and after (blue) UV activation (15 mins, 370 ± 7 nm, 50.6 mW/cm2, light 
dose = 45.5 J/cm2); FPEG-liposomes (4 mol% PEG5000), before (pink) and after (cyan) UV activation; or free doxorubicin 
(black) without UV irradiation. For +UV samples, liposomes were added to cells and immediately irradiated. 2 h 
incubation time includes 15 min irradiation time. In the absence of light, both EPEG- and FPEG-lipo-DOX formulations 
were non-toxic. Following light activation, liposome mediated delivery of doxorubicin resulted in enhanced 
cytotoxicity (F-liposomes, IC50 = approx. 200 µM; E-liposomes, IC50 = approx. 100 µM) compared to free doxorubicin 
(IC50 = approx. 300 µM). In all cases, freshly prepared DOX-filled liposomes were used to minimize the effects of 
DOX leakage over time. b. Intracellular DOX delivery by EPEG-liposomes (200 µM encapsulated DOX, red) and K-
functionalised MDA-MB-231 breast cancer cells, stably expressing GFP, green, before (left) and after (right) UV 
irradiation (15 mins, 370 ± 7 nm, 50.6 mW/cm2, light dose = 45.5 J/cm2). Scale bars=100 μm. c. Timeline of zebrafish 
development, MDA-MB-231 cell injection, liposome injection and quantification in the zebrafish embryo. At 2 dpf, 




engraftment, DOX-filled, EPEG-liposomes (3nl, 4mM total lipid; 200 µM encapsulated doxorubicin) were injected into 
circulation via the posterior cardinal vein. UV irradiation (15 mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 
J/embryo), where appropriate, was performed immediately after the injection of liposomes. Tumor burden 
analysed at 4 dpi. d,e. Visualisation and quantification of cancer proliferation in the zebrafish embryo. Significant 
(P<0.0001) reduction in tumor volume was only observed for DOX-filled, EPEG-liposomes, following in situ light 
activation. In the absence of light activation, tumor progression/burden was unaffected as for untreated controls. 
Data is presented as mean values ± SD, each point on the scatter plots represents one larva. Brackets indicate 
significantly different values (****, p < 0.0001; NS, not significant) based on one-way ANOVA statistical testing. n = 
61 individually injected embryos (untreated group). n = 114 (without UV group) and n = 108 (with UV group). Scale 
bars = 500 μm. 
 
Conclusion  
Here, we successfully demonstrate light triggered targeting of liposomes to xenograft cancer cells in 
vivo. Our approach relies on the light triggered dePEGylation of liposome surfaces, revealing underlying 
targeting functionality. General applicability of this approach was demonstrated using both an 
experimental two component fusion system (peptides E and K) as well as clinically relevant folate-
decorated liposomes. Both EPEG- and FPEG-liposomes, prior to light triggered activation, freely circulated 
throughout the vasculature of the embryonic zebrafish, and showed no significant interactions with 
either target cancer cells or key RES cell types (scavenging endothelial cells or blood resident 
macrophages) within the fish [47]. In mammals, analogous RES cell types, namely liver sinusoidal 
endothelial cells (LSECs), Kupffer cells (hepatic, blood resident macrophages) and splenic macrophages, 
are responsible for the clearance of the majority of i.v. administered nanoparticles from the body [48]. 
While there is currently no established model for the EPR effect in embryonic zebrafish, the implications 
of our findings are that both EPEG- and clinically relevant FPEG-liposomes, prior to light activation, would 
likely evade RES clearance in mammals, prolonging circulation lifetimes and the potential for liposome 
accumulation in pathological tissues with enhanced permeability.  
 
In the case of E-liposome targeting, prior modification of cancer cell membranes with complementary 
peptide K is a pre-requisite. While this system provides us with a fundamental tool to probe alternative 
liposomal drug delivery routes (i.e. fusion vs. endocytosis), as well as a highly selective handle for 
targeting as is shown in this study, the necessity for components displayed from both liposome and 
target cell membranes is a major limitation to further in vivo application. Similarly, the use of UV light 
as a trigger raises valid concerns over applicability in larger, non-transparent mammals, including 
humans. To some extent, these concerns relate to the poor tissue penetration of UV light (approx. 100-
200 µm). As a result, the clinical use of UV light is restricted to the topical treatment of cosmetic skin 
disorders, including psoriasis, acne and eczema [49]. However, these limitations are increasingly being 
overcome, as fundamental advances in fiber optic [18] and wireless LED technologies [19,20] facilitate 
the localized delivery of UV light deep within patients. Alternatively, extended exposure to UV light is 
known to pose a significant health risk, with the potential to cause DNA damage, cytotoxicity and cancer 
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[50]. In this study, applied UV-A (370 ± 7 nm) light doses to zebrafish embryos (12.1 J/cm2) are well 
below recommended (skin) exposure limits (32 J/cm2 @ 375 nm). Furthermore, while single photon 
UV-A (370 nm) light is optimal for the photolysis of o-nitrobenzyl functionalities, the use of 2-photon 
excitation sources [51,52] or photolabile chemistries sensitive to longer wavelength, visible light 
[53,54], offer options for light activation both deep in tissue and with reduced photocytotoxicity. 
 
Finally, this study highlights the unique opportunities offered by the embryonic zebrafish model in the 
design and optimization of nanomedicines. In this study, we were able to 1) generate our desired 
xenograft cancer model without the need for immunosuppression (the adaptive immune system is not 
yet developed zebrafish embryos), 2) directly visualize the changing pharmacokinetics of stimuli-
responsive nanoparticles in situ, in vivo and in real time and 3) set-up and perform efficacy studies, 
involving several hundred animals, within 1 week. The combined level of detailed assessment, low cost 
and experimental speed, afforded by the embryonic zebrafish model, is simply not achievable using 
conventional animal models (eg. mice and rats). As to the predictive potential of the embryonic 
zebrafish, we, and others, have recently shown both pharmacokinetic parameters and key cellular 




Cancer cell-specific drug delivery remains a major unmet challenge for nanomedicines. In this work, we use light 
to ‘turn on’ the targeting of nanomedicines, in situ and in vivo, enabling on demand cancer cell specific drug delivery 
in live zebrafish embryos. 
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Scheme S1a. Chemical structures of cholesterol-PEG and photolysis products, b. Chemical structure of 

























Table S1 Size and zeta potentials of E/K liposomes (containing 1mol% E or K lipopeptide). EPEG-liposomes contain 4 
mol% cholesterol-o-nitrobenzyl-PEG. Base liposome formulation (DOPC:DOPE:Chol; 2:1:1) contains neither 
lipopetide or PEG.  No significant differences in size were observed for EPEG-liposomes containing 2, 6, 8 or 10mol% 
PEG (data not shown). Light irradiation (15 mins, 370 ± 7 nm, 202 mW/cm2) 
 
FPEG-liposomes  
(1mol% DPPE-Folate, 4mol% PEG5000) 
Size d. (nm) PDI Zeta potential (mV) 
-UV 91.3 0.10 -7.9 
+UV 92.1 0.13 -6.2 
 

























Figure S1 TEM images (TPA stained) of EPEG-liposomes (a) and FPEG-liposomes (b) (total lipid =1 mM, 4 mol% PEG5000, 





Figure S2 UV-Vis spectra of the photolysis of a solution of EPEG-Liposomes (total lipid = 5 mM, 4 mol% PEG5000, 1 
mol% lipopeptide E4). Inset: Reaction profile over time as a function of UV absorption at 350 nm. Irradiation times: 
0 (black), 5 (red), 10 (blue), 20 (pink), 30 (green), 40 (navy) and 60 min (violet). The isobestic points appeared at 
250 nm, 287 nm and 322 nm. 






Figure S3 DLS data accompanying liposome-liposome lipid mixing experiments. For EPEG2000-liposomes (left, 4 mol% 
PEG2000) an increase in liposome hydrodynamic diameter was observed in the absence of UV irradiation/PEG 
photolysis. This indicates PEG2000 is not sufficiently long enough to shield E4/K4 recognition and binding. For EPEG5000-
liposomes (right, 4 mol% PEG5000), an increase in liposome size is only observed following UV irradiation (15 mins, 
370 ± 7 nm, 202 mW/cm2), loss of PEG and restoration of the interaction between peptide E and K. 
 
 
















Figure S5 Light templated liposome-cell fusion and concomitant cargo delivery in vitro. Following localized UV 
irradiation (15 mins, 370 ± 7 nm, 50.6 mW/cm2, light dose = 45.5 J/cm2), EPEG-liposomes (400 μM total lipids, 1 mol % 
DOPE-NBD, green lipid probe, 75 μM encapsulated PI, red) fuse with K-functionalized HeLa cell membranes with 
concomittant delivery of PI to the cell cytosol. In the absence of UV irradiation, but within the same experimental 






















Figure S6 UV-A phototoxicity in zebrafish embryos. UV-A phototoxicity in zebrafish embryos. For irradiated embryos, 
a single dose of UV-A light (15 mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 J/embryo) was applied to zebrafish 
embryos (2 dpf). Images were taken 0, 1, 2, 3, 4 days (2-6 dpf) after irradiation using a Leica MZ16FA fluorescent 
microscope (BF mode) coupled to a DFC420C camera. The standard length of embryos was measured from the eye 
to the end of the tail (ImageJ 1.51n). Under these irradiation conditions, embryos developed normally and no 
phenotypic abnormalities were observed. Data presented as mean ± SD. Sample sizes: Control group (d0: n = 20; d 

























Figure S7 (Control for) Cell-specific, light triggered liposome-cell interactions in vivo. MDA-MB-231 human breast 
cancer cells, stably expressing GFP were injected into the circulation of a 2-day old zebrafish embryo and quickly 
accumulated in the caudal hematopoietic tissue (CHT). FDSPE-PEG5000-liposomes (1 mM, 4 mol% DSPE-PEG5000, 
containing 1 mol% DOPE-LR, red) were injected into circulation. In this case, both before and after UV irradiation 
(15 mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 J/embryo), liposomes remained freely circulating, confined 





Figure S8 (Control for) Cell-specific, light triggered liposome-cell interactions in vivo. MDA-MB-231 human breast 
cancer cells, stably expressing GFP were injected into the circulation of a 2-day old zebrafish embryo and quickly 
accumulated in the caudal hematopoietic tissue (CHT). These cells had not been prior functionalized with 
lipopeptide K. EPEG-liposomes (1 mM, 4 mol% PEG5000, containing 1 mol% DOPE-LR, red) were injected into 
circulation. In this case, both before and after UV irradiation (15 mins, 370 ± 7 nm, 13.5 mW/cm2, light dose = 0.45 
























Figure S9  Doxorubicin release curves for EPEG- and FPEG-lipo-DOX formulations, before and after UV (15 mins, 370 ± 




Figure S10  (Control for) Cell-specific doxorubicin delivery to xenograft cancer cells in vivo. MDA-MB-231 human 
breast cancer cells, stably expressing GFP were injected into the circulation of a 2-day old zebrafish embryo. These 
cells had not been prior functionalized with lipopeptide K. No reduction in tumor volume was observed following 
injection of doxorubicin-filled (200 µM doxorubicin) EPEG-liposomes, both before (top) and after (bottom) in situ UV 













Cancer is still a leading cause of death worldwide. Chemotherapy is often the treatment of choice to 
treat cancer, although side effects alter normal cell physiology and may affect the patient’s quality of 
life. Progress in biomedical research has shown that pharmacological targeting of cancer cells is not the 
only therapeutic option. Interactions between tumour cells and their surrounding stroma may support 
cancer cell survival and spreading, and offer a potential new treatment strategy. In addition, the 
application of new inducible photosensitizers and specific drug delivery carriers can improve selectivity 
of anti-cancer treatments. Zebrafish models have increasingly been applied to cancer research and drug 
discovery. In this thesis, a zebrafish embryonic cancer model is presented as an innovative model 
organism to study the role of macrophages in tumour angiogenesis. In addition, we successfully 
demonstrated that zebrafish provide a fast-vertebrate cancer model to test the administration regimen 
of drugs, conditions of light irradiation, host toxicity and anti-cancer efficacy of photodynamic therapy 
and photoactivated therapy drugs. Finally, we observed that light-triggered, cell-specific delivery of 
liposome-encapsulated doxorubicin reduced cancer cell burden without enhanced cytotoxicity in live 
zebrafish embryos.  
 
In chapter 2, we explored the function of zebrafish macrophages in tumour xenografts. He et al had 
shown that transient depletion of macrophages by Pu.1 morpholino treatment blocked tumour 
angiogenesis at the primary site of metastatic onset [1]. Here, we used metronidazole to chemically 
deplete macrophages in Tg zebrafish (Mpeg:GAL4:UAS:NTR:mCherry) engrafted with cutaneous 
melanoma cells and observed that  after macrophages depletion, tumour angiogenesis was impaired. 
The macrophages were attracted into tumour sites and promoted tumour vessel formation. Emerging 
evidence suggests that lactic acid as a product of glycolysis can attract macrophages and induce 
angiogenesis targeting highly glycolytic cancer cells [2]. To test this, a macrophage attraction assay was 
performed by injecting lactic acid into the zebrafish hindbrain. By counting the number of macrophages, 
we observed that lactic acid indeed attracted zebrafish macrophages. Chemical inhibition of tumour cell 
glycolysis by 2-Deoxyglucose (2DG) blocked the lactate secretion. Engraftment of these cells into 
zebrafish embryos reduced attraction of macrophages and impaired tumour angiogenesis suggesting 
that macrophages provided specific cytokines to support angiogenesis.  
 
In chapter 3, we validated a photodynamic therapy (PDT) compound, TLD1433, in zebrafish ectopic and 
orthotopic models. Importantly, this ruthenium-based photosensitizer has passed a phase I clinical trial 
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for PDT treatment of bladder cancer. In our study we investigated a possible repurposing of this drug 
for treatment of conjunctival melanoma (CM). Firstly, the therapeutic potential of light activated 
TLD1433 was tested on several cell lines derived from conjunctival melanoma (CRMM1, CRMM2 and 
CM2005), uveal melanoma (OMM1, OMM2.5, MEL270), epidermoid carcinoma (A431) and cutaneous 
melanoma (A375). The best responding cell lines, CRMM1 and CRMM2 were selected for in vivo testing 
of this PDT compound. The maximally-tolerated dose of TLD1433 was determined in wild type embryos 
and embryos engrafted with CM cells by applying three drug-administration routes (water 
administration, intravenous and retro-orbital administration). The zebrafish embryos engrafted with CM 
cells tolerated less TLD1433 compared with wild type embryos. Using the maximally-tolerated dose of 
TLD1433, we observed that TLD1433 sensitizer inhibited tumour growth in the CM ectopic model after 
intravenous (IV) and retro-orbital (RO) administrations, and in the CM orthotopic model after RO 
administration. These results clearly illustrate that the zebrafish embryonic cancer models can be 
utilized to optimise the route of administration and the dose for photoactivated chemotherapy 
compounds. 
 
In chapter 4, the light-activated anticancer properties of a novel trisheteroleptic ruthenium complex 
[2](PF6)2 were validated in vitro and in an embryonic zebrafish CM  model.  The metal complex [2]2+ was 
designed based on previous work in order to increase cellular uptake, its photoinduced anticancer 
activity with a low dark toxicity.  This photoactivated chemotherapy (PACT) compound can be light-
activated via an oxygen-independent photosubstitution reaction. It is for the first time that the toxicity 
and efficacy of such a ruthenium-based complex was tested in the zebrafish embryonic cancer model. 
Different concentrations and administration methods of this drug were examined to find an optimal 
balance between toxicity and a therapeutic effect. Our results revealed a higher efficacy of this 
ruthenium compound in the in vivo orthotopic CM model than in the ectopic CM model, indicating that 
this novel compound should be further explored in the local treatment of conjunctival melanoma in 
more advance preclinical models.  
 
In chapter 5, we demonstrated that light-triggered and cell-specific targeting of doxorubicin-filled 
liposomes diminished growth of xenografted breast cancer cells in a zebrafish embryonic model. Light-
induced dePEGylation was used to shield the E4/K4 peptide interaction. The liposome-cell interactions 
depend on the recognition and binding of two coiled-coil forming peptides – peptide E on liposomes 
and peptide K on cancer cells. Light-triggered dePEGylation improved cancer cell-liposome fusion and 
allowed specific delivery of liposomal doxorubicin to target cancer cells. In addition, folate-decorated 
liposomes (F-liposomes) targeted the overexpressed folate receptor on xenograft MDA-MB-231 cells 
and also promoted direct fusion of liposome and cell membranes. The experimental component fusion 
systems (peptides E and K) and tumour-cell specific receptor folate-decorated liposomes both delivered 
doxorubicin to tumour cells to induce tumour cell death. As the liposomes and tumour cells expressed 




fluorescence areas and intensity. This work illustrates that the zebrafish embryonic cancer model can 
serve as an efficient platform for optimization of nanomedicine toxicity, biodistribution, stability and 
anti-cancer efficiency. 
 
In conclusion, we started out to use the zebrafish embryonic tumour model to investigate the 
interaction between host macrophages with their tumour microenvironment. The lactic acid secreted 
by tumour cells could attract macrophages and then induced tumour angiogenesis. Secondly, we used 
zebrafish embryonic cancer models for PDT and PACT compound testing. The PDT compound TLD1433, 
and PACT compound [2](PF6)2 showed a selective anti-cancer efficacy. Finally, in order to increase the 
cellular uptake of compounds, cell-specific targeting of liposomes was introduced. Liposome-
encapsulated doxorubicin was delivered into tumour cells upon light-activation and reduced tumour 
burden.  
Collectively, in this thesis we demonstrated that zebrafish embryonic cancer models are excellent for 
the discovery of new drugs and their use has the potential to speed up development of novel anti-
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Kanker is nog altijd een van de grootste doodsoorzaken wereldwijd. Chemotherapie is vaak de eerste 
keuze voor de behandeling van kanker, maar de bijwerkingen hiervan veranderen de normale fysiologie 
van cellen en hebben grote gevolgen voor kwaliteit van leven van patiënten. Vooruitgang in biomedisch 
onderzoek heeft laten zien dat er ook andere therapeutische mogelijkheden zijn. De overleving en 
verspreiding van tumorcellen kan bevorderd worden door interacties met het omliggende weefsel. 
Ingrijpen op dit proces is een mogelijke nieuwe behandelingsstrategie. Daarnaast zou de selectiviteit 
van behandelingen tegen kanker verbeterd kunnen worden door medicijnen lichtgevoelig te maken 
(met fotosensitizers) en door de ontwikkeling van dragers (bijvoorbeeld liposomen) die zorgen voor een 
specifieke medicijnafgifte. De zebravis wordt in toenemende mate toegepast als modelorganisme bij 
kanker- en geneesmiddelenonderzoek. In dit proefschrift worden zebravisembryo’s gepresenteerd als 
een innovatief modelsysteem om de rol van macrofagen bij bloedvatontwikkeling (angiogenese) in 
tumoren te bestuderen. Bovendien laten wij zien dat de zebravis een geschikt kankermodel is voor het 
testen van de toedieningswijze van geneesmiddelen, de condities voor activering van lichtgevoelige 
verbindingen, de toxiciteit voor het organisme en de effectiviteit van foto-dynamische en foto-
activeerbare therapieën. Ten slotte hebben wij aangetoond dat licht-geïnduceerde, cel-specifieke 
aflevering van een in liposomen verpakt geneesmiddel (doxorubicine) de groei van humane 
kankercellen in de zebravis kan remmen zonder cytotoxische bijwerkingen.  
In hoofdstuk 2 hebben we de functie van macrofagen van de zebravis bij de xenotransplantatie van 
humane tumorcellen onderzocht. Eerder onderzoek van onze groep had laten zien dat tijdelijke 
onderdrukking van de ontwikkeling van macrofagen (door uitschakeling van de transcriptiefactor Pu.1) 
de angiogenese van tumoren blokkeert op de primaire locatie waar metastasering begint. In dit 
hoofdstuk hebben wij metronidazole gebruikt voor chemische ablatie van macrofagen in transgene 
zebravissen (Mpeg:GAL4:UAS:NTR:mCherry) waarin huidmelanoomcellen waren getransplanteerd. We 
zagen dat de tumor-angiogenese was verstoord in de afwezigheid van macrofagen, terwijl in de 
controlegroep de macrofagen werden aangetrokken naar plaatsen van tumorgroei en daar de vorming 
van bloedvaten bevorderden. Er is toenemend bewijs dat lactaat als product van de glycolyse 
macrofagen kan aantrekken en angiogenese induceren bij sterk glycolytisch actieve kankercellen. Om 
deze mogelijkheid te onderzoeken hebben wij lactaat geïnjecteerd in een hersenventrikel van de 
zebravis en konden aantonen dat deze stof de aantrekking van macrofagen verhoogt. Chemische 
remming van de glycolyse van tumorcellen met  2-Deoxyglucose (2DG) blokkeerde de uitscheiding van 
lactaat. Wanneer deze cellen werden getransplanteerd in zebravisembryo’s was de tumor-angiogenese 
verminderd, wat suggereert dat de macrofagen die door lactaat worden aangetrokken, specifieke 
cytokinen produceren die de angiogenese bevorderen.  
 
In hoofdstuk 3 valideren wij een chemische verbinding (TLD1433) voor foto-dynamische therapie (PDT) 
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in ectopische en orthotopische zebravismodellen voor conjunctivaal melanoom. Eerst werd TLD1433 
getest op verschillende cellijnen afgeleid van conjunctivaal melanoom (CRMM1, CRMM2, CM2005), 
uveaal melanoom (OMM1, OMM2.5, MEL270), epidermoïde carcinoom (A431) and cutaan melanoom 
(A375). De beste kandidaten (cellijnen CRMM1 en CRMM2) werden geselecteerd om de PDT-verbinding 
in vivo te testen. De maximaal getolereerde dosis van TLD1433 werd bepaald in zowel wildtype embryo’s 
als in embryo’s waarin conjunctivaal melanoomcellen (CM)  getransplanteerd waren. TLD1433 werd 
vervolgens toegediend aan de embryo’s via drie routes (in het water, intraveneus en retro-orbitaal). De 
CM-getransplateerde embryo’s tolereerden minder TLD1433 dan wildtype embryo’s. TLD1433 remde 
tumorgroei in het ectopische CM-model na intraveneuze en retro-orbitale toediening en in het 
orthotopische CM-model na retro-orbitale toediening. Deze resultaten illustreren duidelijk dat ons 
zebravis-kankermodel kan worden toegepast om de toedieningsroute en de dosis van licht-geactiveerde, 
chemotherapeutische verbindingen te optimaliseren. 
 
In hoofdstuk 4 hebben wij ons gericht op een foto-activeerbare therapie (PACT) en daarbij de anti-
kanker eigenschappen van een nieuw trisheteroleptisch rutheniumcomplex ([2](PF6)2) gevalideerd in 
vitro en in een zebravisembryomodel voor CM.  Het metaalcomplex [2]2+ was op basis van eerder 
onderzoek ontworpen om de cellulaire opname en de licht-geïnduceerde anti-kanker activiteit te 
vergroten en daarbij een lage toxiciteit in het donker te behouden. De familie van 
rutheniumverbindingen kan door licht geactiveerd worden via een zuurstof-onafhankelijke 
fotosubstitutiereactie. Dit is de eerste keer dat de toxiciteit en effectiviteit van zo’n ruthenium-
gebaseerd complex is getest in het zebraviskankermodel. Verschillende toedieningswijzen werden 
onderzocht om een optimale balans te vinden tussen toxiciteit en therapeutisch effect. Wij vonden een 
hogere effectiviteit van de rutheniumverbinding in het in vivo orthotopische CM-model dan in het 
ectopische CM-model. Deze resultaten vormen een goede basis voor verder onderzoek naar de 
toepassing van deze nieuwe verbinding voor de lokale behandeling van CM in meer geavanceerde 
preklinische modellen. 
 
In hoofdstuk 5 hebben wij aangetoond dat de groei van getransplanteerde borstkankercellen in 
zebravisembryo’s geremd kan worden via een licht-geïnduceerde en cel-specifieke therapie met 
doxorubicine-bevattende liposomen. Wij hebben hierbij een licht-induceerbare verwijderingsmethode 
van het polyethyleenglycol van de liposomen onderzocht door de interactie te reguleren tussen twee 
peptiden (E op liposomen en K op tumorcellen) die nodig zijn voor de fusie van liposomen met 
celmembranen van tumorcellen en specifieke afgifte van medicijnen. Wij konden een directe fusie 
tussen liposomen en celmembranen van tumorcellen bewerkstelligen met het experimentele twee-
componenten-systeem (fusie van peptiden E en K) evenals met een systeem van folaat-omhulde 
liposomen (F-liposomen) die gericht zijn op de folaatreceptor die tot overexpressie komt op 
getransplanteerde MDA-MB-231-cellen. Beide systemen leverden voldoende doxorubicine aan 




konden zij makkelijk gedetecteerd worden in de zebravisembryo’s en was het mogelijk om oppervlakte 
en intensiteit te kwantificeren. Dit onderzoek illustreert dat het zebraviskankermodel dienst kan doen 
als een efficiënt platform voor optimalisatie van de toxische eigenschappen, biodistributie, stabiliteit en 
anti-kanker werkzaamheid van nanomedicijnen. 
 
Concluderend, wij hebben kankermodellen gebaseerd op zebravisembryo’s succesvol gebruikt om de 
rol van macrofagen in de micro-omgeving van getransplanteerde tumorcellen te onderzoeken. Het 
lactaat dat door tumorcellen wordt uitgescheiden bleek macrofagen te kunnen aantrekken en 
vervolgens tumor-angiogenese te induceren. Daarnaast hebben we deze zebraviskankermodellen 
gebruikt om PDT- en PACT-strategieën te testen. De PDT-verbinding TLD1433 en de PACT-verbinding 
[2](PF6)2 vertoonden een selectieve anti-kanker werkzaamheid. Ten slotte hebben een cel-specifieke 
therapie getest waarbij liposomen worden gebruikt om de cellulaire opname van anti-kanker 
verbindingen te vergroten. Hierbij zijn wij erin geslaagd om doxorubicine in liposomen te verpakken en 
af te leveren aan tumorcellen na foto-activatie.  
 
Bij elkaar genomen toont dit proefschrift aan dat zebraviskankermodellen uitstekend geschikt zijn voor 
de ontdekking van nieuwe geneesmiddelen en de potentie hebben om de ontwikkeling van nieuwe anti-
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